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ABSTRACT 
In many respects the process of nuclear pre-mRNA splicing is similar in cells 
of the yeast, Saccharomyces cerevisiae, and of higher eukaryotes. The availability of 
yeast mutants which are deficient for this reaction provides the means to characterise 
components of the splicing machinery. The PRP8 gene has previously been cloned, by 
complementation of thegrowth defect of a strain carrying the prp8-1 temperature 
sensitive mutation, and has been shown to encode a 28OkD protein which is required 
for pre-mRNA splicing. In this thesis, I describe the further analysis of this protein: 
Two gene fusions were constructed to allow synthesis of j-galactosidase fusion 
proteins containing regions of the PRP8 protein, not represented in previous constructs, 
which were used as antigens to raise antisera in rabbits. Both these antisera detected 
the 280kD protein in yeast cell extracts by immunoblotting, but only one was able to 
immunoprecipitate PRP8. 
These, and existing, antisera were used to analyse the interactions of the PRP8 
protein in yeast splicing extract. 	Using this immunological approach, it was 
demonstrated that the full-length PRP8 protein is stably associated with the spliceosomal 
U5 snRNA. Following incubation of the splicing extract in the presence of ATP, PRP8 
becomes additionailly associated with U4 and U6 snRNAs, which normally exist together 
in a single snRNP particle. These data suggest that PRP8 is a component of the U5 
snRNP particle and that this particle associates with the U4/U6 snRNP particle in an 
ATP-dependent manner. 
Attempts were made to reconstitute the U5 snRNP particle in yeastextracts using 
radiolabelled U5 snRNA, transcribed in vitro from a synthetic gene. However, binding 
of snRNP-specific proteins could not be demonstrated, presumably due to competition 
by non-sequence specific RNA-binding proteins. A fusion protein containing part of the 
PRP8 protein was shown to bind RNA in a non-sequence specific manner by blot assay. 
A 220kD HeLa cell protein was detected by antisera to three different fusion 
proteins and by affinity purified antibodies specific to the PRP8 portions of these 
fusions. This species is present in purified human U5 snRNP fraction, is precipitable 
by anti-Sm antibodies and, as assayed on blots, binds RNA with no apparent sequence 
specificity. This provides suggestive evidence that this protein is a true homologue of 
the yeast PRP8 protein. In addition, preliminary evidence indicates the existence of a 
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1.1 	RNA SPLICING 
Data suggesting that the coding regions of genes are not necessarily continuous, 
but can be interrupted by stretches of non-coding sequence, led to the proposal, in early 
1977, that such sequences are removed from the transcribed RNA (reviewed in 
Witkowski, 1988). Since then, such intervening sequences, or introns, have been 
identified in eukaryotic genes encoding tRNA, rRNA, mRNA and snRNA, in 
archaebacterial tRNA genes and in eubacterial phage genes encoding mRNA. The 
non-intronic regions of the transcript are called exons and the cleavage and ligation 
reaction by which introns are removed is termed RNA splicing. 
Introns, and the reactions by which they are excised, have been divided into four 
classes: 
those found in tRNA genes (Abelson, 1979), 
the so-called Group I introns first described in the Tetrahymena rRNA, but also 
many fungal mitochondrial introns, chloroplast introns and bacteriophage T4 
introns (Cech and Bass, 1986), 
the Group II introns of fungal mitochondrial and chloroplast genes, with 
conserved sequences and proposed secondary structures distinct from those of 
Group I introns (Cech and Bass, 1986), 
those found in nuclear protein-encoding genes (Green, 1986; Padgett et al., 
1986; Sharp, 1987a). 
This thesis is concerned with the machinery for the removal of introns from 
nuclear pre-mRNA and, accordingly, the introductory chapter will primarily constitute 
1 
an overview of the present state of understanding of this process. Its relationship to 
the other classes of splicing will be discussed in Section 1.10. 
1.2 	INTRONS IN NUCLEAR PROTEIN-ENCODING GENES 
In higher eukaryotes, most nuclear protein-encoding genes are interrupted by at 
least one intron and, indeed, can contain as many as 50 (Wozney et al., 1981) and these 
can range in size from 31bp (Ghosh et al., 1978) up to approximately 60kb (Garber et 
al., 1983; Scott et al., 1983). In Saccharomyces cerevisiae, on the other hand, very few 
genes contain introns and only the MATa1 gene (Miller, 1984) has more than one. All 
those except the second intron of the MATa1 gene are located close to the 5' terminus 
of the pre-mRNA. Fink (1987) has suggested a mechanism whereby the yeast genome 
has lost its introns due to homologous recombination between chromosomal genes and 
cDNAs reverse transcribed from processed mRNAs, the mechanics of which would 
explain the retention of introns near the transcriptional start sites. The largest intron 
identified in yeast is 513bp (Leer et al., 1984). 
Sequence comparisons of mammalian introns revealed homologies at the 5' and 
3' splice sites (Breathnach and Chambon, 1981; Mount, 1982) and the consensus 
sequences for these elements are shown in Figure 1.1A. Natural (Weiringa et al., 1984) 
or synthetic (Rautmann et al., 1984) splice site consensus sequences were sufficient to 
direct accurate excision of unrelated viral or bacterial sequence placed between them. 
In the known yeast introns, the splice site sequences are almost invariant 
(Guthrie et al., 1986: Figure 1.1A), but, unlike mammalian introns, deletional analysis 
revealed a requirement for an element in the 3' portion of the intron (Langford and 
Gallwitz, 1983; Pikielny et al., 1983). Sequence comparisons led to the suggestion that 
the absolutely conserved TACTAAC sequence located 20-60bp upstream of the 3' splice 
site was the essential element and this was confirmed by point mutational analyses (see 
Section 1.4.2). 
1.3 	MECHANISM OF THE SPLICING REACTION 
While in vivo experiments allowed investigation of the importance of pre-mRNA 
sequence and structural elements for the splicing reaction, detailed analysis of the 
2 
FIGURE 1.1: INTRON STRUCTURE AND SPLICING MECHANISM 
(A) 	Conserved sequence elements in pre-mRNA introns, where the 5' and 3' splice 
sites are indicated by vertical lines. Very highly conserved residues of metazoan introns 
are underlined, while the asterisk indicates the branch-point in yeast introns. 
(B) 	Mechanism of nuclear pre-mRNA splicing in metazoa and S. cerevisiae. 
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mechanism and biochemistry of the reaction required the development of a cell-free 
in vitro system which would faithfully splice pre-mRNA. Early systems relied on 
coupled transcription and splicing and were therefore inefficient and allowed little scope 
for dissection (Weingartner and Keller, 1981; Kole and Weissmann, 1982; Padgett et al., 
1983). The first uncoupled systems (Goldenberg and Raskas, 1981; Goldenberg and 
Hauser, 1983) employed, as substrate, poly(A)+ nuclear RNA and were therefore 
unsuitable for routine experiments. The development of systems which used HeLa cell 
nuclear extracts to splice in vitro synthesised pre-mRNA permitted the elucidation of 
the mechanism and biochemical requirements of the reaction (Hernandez and Keller, 
1983; Hardy et al., 1984; Grabowski et al., 1984; Padgett et al., 1984; Kramer et al., 
1984; Ruskin et al., 1984; Konarska et al., 1985a). 
These studies resulted in the formulation of the two-step splicing pathway 
represented in Figure 1.113. In each of the mammalian systems, a lag of approximately 
30 minutes is observed before spliced mRNA can be detected, after which production 
of this species proceeds linearly. After the lag phase, the first detectable chemical 
change involves cleavage at the 5' splice site to generate the intermediates of the 
reaction, i.e. free exon 1 with a 3' hydroxyl group and intron-exon 2 in which the 5' end 
of the intron has formed a 2'-5' phosphodiester bond with an adenosine residue near 
the 3' end of the intron, a structure termed a "lariat". This constitutes "step 1" of the 
reaction. 
The next stage of the reaction, "step 2", involves cleavage of the phosphodiester 
bond between the intron and exon 2 and ligation of the two exons to give the spliced 
mRNA product and the excised intron, still in lariat form, with a 3' hydroxyl group. 
Although ATP is strictly required for the in vitro splicing reaction, neither step 1 nor 
step 2 results in a net change in the number of phosphodiester bonds and so they could, 
theoretically, proceed without input of energy. 
If the events observed in the in vitro splicing reaction reflect the in vivo process, 
then equivalent intermediate and product species should be detectable in mammalian 
cells. It was shown that polyadenylated hnRNA from HeLa cells contains branched 
molecules (Wallace and Edmonds, 1983), while analysis of $-globin transcripts from 
rabbit foetal liver cells (Zeitlin and Efstradiatis, 1984) revealed a series of species, some 
of which correspond to the lariat forms observed in vitro for the same transcript 
(Ruskin et al., 1984). 
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Lariat structures were also identified as in vivo products of the pre-mRNA 
splicing reaction in Saccharomyces cerevisiae and the branch-point was mapped to the 
last adenosine residue of the TACTAAC sequence (Domdey et al., 1984; Rodriguez et 
al., 1984). Subsequent development of a yeast in vitro splicing system (Lin et al., 1985) 
revealed an ATP-dependent, two-step pathway analagous to that in mammalian splicing. 
With the finding that in yeast the 2'-5' phosphodiester bond forms within a 
highly conserved sequence element, a conserved branch-point sequence was sought in 
metazoan introns. By searching for homology to the yeast TACTAAC element in 
introns from a wide range of higher eukatyotes, the consensus sequence PyTPuAPy was 
formulated (Keller and Noon, 1984; 1985). Analysis of lariat-containing RNA species 
generated during in vitro splicing of a wide range of substrates revealed that branch 
formation generally occurs at an adenosine residue within a sequence conforming to this 
consensus (Reed and Maniatis, 1985). 
1.4 	ANALYSIS OF PRE-mRNA SEQUENCE AND STRUCTURE REQUIREMENTS 
1.4.1 Mammalian Pre-mRNA 
Naturally occurring mutations in the 5' splice site of the first intron of the 
human -globin gene result in activation of cryptic 5' splice sites both in vivo (Treisman 
et al., 1983) and in vitro (Kramer et al., 1984). Point mutational analysis of the 
f3-globin 5' splice site revealed that, in general, deviation from the consensus sequence 
led to a decrease in the efficiency of utilisation of the site (Aebi et al., 1986; Eperon 
et al., 1986; Aebi et al., 1987). Several of the mutations permit step 1 of the splicing 
reaction to occur, while abolishing step 2 (Aebi et al., 1987). 
Deletion of the 3' splice site results in a complete abolition of splicing, both in 
vivo and in vitro (Reed and Maniatis, 1985). There are conflicting reports on the 
requirement for the highly conserved AG dinucleotide for step 1 of the splicing 
reaction, indicating either that it is dispensible (Ruskin and Green, 1985a) or important 
(Aebi et al., 1986) for this step. The importance of the polypyrimidine tract is 
demonstrated by the finding that progressive reduction of the size of this element results 
in a reduction in splicing efficiency (Weiringa et al., 1984; van Santen and Spritz, 1985). 
Mutation of this region leads to a complete block in step 1 of the reaction (Frendeway 
and Keller, 1985; Ruskin and Green, 1985a). 
Deletion of the authentic branch-point region results in the utilisation of cryptic 
sites, with little apparent sequence requirement but, seemingly, with a strong distance 
constraint in that they all occur between 22 and 37 nucleotides upstream of the 3' 
splice site (Ruskin et al., 1985). The branch usually forms at an adenosine residue, but 
mutations at the branch nucleotide reveal that, although an adenosine residue is 
favoured, any nucleotide can act as the branch acceptor (Hornig et al., 1986). However, 
lariats branched at a uracil or guanosine residue do not undergo step 2 of the reaction 
(Hornig et al., 1986). Taken together with the results obtained with point mutations 
of the first nucleotide of the intron (see above) these results indicate a requirement for 
specific nucleotide residues on either side of the 2'-5' phosphodiester bond in order for 
step 2 to take place. Reed and Maniatis (1988) set up an in vivo -competition assay 
to determine the importance of the surrounding sequence in branch-point selection. By 
the removal of all possible cryptic sites, they were able to demonstrate that the 
conserved nucleotides around the branch-point do, indeed, play a role in its selection 
and utilisation. 
Synthetic consensus splice sites are only utilised when inserted in close proximity 
to authentic splice sites, thus implying a role for the "context", be it primary or 
secondary structure, of the splice site in its selection (Nelson and Green, 1988). 
Similarly, deletion, substitution, or even subtle changes in adjacent exon sequences were 
found to alter the efficiency of selection of a splice site (Reed and Maniatis, 1986). 
The minimum intron size requirement for splicing was shown, by deletional 
analysis, to be in the order of 80 nucleotides (Weiringa et al., 1983; van Santen and 
Spritz, 1985). A 5' exon of 20nt is sufficient to allow splicing (Parent et al., 1987), while 
a pre-mRNA lacking a 3' exon can undergo step 1 (Frendeway and Keller, 1985) and 
one with as little as 4nt can be spliced (Turnbull-Ross et al., 1988). 
The cap structure, m7G(5')ppp(5')N, which is added to pre-mRNA in vivo, is 
not essential for splicing of an exogenous substrate in a HeLa cell nuclear extract, but 
does improve the efficiency of the reaction (Kramer et al., 1984). Splicing in vitro does 
not require 3' cleavage or polyadenylation of the pre-mRNA (Kramer et al., 1984). 
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1.4.2 Yeast pre-mRNA 
Unlike the case in mammalian pre-mRNA, deletion of the authentic 5' splice site 
of a yeast intron does not result in activation of cryptic sites (Gallwitz, 1982). Point 
mutation of either of the first two nucleotides generally permits step 1 to occur, but not 
step 2 (Newman et al., 1985; Fouser and Friesen, 1986; Vijayraghavan et al., 1986), 
while mutation of position 5 results in an aberrant 5' cleavage event, upstream of the 
authentic site (Parker and Guthrie, 1985; Fouser and Friesen, 1986; Vijayraghavan et 
al., 1986). The aberrant cleavage sites have no similarity to the authentic site and, 
therefore, it seems that the cleavage event is separate from the 5' splice site recognition 
event and that the invariant guanosine residue at position 5 is important for this. 
Deletion of the branch-point sequence generally leads to a block in splicing 
(Langford and Gallwitz, 1983; Langford et al., 1984; Pikielny et al., 1983), although, in 
the case of the actin transcript, a cryptic branch-point sequence, UACUAAG, is utilised 
(Cellini et al., 1986a). Point mutations within the conserved branch-point sequence 
inhibit splicing to varying extents (Langford et al., 1984; Newman et al., 1985; 
Vijayraghavan et al., 1986; Fouser and Friesen, 1986; Jacquier et al., 1985; Jacquier and 
Rosbash, 1986). When the branch-point adenosine nucleotide is mutated, either splicing 
is completely abolished (Langford et al., 1984; Newman et al., 1985) or step 1 and a low 
level of step 2 can take place (Fouser and Friesen, 1986; Jacquier and Rosbash, 1986; 
Vijayraghavan et al., 1986). The conflicting nature of these data may reflect the 
different pre-mRNAs used or differences in the sensitivity of the detection methods. 
However, it is clear that the branch-point is fixed as the penultimate residue of the 
sequence element and that, when a branch is formed at a mutated residue in this 
position, step 2 is severely inhibited. As is the case in mammalian introns, therefore, 
the residues linked by the 2'-5' phosphodiester bond are important for the second, 
rather than the first, step of the splicing reaction. 
When the 3' splice site AG dinucleotide is deleted, the first AG downstream of 
the branch-point is utilised as an alternative site (Langford and Gallwitz, 1983). A 
transcript lacking a downstream AG can still undergo step 1 of the reaction (Rymond 
and Rosbash, 1985), provided that it extends at least 29nt beyond the branch-point 
sequence (Rymond et al., 1987), while, for step 2, the AG dinucleotide is important 
(Vijayraghavan et al., 1986; Fouser and Friesen, 1987) and the distance between the 
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branch-point sequence and the 3' splice site must lie between 8 and 66nt (Fouser and 
Friesen, 1987; Cellini et al., 1986b). 
A role for non-conserved sequences of certain yeast introns has been suggested 
by the finding that deletion of a region upstream of the branch-point sequence of the 
CYH2 intron leads to an inhibition of splicing (Newman, 1987). Further deletion of a 
region near the 5' end of the intron restores splicing, suggesting the presence of an 
inhibitory element in this region which must be complemented by the 3' element or 
deleted to allow efficient splicing. In the case of the rp51A transcript, deletion of a 
non-conserved region near the 5' splice site leads to a reduction in splicing efficiency 
(Pikielny and Rosbash, 1985). 
Enlarging the actin intron leads to a reduction in the efficiency of its removal 
from pre-mRNA (Klinz and Gallwitz, 1985), while a reduction of the distance between 
the 5' splice site and the branch-point to less than 44nt abolishes splicing 
(Thompson-Jager and Domdey, 1988). The shortest natural introns are those in the 
MATa1 transcript with 43nt (intron 1) and 42nt (intron 2) separating the 5' splice sites 
and the branch-points (Miller, 1984) and removal of 6nt from intron 1 completely 
abolishes splicing (Köhrer and Domdey, 1988). 
The location of almost all yeast introns near the 5' end of the pre-mRNAs might 
suggest a preference for a short first exon and, indeed, it was shown that moving the 
intron further from the 5' end of the actin transcript resulted in a reduction in the 
efficiency of, but did not abolish, splicing (Klinz and Gallwitz, 1985). The shortest first 
exon which supports splicing is 12nt, although one consisting of only one nucleotide 
allows step 1 to take place (Duchene et al., 1988), while a downstream exon of lOnt is 
sufficient (Rymond and Rosbash, 1985). 
Neither a cap structure nor a poly(A) tail is required for the efficient splicing 
of exogenous substrate in a yeast in vitro splicing system (Lin et al., 1985). 
1.4.3 Comparison of Mammalian and Yeast Requirements 
The major contrast between the recognition of yeast and mammalian introns 
appears to be in the relative importance of the branch-point and 3' splice site conserved 
sequences. In mammalian introns, the polypyrimidine tract is essential for step 1 of the 
reaction and the branch-point appears to be determined, at least in part, by its distance 
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upstream of the 3' splice site. However, the degree of match to the consensus 
branch-point does play a role in the efficiency of utilisation of a mammalian 
branch-point, so clearly this element must be directly recognised by a component of the 
splicing apparatus. In yeast introns, on the other hand, recognition of the branch-point 
UACUAAC sequence appears to constitute an early event and the position of the 3' 
splice site is determined as the first AG dinucleotide downstream of this element. 
The strict requirement for the UACUAAC element for recognition of introns 
in yeast is reflected in the finding that mammalian introns, which do not carry this 
sequence, are not spliced in yeast cells (Beggs et al., 1980). Conversely, the yeast 
rp51A transcript is spliced in HeLa cell nuclear extract, but with utilisation of a 
different branch-point (Ruskin et al., 1986), illustrating the differing mechanisms of 
branch-point selection between these organisms. 
Although cryptic 5' splice site activation is not observed in yeast, mutations at 
the first two nucleotides of the intron have similar effects in mammalian and yeast 
introns. The effect of mutation of position 5 of the yeast sequence, i.e. shifting the 5' 
cleavage event to a position with no match to the consensus, has not been seen with 
mammalian introns. 
1.5 	SMALL NUCLEAR RIBONUCLEOPROTEIN PARTICLES 
1.5.1 Mammalian snRNPs 
1.5.1.1 Introduction 
Small nuclear ribonucleoprotein particles are present in the nuclei of all 
eukaryotic cells so far analysed and consist of a snRNA moiety complexed with a set 
of polypeptides (reviewed in Steitz, 1988). The major species, Ui, U2, U4, US and U6, 
range in size from 106-189nt, are abundant (2 x 105 -1 x 106  copies/cell) and, with the 
exception of U6, possess a trimethylguanosine cap. The U4 and U6 species are found 
in a single particle, base-paired to one another (Hashimoto and Steitz, 1984; Bringmann 
et al., 1984). The analysis of the structure and function of these particles has been 
facilitated by the availability of certain antibodies against their components. Antibodies 
against trimethyl guanosine recognise the cap structure and so can be used to precipitate 
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all these species, including U6 via its interaction with U4 (Bringmann et al., 1983; Smith 
and Eliceiri, 1983). Sera from human patients with certain autoimmune diseases 
recognise all the major snRNPs (anti-Sm), Ui only (anti-(U1)-RNP), U2 only 
(anti-(U2)-RNP), or Ui and U2 (anti-(U1,U2)-RNP) through their protein components 
(reviewed in van Venrooij, 1987). 
1.5.1.2 Elucidation of Role in Splicing 
The first proposals that the U-snRNPs are involved in pre-mRNA splicing were 
based on the sequence complementarity between the highly conserved 5' terminus of the 
Ui snRNA and the 5' and 3' splice site consensus sequences and suggested that the Ui 
snRNP might act to align the two splice sites for the splicing reaction (Lerner et al., 
1980; Rogers and Wall, 1980). Subsequently, evidence accumulated for the involvement 
of Ui snRNP in splicing and, particularly, in recognition of the 5' splice site. Splicing 
in isolated HeLa cell nuclei (Yang et al., 1981) and in HeLa whole cell extract (Padgett 
et al., 1983) was inhibited by both anti-Sm and anti-(U1)-RNP sera and inhibition of in  
vivo splicing by these same two types of antisera was demonstrated by microinjection 
into oocytes of Xenopus laevis (Bozzoni et al., 1984; Fradin et al., 1984). 
Analysis of protected RNA fragments after immunoprecipitation with 
anti-(Ui)-RNP antibodies and RNase Ti digestion showed that the UI snRNP binds 
the 5' splice site of pre-mRNA and that the association depended upon the integrity of 
both the snRNA and the protein components of the snRNP (Mount et al., 1983). 
Selective removal of the 5' end of the Ui snRNA, by treatment with a complementary 
oligonucleotide and RNase H, abolished splicing in an in vitro system (Kramer et al., 
1984; Kramer and Maniatis, 1985). 
Direct genetic evidence for the recognition of the 5' splice site by base-pairing 
with the 5' end of Ui snRNA was provided by the ability of compensatory mutations 
in a transfected Ui gene to suppress mutations in a 5' splice site in vivo (Zhuang and 
Weiner, 1986). However, suppression of one mutant was much more efficient than of 
another, suggesting that the 5' splice site sequence may be recognised by an additional 
factor. This is supported by the finding that Ui snRNP binds to synthetic and cryptic 
splice sites which are not utilised (Chabot and Steitz, 1987a; Nelson and Green, 1988). 
Therefore, base-pairing of the Ui snRNA is necessary, but not sufficient, for 5' splice 
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site selection. Analysis of the 5' splice site sequences of several thousand introns from 
evolutionarily diverse organisms revealed that, although the geometry of the interaction 
between the absolutely conserved 5' end of Ui snRNA and the 5' splice site was 
variable, the 5' cleavage always occurred opposite the junction between residues 9 and 
10 of the snRNA (Jacob and Gallinaro, 1989). This suggests that the 5' cleavage site 
is determined by the interaction with Ui snRNP, and is supported by mutational 
analyses of the 5' splice site which showed that the cleavage site could be predicted 
from the most favourable base-pairing interaction with Ui snRNA (Aebi et al., 1987; 
Weber and Aebi, 1988). 
The involvement of the U2 snRNP was indicated by the inhibition of the in vitro 
splicing reaction which results from RNase H-directed cleavage of the snRNA 
component (Black et al., 1985; Kramer and Maniatis, 1985), while immunoprecipitation 
with anti-(U2)-RNP antibodies followed by RNase Ti digestion revealed an interaction 
of the U2 snRNP with the branch-point region of the pre-mRNA (Black et al., 1985). 
This interaction requires the presence of a functional 3' splice site downstream of the 
branch-point region (Chabot and Steitz, 1987b). RNase H-directed cleavage of U4 and 
U6 snRNAs also revealed a requirement for the U4/U6 snRNP in splicing, but the U5 
snRNA remained refractory to specific degradation (Black and Steitz, 1986; Berget and 
Robberson, 1986). 
In protection assays, such as those which determined the sites of Ui and U2 
snRNP interaction with the pre-mRNA, it was found that the 3' splice site was 
protected by a factor which was precipitable with anti-Sm and anti-m3G antibodies, but 
was resistant to digestion by micrococcal nuclease (Chabot et al., 1985). Of the 
abundant Sm-precipitable snRNPs, only that containing US snRNA shows such 
resistance to micrococcal nuclease, giving rise to the suggestion that the U5 snRNP 
recognises and binds the 3' splice site. 
1.5.1.3 Mammalian snRNP Proteins 
The relative abundance of the major snRNP particles in mammalian cells, and 
the availability snRNP-specific sera, has facilitated their purification and the 
determination of their protein composition (Hinterberger et al., 1983; Kinlaw et al., 
1983; Bringmann and LUhrmann, 1986; reviewed in Luhrmann, 1988). Each of the 
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major snRNP particles contains 7 common, "core" proteins (B', B, D, D', E, F, and G), 
while the Ui snRNP has 3 unique proteins (U1-70K, A and C) and the U2 snRNP has 
2 unique proteins (A' and B"). A proportion of purified U5 snRNPs contains, in 
addition to the core proteins, up to 7 unique species (Bach et al., 1989). 
Cross-reactivity of rabbit sera raised against purified proteins, and similarities in peptide 
patterns after proteolytic digestion, has revealed that B and B' are closely related and 
that A and B" share homologus regions (Reuter et al., 1987). It is through direct 
recognition of subsets of core and specific proteins that the various autoimmune sera 
are able to precipitate snRNP particles (van Venrooij, 1987). 
The snRNA species Ui, U2, U4 and U5 each carries the so-called "domain A" 
motif, consisting of the sequence PuA(U)GPu (n>3) in a single-stranded region 
flanked by double-stranded stems (Branlant et al., 1982). Intensive nuclease digestion 
of snRNP particles results in core protection of this site by the D, E, F, and G proteins 
(Liautard et al., 1982) and, indeed, this motif alone is sufficient to direct unrelated 
RNAs to become Sm-precipitable (Mattaj, 1986). The core snRNP proteins associate 
to form a 6S complex in the absence of snRNA (Fisher et al., 1985), suggesting that this 
subcomplex then recognises and binds the snRNA by virtue of the "domain A" structure. 
Only the F core protein can be covalently cross-linked to snRNA by UV-irradiation, 
implying that this species may play a role in binding directly to the "domain A" region 
(Woppmann et al., 1988). 
The cDNAs encoding several of the snRNP proteins have been isolated and the 
sequences determined: U1-70K (Theissen et al., 1986), A (Sillekens et al., 1987), C 
(Sillekens et al., 1988), A' (Sillekens et al., 1989), B" (Habets et al., 1987), D (Rokeach 
et al., 1988), E (Wieben et al., 1985). The Ui-70K, A and B" proteins contain regions 
of similarity to an 80 amino acid consensus sequence postulated to play a role in 
RNA-binding (Dreyfuss et al., 1988), and, for U1-70K, this motif has been shown to be 
a component of the Ui snRNA-binding domain (Query et al., 1989). 
Analysis of the functions of the snRNP proteins will be facilitated by the 
development of in vitro reconstitution systems for the snRNP particles, as has been 
achieved for Ui (Patton et al., 1987; Hamm et al., 1987). This approach has allowed 
an analysis of snRNA-protein interactions and given rise to models for the overall 
structural arrangement of the Ui snRNP particle (Patton and Pederson, 1988; Hamm 
et al., 1988). It may be possible to assemble snRNP particles which are lacking a 
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particular protein and determine the effect on splicing in an in vitro system, thus 
providing clues to the function of the omitted species. Recently, the B and B" proteins 
have been shown to possess an endonucleolytic activity which is inactive in native 
snRNP particles (Temsamani et al., 1989). Whether this is functionally important for 
splicing is not clear, as it may play a role in snRNA maturation or in snRNP turnover. 
Two different studies have identified a protein, with an apparent molecular 
weight of lOOkD (Tazi et al., 1986) or 70kD (Gerke and Steitz, 1986), which binds the 
3' splice site region of pre-mRNA. The 70kD species probably represents a degradation 
product of the lOOkD species, reflecting the different purification procedures. This 
intron-binding protein (IBP) co-purifies with the U5 snRNP, under certain conditions, 
and is precipitable with the monoclonal anti-Sm antibodies used by Gerke and Steitz 
(1986). The binding of this factor, which occurs at 0°C in the absence of ATP, may 
result in the 3' splice site protection seen under such conditions and if associated with 
the U5 snRNP, would explain the precipitability of the protected fragment with anti-Sm 
and anti-m3G antibodies (Chabot et al., 1985). 
1.5.2 Yeast snRNPs 
1.5.2.1 Identification of Yeast U-snRNAs 
Several dozen snRNAs were identified in Saccharomyces cerevisiae, equivalent 
to the metazoan U-class on the basis of 5' cap structure, metabolic stability, nuclear 
localisation and presence of modified bases (Wise et al., 1983; Riedel et al., 1986). At 
less than 200 copies/cell, they are, however, considerably less abundant than the 
mammalian species. Many of these are not essential for cell viability (e.g. Parker et al., 
1988), but the homologues of each of the mammalian species involved in pre-mRNA 
splicing have been identified and shown to be encoded by single-copy, essential genes. 
The yeast U2 is 1 175nt in length and, over lOOnt at its 5' end, is similar in its 
primary sequence and predicted secondary structure to metazoan U2 snRNA (Ares, 
1986). The reason for the enormous size discrepancy in U2 between yeast and 
metazoan cells is unclear, since approximately 950nt from the middle of the yeast species 
can be deleted without affecting cell viability (Igel and Ares, 1988; Shuster and Guthrie, 
1988). Direct recognition of the branch-point sequence by base-pairing to U2 snRNA 
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was indicated by the ability of compensatory mutations in the latter to suppress the 
effects of mutations in the former (Parker et al., 1987). This suppression is not 
complete, indicating additional requirements on the branch-point sequence than 
base-pairing to U2 snRNA. These results, however, provide compelling evidence that 
base-pairing between the U2 snRNA and the pre-mRNA also plays a role in mammalian 
branch-point recognition. 
The yeast U5 is present in two forms, of 179nt and 214nt, which are transcribed 
from the same gene and differ only in the presence or absence of a 35nt 3' extension 
(Patterson and Guthrie, 1987). The predicted secondary structure for these species is 
similar to that for the metazoan U5 snRNA and a 9nt region, which occurs in a 
predicted single-stranded loop, is absolutely conserved. The yeast U4 and U6 snRNAs 
are, like their metazoan counterparts, found in the same snRNP particle, base-paired 
to one another (Siliciano et al.,1987a; Brow and Guthrie, 1988). The yeast U4 snRNA 
exhibits considerable identity with the mammalian species over its first 68nt and the U6 
species are 60% identical over their entire lengths, while the predicted base-pairing 
interaction is similar in both cases. 
The yeast Ui snRNA, at 568nt, is considerably larger than its mammalian 
counterpart, with which it shares a perfect sequence match over its first lOnt and a 
similar predicted secondary structure (Kretzner et al., 1987; Siliciano et al., 1987b). 
That this species recognises the 5' splice site by a base-pairing interaction has been 
demonstrated by the partial suppression of mutations in the consensus sequence by 
compensatory mutations in the 5' end of the yeast Ui snRNA (Seraphin et al., 1988; 
Siliciano and Guthrie, 1988). However, restoration of base-pairing does not prevent the 
aberrant 5' cleavage events obtained with pre-mRNAs carrying mutations at position 5 
of the 5' splice site consensus, nor does it restore step 2 of the reaction in pre-mRNAs 
with mutations at position 1 of the intron. This agrees with the findings in the 
mammalian system (Zhuang and Weiner, 1986) that base-pairing to Ui snRNA is 
necessary, but not sufficient, to define the 5' splice site. 
1.5.2.2 Yeast snRNP Proteins 
The relatively low abundance of snRNP particles in Saccharomyces cerevisiae 
means that their purification in sufficient quantities for protein analysis is very difficult. 
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The yeast Ui, U2, U4 and U5 snRNAs all carry the "domain A" protein-binding site, 
as found in mammalian species, and are packaged into Sm-precipitable complexes upon 
injection into Xenopus oocytes (Tollervey and Mattaj, 1987; Riedel et al., 1987). In 
addition, the yeast splicing snRNPs are directly precipitable with certain anti-Sm sera 
(Tollervey and Mattaj, 1987; Siliciano et al., 1987; M.Dalrymple, personal 
communication). Taken together, these results indicate that there must be some 
conservation of snRNP proteins between yeast and mammalian cells. 
The PRP8 protein, identified as being a pre-mRNA splicing factor by the genetic 
approach discussed in Section 1.6.2, has been shown to be a yeast snRNP component 
(this thesis; Lossky et al., 1987). Another protein, PRP4, appears to be associated 
specifically with the U4/1J6 snRNP (Peterson-Bjorn et al., 1989; Banroques and 
Abelson, 1989). 
1.6 	OTHER PROTEIN FACTORS 
1.6.1 Mammalian Factors 
1.6.1.1 hnRNP Proteins 
Pre-mRNA does not occur as naked nucleic acid, but rather as heterogeneous 
nuclear ribonucleoprotein (hnRNP), complexed with specific proteins as a linear array 
of globular, 200A monoparticles (reviewed in Dreyfuss et al., 1988). The first indication 
that such proteins play a role in pre-mRNA splicing was the finding that the hnRNP 
C-proteins were required for the in vitro splicing reaction (Choi et al., 1986). The 
C-proteins have a strong sequence preference for binding poly(U) (Swanson and 
Dreyfuss, 1988a) and, along with the hnRNP proteins Al and D, have been shown to 
associate specifically with the polypyrimidine tract and branch-point sequences of 
pre-mRNA (Swanson and Dreyfuss, 1988b). Mattaj (1989) has proposed several possible 
roles for the hnRNP proteins in pre-mRNA splicing; (i) they may bind the intron to 
keep it free of unfavourable secondary structure or non-specific proteins, (ii) they may 
facilitate or stabilise adjacent protein binding, or (iii) they may block transport to the 
cytoplasm until splicing is complete. 
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1.6.1.2 Factors Identified by Fractionation 
Chromatographic fractionation of crude HeLa cell nuclear extract has resulted 
in the definition of a number of splicing factors, necessary for either step 1 or step 2 
(Kramer and Maniatis, 1985; Kramer and Keller, 1985; Furneaux et al., 1985; Perkins 
et al., 1986; Kramer et al., 1987). The lack of success in purifying such factors probably 
reflects the presence of several other essential factors in the fractions containing them. 
A factor, U2AF, which is required for the binding of U2 snRNP to the 
pre-mRNA, has been identified and partially characterised, although its activity has 
proved too labile for purification (Ruskin et al., 1988). This factor is not hnRNP C-
protein (Section 1.6.1.1) nor is it the intron-binding protein described in Section 1.5.1.3 
and, in fact, binds independently of it. It binds pre-mRNA, requiring the polypyrimidine 
tract and the AG dinucleotide of the 3' splice site for efficient interaction. In a 
different study, two protein factors were shown to be essential for U2 snRNP 
interaction with pre-mRNA (Kramer, 1988). The relationship of these to previously 
described factors has not been fully investigated and the author points out that they may 
represent U2AF and intron-binding protein. 
The results showing that base-pairing with Ui snRNA was not sufficient for 
selection of a 5' splice site (see Section 1.5.1.2), suggested the involvement of other 
factors in this recognition step. The existence of a protein factor which enhanced the 
binding of the Ui snRNP to the 5' splice site was suggested by fractionation 
experiments (Mayeda et al., 1986). A very simple, centrifugal fractionation procedure 
has revealed the requirement of a soluble, protein factor for the correct recognition of 
the 5' splice site by the Ui snRNP (Zapp and Berget, 1989). 
1.6.2 Yeast Factors 
In Saccharomyces cerevisiae, it is possible to define splicing factors genetically, 
as well as biochemically. The isolation of conditional-lethal mutants which are 
specifically defective in pre-mRNA splicing allows characterisation of the defect and 
isolation of the wild-type gene. 
Of 400 mutants isolated for a heat-sensitive defect in macromolecular synthesis 
(Hartwell, 1967), 23, falling into 9 complementation groups (p-prp10/1 1), were 
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subsequently shown to accumulate pre-mRNA at the non-permissive temperature 
(Rosbash et al., 1981). Extracts from strains carrying these mutations, except P06 and 
exhibit a higher degree of heat-sensitivity for the in vitro splicing reaction than 
do extracts from wild-type strains (Lustig et al., 1986), suggesting that the products of 
the mutated genes play a direct role in the reaction. 
Several of the wild-type PRP genes have been isolated, selected from yeast 
genomic libraries on the basis of their ability to suppress the growth defects conferred 
by the mutations (Lee et al., 1984; Last et al., 1984; Soltyk et al., 1984; Jackson et al., 
1988). The raising of antibodies to proteins produced from the cloned genes in E.coli 
provides the means to identify the protein products of the PRP genes (Lee et al., 1986; 
Last and Woolford, 1986; Chang et al., 1988; Peterson-Bjorn et al., 1989; Jackson et al., 
1988) and to begin analysis of their roles in the pre-mRNA splicing reaction. In this 
way, the PRP8 and PRP4 proteins have been identified as components of snRNP 
particles (see Section 1.5.2.2) and the PRP11 protein has been shown to be a 
component of the spliceosome, but not stably associated with a snRNP (Chang et al., 
1988). The PRP proteins could be purified by fractionation of a yeast splicing extract 
or by immunoaffinity chromatography, using complementation of heat-inactivated splicing 
extracts as assays of activity to monitor purification. 
With the failure to develop a successful method for direct selection, the ways 
to isolate new pj mutations are; (i) to screen large banks of heat-sensitive mutants for 
accumulation of pre-mRNA, (ii) to isolate suppressors of the existing prp mutations, a 
method which has been used in this laboratory to isolate cold-sensitive suppressors of 
pM2 and pa,8 or (iii) to isolate suppressors of mutations in conserved sequences of 
pre-mRNA which abolish splicing. This third approach has resulted in the isolation of 
a mutation, prp16, which allows splicing of a pre-mRNA carrying a branch-point 
sequence mutation (Couto et al., 1987). This gene encodes a factor distinct from U2 
snRNA, which is, presumably, required in addition to U2 snRNA for branch-point 
recognition. 
By fractionation of a yeast splicing extract, a factor essential for step 2 of the 
splicing reaction was defined (Cheng and Abelson, 1986). 	Subsequently, 
complementation studies on a heat-inactivated extract from a VW2 strain permitted the 
definition of two further yeast splicing factors, one required for step 1 and one for step 
2 (Lin et al., 1987). 
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In extracts in which U2 snRNP was inactivated by RNase H-directed cleavage 
of its snRNA component, a factor was defined which commits the pre-mRNA to the 
splicing reaction upon complementation of the U2 depletion (Legrain et al., 1988). This 
factor binds stably to the pre-mRNA, in the absence of ATP, and requires the presence 
of intact 5' splice site and branch-point sequences. It cannot be excluded that this 
factor is, in fact, the Ui snRNP particle. 
1.6.3 Schizosaccharomyces pombe 
The genetic approach to definition of splicing factors is also available in the 
fission yeast Schizosaccharomyces pombe. Pre-mRNA splicing in this organism appears, 
in some ways, to be more characteristic of that in higher cukaryotes than is the process 
in Saccharomyces cerevisiae. Introns are common, with some genes having four 
(Hindley and Phear, 1984), the U-snRNAs are similar in size to those of metazoa 
(Tollervey, 1987; Brennwald et al., 1988) and a mammalian intron can be spliced in 
S.pombe (Kaufer et al., 1985), although this is not the general case because other 
mammalian introns are not spliced (Potashkin and Frendeway, personal communication). 
Three heat-sensitive S.pombe pre-mRNA splicing mutants have been isolated (Potashkin 
et al., 1989), but a full analysis of the products of these genes must await the 
development of a reliable in vitro splicing system. 
1.7 	SPLICING COMPLEXES 
1.7.1 Mammalian Splicing Complexes 
1.7.1.1 Identification and Composition 
The association of splicing factors with the pre-mRNA results in the formation 
of a large ribonucleoprotein complex, in which the splicing reaction takes place. This 
was first identified by centrifugation of in vitro splicing reactions in glycerol gradients, 
when it was shown that, during the lag phase, the pre-mRNA is first formed into a 
35/40S complex which then diminishes as a 50160S complex is formed, where step 1 
occurs (Frendeway and Keller, 1985; Grabowski et al., 1985). These first reports 
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indicated that only formation of the larger complex required ATP, but subsequently it 
was shown that formation of the smaller was also ATP-dependent (Steitz et at., 1988). 
The larger complex, which has been termed the "spliceosome", can be purified and, 
upon addition of nuclear extract, its pre-mRNA undergoes steps 1 and 2 without a lag 
phase (Grabowski et al., 1985). As expected, the spliceosome contains snRNPs as 
evidenced by its precipitability with anti-Sm antibodies (Grabowski et al., 1985). 
By non-denaturing gel electrophoresis, the formation of two ATP-dependent 
splicing complexes could be detected (Konarska and Sharp, 1986). On the basis of the 
kinetics of their appearance, and of snRNP composition (see below), the fast and slow 
migrating complexes correspond to the 35140S and 50160S complexes respectively, and 
I will refer to these as A and B after the nomenclature of Konarska and Sharp (1986). 
Using a different substrate, it was possible to resolve complex B into two separate 
complexes (Lamond et at., 1987). 
Splicing complexes have also been purified by chromatographic means. In two 
independent studies, biotinylated pre-mRNA was used as splicing substrate and then 
purified, along with associated factors, on streptavidin columns (Grabowski and Sharp, 
1986; Bindereif and Green, 1987). In addition, spliceosomes have been purified by gel 
filtration chromatography and visualised in the enriched fractions by electron microscopy 
(Reed et at., 1988). 
By using these approaches, or combinations of them, it has been possible to 
determine the snRNA components of the splicing complexes. Several such studies failed 
to detect Ui snRNA in any splicing complexes (Konarska and Sharp, 1986; Grabowski 
and Sharp, 1986; Lamond et al., 1987) which was surprising, since its rote in 5' splice 
site binding was established. Also, the ability of anti-(U1)-RNP antibodies to precipitate 
splicing intermediates indicated that at least one component of this snRNP was still 
present after step 1 had occurred (Grabowski et at., 1985; Bindereif and Green, 1986; 
Chabot and Steitz, 1987a; Reed et al., 1988). It was subsequently shown that the 
conditions used in the earlier studies, i.e. high salt concentration and presence of 
heparin to compete non-specific RNA-binding, selectively dissociate the Ui snRNP from 
the splicing complexes. Therefore, under milder conditions, Ui snRNP could be 
detected in complexes A and B on sucrose gradients (Bindereif and Green, 1987), in 
gels (Zillmann et al., 1988) and in spliceosome fractions from gel filtration 
chromatography (Reed et al., 1988). 
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The U2 snRNA is present in complexes A and B (Grabowski and Sharp, 1986; 
Bindereif and Green, 1987; Konarska and Sharp, 1986), while U4, U5 and U6 snRNAs 
are present in B, but not A (Grabowski et al., 1986; Bindereif and Green, 1987; 
Konarska and Sharp, 1987). These results suggest that Ui and U2 snRNPs are present 
in complex A and that, in the transition to complex B, U5 and U4/U6 snRNPs join the 
forming spliceosome. 
When complex B can be resolved into two separate complexes, using /3-globin 
substrate, it is found that the faster migrating of these contains pre-mRNA and U2, 
U4, U5 and U6 snRNAs, while the slower migrating contains splicing intermediates and 
lacks U4 snRNA (Lamond et al, 1988). This suggests that U4 snRNP leaves the 
spliceosome just prior to, or concomitant with, step 1 of the reaction. However, since 
Ui snRNA cannot be detected in complexes in this gel system, it is possible that, in the 
active complex, the U4 snRNP is present, but can be dissociated under the 
electrophoresis conditions. However, these results show, at the very least, that some 
conformational change takes place just prior to, or at the same time as, step 1. 
1.7.1.2 Splicing Complex Formation 
With respect to the pre-mRNA sequence requirements for spliceosome 
formation, it has been shown that the polypyrimidine tract of the 3' splice site is 
essential (Frendeway and Keller, 1985; Bindereif and Green, 1986), while the AG 
dinucleotide is not necessary for, but enhances the efficiency of, complex formation 
(Frendeway and Keller, 1985). Early studies indicated that complex A could form in 
the absence of a 5' splice site (Frendeway and Keller, 1985; Konarska and Sharp, 1986), 
but it was later shown that the complex formed on such a substrate can be resolved as 
migrating faster on a non-denaturing gel than authentic complex A and, therefore, 
presumably lacks factor(s) present in complex A (Zillmann et al., 1988). Analysis of 
complex formation on substrates with point mutations at both 5' and 3' splice sites 
reveals that recognition of both is important for complex A assembly (Lamond et al., 
1987). 
As discussed in Section 1.5.1.2, the Ui snRNP binds to the 5' splice site region 
of the pre-mRNA. This interaction can occur at 0°C in the absence of ATP and, under 
splicing conditions, Ui is the first snRNP to associate stably with the substrate 
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(Bindereif and Green, 1987). Oligonucleotide-directed RNase H inactivation of U2 or 
U4 snRNPs has no effect on U1 binding, but immunodepletion of Ui snRNP inhibits 
subsequent binding of the other spliceosome snRNPs, indicating a key role for Ui 
snRNP binding in early complex assembly (Zillmann et al., 1987). However, Ui snRNP 
still associates with pre-mRNA which lacks a 5' splice site (Zillmann et al., 1987), 
suggesting that the initial interaction is not mediated by base-pairing between the Ui 
snRNA and the 5' splice site, but perhaps by recognition of sequences or factors at the 
3' end of the intron. This idea is supported by the finding that formation of the A-like 
complex on substrates lacking the 5' splice site still requires the presence of intact Ui 
snRNP (Zillmann et al., 1988). 
As was described in Section 1.5.1.2, the U2 snRNP binds to the branch-point 
region of the pre-mRNA in an ATP-dependent manner, this being a necessary step in 
complex A formation. Complex A formation is blocked by the directed cleavage of the 
5' end of the U2 snRNA, but not by cleavage of the region proposed to base-pair with 
the branch-point sequence (Zillmann et al., 1988). This indicates that the base-pairing 
interaction is not necessary for complex A assembly, so U2 snRNP must recognise pre-
bound Ui snRNP and factors at the 3' splice site, i.e. U2AF (see Section 1.6.1.2), IBP 
(see Section 1.5.1.3), hnRNP C-protein (see Section 1.6.1.1). Recognition of the 
branch-point by base-pairing must play a role in subsequent steps, as evidenced by the 
demonstration that certain point mutations in this sequence allow splicing complex 
assembly, but block step 1 of the reaction (Reed and Maniatis, 1988). 
To assemble complex B, the U4/U6 and U5 snRNPs must join the growing 
spliceosome. The ATP-dependent formation of a U4/U5/U6 snRNP complex has been 
detected (Konarska and Sharp, 1987; D. Black, personal communication) and this may 
represent an intermediate in spliceosome assembly. 
When step 2 of the splicing reaction has occurred, the products remain in 
ribonucleoprotein complexes, as assayed by centrifugation in sucrose gradients (Bindereif 
and Green, 1986). The spliced mRNA is released from snRNP-containing complexes, 
while the excised intron lariat appears to remain complexed with U2, U5 and U6 
snRNPs (Konarska and Sharp, 1987; Zillmann et al., 1988). 
Many studies have focussed on the protection of the pre-mRNA from 
degradation by RNases to analyse interactions with splicing factors through the course 
of splicing complex assembly and the splicing reaction (Black et al., 1985; Ruskin and 
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Green, 1985b; Chabot et al., 1985; Bindereif and Green, 1986; Chabot and Steitz, 
1987b; Zillmann et al., 1988). Some of the results have been discussed in Section 
1.5.1.2, whereby the 5' splice site is protected by the Ut snRNP and the 3' splice site 
factor by another, possibly U5 snRNP-associated, factor, both interactions occurring at 
0°C in the absence of ATP. Also, the branch-point region is protected by the U2 
snRNP in an interaction which requires incubation in the presence of ATP, i.e. splicing 
complex formation. 
In the transition from complex A to complex B, changes in the nature of these 
interactions are indicated by changes in the boundaries of the protected branch-point 
fragment (Chabot and Steitz, 1987b) and by an expansion of the protected fragment at 
the 5' splice site (Chabot and Steitz, 1987b; Bindereif and Green, 1987). Directed 
cleavage of U4 and U6 snRNAs has no effect on the pattern of fragment protection, 
so this approach gives little indication of the possible roles of these particular snRNPs 
in the spliceosome (Chabot and Steitz, 1987b). Following step 1 of the reaction, a 
protected fragment from exon 1 is detected, presumably reflecting the binding of a 
factor which holds this intermediate in the spliceosome in order for step 2 to take place 
(Chabot and Steitz, 1987b). 
1.7.2 Yeast Splicing Complexes 
1.7.2.1 Identification 
As in the mammalian case, yeast splicing complexes were initially identified by 
velocity sedimentation through glycerol gradients as 40S complexes which require ATP 
for formation and contain splicing intermediates (Brody and Abelson, 1985). They were 
subsequently analysed by non-denaturing gel electrophoresis (Pikielny and Rosbash, 
1986), whereby they could be resolved into three complexes, termed I, II and III, in 
order of increasing mobility (Pikielny et al., 1986). Complex III is the first to appear, 
then complex I and, finally, complex II, where the splicing intermediates are found, 
suggesting that they represent a pathway of spliceosome assembly. Splicing complexes 
have also been isolated by affinity chromatography, relying on interaction between a 
poly(A) tail on the substrate and immobilised oligo(dT) (Pikielny and Rosbash, 1986) 
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or on biotinylated substrate interacting with immobilised streptavidin (Kretzner et al., 
1987; Ruby and Abelson, 1988). 
Analysis of the snRNA contents of the complexes observed on gels revealed that 
complex III contains only U2, complex I contains U2, U4 and U5, while complex II 
contains U2 and U5 (Pikielny et al., 1986). As for the analysis of mammalian splicing 
complexes on non-denaturing gel systems, Ui was not detected, but it was shown to be 
a component of affinity purified spliceosomes (Kretzner et al., 1987; Ruby and Abelson, 
1988). Yeast U6 snRNA had not been described when the analysis of the complexes 
was undertaken, but it, also, was shown to be a component of spliceosomes (Ruby and 
Abelson, 1988). Therefore, all the yeast counterparts of the mammalian spliceosomal 
U-snRNPs are also components of the spliceosome. Moreover, the yeast U4 snRNP, 
like its mammalian homologue, appears to dissociate from the spliceosome just prior to, 
or at the same time as, step 1 of the reaction. 
1.7.2.2 Yeast Splicing Complex Formation 
All the mutations of the 5' splice site and branch-point sequences which abolish 
step 1 of the splicing reaction (see Section 1.4.2), also block spliceosome formation, 
while the 3' splice site is totally dispensible, as it is for step 1. A study which analysed 
the effects of chemical modifications, introduced at random in the pre-mRNA, on 
splicing complex formation revealed that the mutations in the conserved sequence 
elements can have effects at several levels of spliceosome formation and, therefore, 
suggested that these elements must be recognised more than once in the assembly 
process (Rymond and Rosbash, 1988). 
The yeast Ui snRNP, like its mammalian homologue, is the first to stably bind 
the pre-mRNA, for which an intact branch-point sequence, but no ATP, is required, 
and this association is necessary for the subsequent ATP-dependent binding of the U2 
snRNP (Ruby and Abelson, 1988). However, some pre-mRNA mutations which allow 
residual binding of Ui abolish U2 binding, so the binding of Ui snRNP is not sufficient, 
in itself, to direct the binding of the other snRNPs (Ruby and Abelson, 1988). The U2 
snRNP binds the branch-point by direct base-pairing with its snRNA component (Parker 
et al., 1987), but this base-pairing interaction is not necessary for early complex 
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formation (Rymond and Rosbash, 1988). For the transition of complex III to complex 
I, the U5 and U4/U6 snRNPs join the spliceosome. 
The 5' splice site and branch-point regions were found to be protected from 
oligonucleotide-directed RNase H cleavage in splicing complexes (Rymond and Rosbash, 
1986). Interestingly, the degree of protection of the 5' splice site increases during the 
complex III to complex I/TI transition, mirroring the results obtained in mammalian 
RNase protection studies (see Section 1.7.1.2). 
1.8 	CONTROL OF GENE EXPRESSION AT THE LEVEL OF PRE-mRNA 
SPLICING 
Alternative splicing of a pre-mRNA occurs when at least one pair of splice sites 
which are spliced together to form one mRNA are not spliced in formation of another, 
i.e. each may remain unspliced or be spliced to an alternative partner. Each alternative 
mRNA may encode a protein product, or may be inactive, due to the presence of an 
in-frame termination codon. 
In some cases, utilisation of alternative promoters or 3' end-processing sites 
results in pre-mRNA structures which dictate the subsequent choice of alternative splice 
sites. Such examples are beyond the scope of this discussion. Alternative mRNAs can 
be generated from a single pre-mRNA in several ways (reviewed in Breitbart et al., 
1987); (i) retention or excision of a single intron, (ii) splicing of alternative 5' splice 
sites to a single 3' splice site, or vice versa, (iii) the incorporation of one or other of 
a pair of mutually exclusive exons in the mRNA, or (iv) the retention or omission of 
a single exon. 
An example of regulated alternative splicing to produce different isoforms of the 
protein product is provided by the troponin T gene, where each of four short exons can 
be included or omitted and two further exons are mutually exclusive, giving rise, 
potentially, to 64 protein isoforms, in a developmental stage and tissue-specific pattern 
(Breitbart et al., 1985). The rat a-tropomyosin gene carries three pairs of mutually 
exclusive introns which are alternatively spliced to give mRNAs encoding the smooth 
or striated muscle or nonmuscie isoforms of the protein (Wieczorek et al., 1988). 
Examples where the retention of a particular intron results in failure to produce 
a functional mRNA include the inhibition of splicing of a pre-mRNA by the protein 
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product of the spliced mRNA, i.e. feedback autoregulation, which is observed in the 
expression of certain ribosomal protein genes (Amaldi et aL, 1989; Dabeva et al., 1986) 
and the suppressor-of-white-apricot gene of Drosophila melanogaster (Zachar et al., 
1987; Chou et al., 1987). Such on/off control of gene expression can be regulated in 
a tissue-specific manner, as evidenced by the Drosophila P-element whose transcript 
carries three introns, the last of which is only excised, to give functional transposase-
encoding mRNA, in germ-line cells (Laski et al., 1986). 
Perhaps the most striking example of regulated pre-mRNA splicing occurs in 
Drosophila sex determination, where a cascade of alternative splicing connects the initial 
signal, i.e. the ratio of X chromosomes to autosomes, to final sexual differentiation 
events (reviewed in Hodgkin, 1989). Two of the genes involved in this regulatory 
pathway, sx1 and Lra, only give rise to active protein products in females, while the dsx 
gene gives rise to different proteins in males and females, all as a result of alternative 
splicing. The sxl gene product acts to regulate splicing of its own pre-mRNA and to 
confer female-specific splicing upon the tra gene pre-mRNA. The tra gene product 
acts, in turn, to regulate alternative splicing of the dsx gene pre-mRNA to give rise to 
the female-specific protein. In males, alternative splicing means that there is no active 
sxl gene product and, hence, no active tra gene product. This results in splicing of the 
dsx pre-mRNA such that the male-specific protein is expressed. 
While alternative splicing could occur by an essentially random selection of splice 
sites, giving rise to a fixed ratio of different mRNAs, tissue or developmental 
stage-specific regulation of splicing must be controlled by the action of trans-acting 
factors. Such factors could act to specifically degrade certain alternative forms of mRNA 
or to modulate the selection of splice sites, either by altering the affinity of splicing 
factors for the alternative sites or by altering the pre-mRNA secondary structure, and 
hence the availability of alternative splice sites. Evidence that trans factors operate to 
modulate splice site selection is provided by the finding that only differentiated muscle 
cells give correct alternative splicing of troponin T pre-mRNA (Breitbart and 
Nadal-Ginard, 1987). 
Candidates for splicing factors which could regulate alternative splicing include 
snRNAs, since the expression of different subclasses of Ui and U4 has been shown to 
be subject to developmental stage and tissue-specific control (Forbes et al., 1984; Lund 
et al., 1985; Lund et al., 1987; Lund and Dahlberg, 1987; Korf et al., 1988)). A snRNP 
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protein, termed N, which is closely related to the B and B' core proteins, is expressed 
only in brain and, to a lesser extent, heart tissues (McAllister et al., 1988; 1989). 
SnRNP particles formed with alternative snRNA or protein components could have 
modified recognition properties which change their affinities for alternative splice sites. 
Analysis of -acting elements which can control splice site selection has been 
performed in vivo (e.g. Noble et al., 1988; Kedes and Steitz, 1988; Eperon et al., 1988), 
but attempts to reproduce the patterns of in vivo splice site selection in vitro have been 
unsuccessful (Noble et al., 1986; Lowery and van Ness, 1988). Identification and 
analysis of trans-acting factors requires that faithful, alternative splicing be achieved in 
vitro. 
1.9 	TRANS SPLICING 
Trans-splicing is the process by which cxons on distinct RNA transcripts, i.e. two 
"half-substrates", can be spliced together to give mRNA. That a mechanism might exist 
for such a reaction was first suggested by the finding that all mRNAs in the unicellular 
parasite Trypanosoma brucei share 35nt in common at their 5' termini (van der Ploeg, 
1986). The sequences encoding this "leader" occur in repetitive clusters and are 
transcribed to give 137nt RNAs with the leader sequence at their 5' ends, followed by 
a consensus 5' splice site, while the bodies of each mRNA carry 3' splice site consensus 
sequences near their 5' termini. Branched intermediates were detected, which indicated 
that trans-splicing does, indeed, take place, and that it occurs by a two-step pathway 
similar to that of -splicing (Murphy et al., 1986; Sutton and Boothroyd, 1986). This 
process is not limited to trypanosomes, as a 	-spliced leader is also present on as 
many as 10% of the mRNAs of Caenorhabditis elegans (Blumenthal and Thomas, 1988) 
and on the mRNAs of other nematodes (Bektesh et al., 1988). 
Two mechanisms for 	-splicing have been proposed. In the first, the 
half-substrates associate with one another by base-pairing between complementary 
regions within the intron" and are spliced as for the normal 	-reaction. In vitro 
studies showed that such a scheme was viable (Solnick, 1985: Konarska et al.,1985b), but 
no sequence complementarity exists between the leader RNA and the region upstream 
of the 3' splice site on the mRNA body in trypanosomes or nematodes. Low levels of 
trans-splicing were observed in vitro in the absence of base-pairing between the RNAs, 
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indicating that physical attachment of the two half-substrates was not a pre-requisite of 
the reaction (Konarska et at., 1985b). 
This led to the proposal that splicing factors could recognise, and bind, the two 
half-substrates independently and then coalesce to form the spliceosome (Sharp, 1987b). 
Support for this is provided by the finding that the C.elegans leader RNA forms into 
a snRNP particle, i.e. it carries a "domain A" Sm-binding site, is Sm-precipitable and 
carries a m 3  G cap structure (Thomas et at., 1988; van Doren and Hirsch, 1988; Bruzik 
et al., 1988). Thus, factors binding the 3' half-substrate may be recognised and bound 
by the leader snRNP, carrying the 5' exon with it, in the formation of the 
"-spliceosome". In this way, the leader snRNP may replace the Ui snRNP in such 
a reaction (Bruzik et al., 1988). Support for this notion is provided by the failure to 
detect an analogue of Ui snRNA in T.brucei, where all mRNAs are formed by 
trans-splicing (Mottram et at., 1989). 
1.10 PRE-mRNA SPLICING AND EVOLUTION 
A comparison of the mechanisms of splicing of introns of nuclear pre-mRNA 
and Group I and Group II introns reveals striking similarities (Cech and Bass, 1986). 
All occur by two-step reactions in which the first step involves nucleophilic attack of 
the 5' splice site phosphodiester bond, by a guanosine nucleotide for Group I splicing 
and by the 2' hydroxyl group of a residue near the 3' end of the intron for Group II 
and nuclear pre-mRNA splicing. The intermediates are, therefore, free exon 1 and 
intron-exon 2, in a linear form for Group I splicing and as a lariat for the other two 
types. The second step involves nucleophilic attack of the 3' splice site phosphodiester 
bond by the hydroxyl group on the 3' end of free exon 1 to give spliced RNA and 
excised intron. These mechanistic similarities strongly suggest that these three types of 
intron are related and, therefore, evolved from a common ancestor. 
There are examples of Group I and Group II introns which can undergo 
"self-splicing" reactions in vitro, i.e. without any requirement for protein. Since all 
introns of each type carry conserved primary and secondary structure elements, it is 
assumed that all such splicing occurs by an RNA-catalysed reaction, the rate of which 
is enhanced in vivo by the binding of proteins. The related nuclear pre-mRNA reaction 
may also occur by a process of RNA catalysis, where the catalytic RNA activity is 
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provided by snRNAs in the spliceosome, rather than, as for Group I and Group II 
intron self-splicing, by the intron itself. It is not difficult to envisage the evolutionary 
progression from a situation where the catalytic configuration is conferred by the 
secondary structure of the intron in association with specific proteins to one where such 
structures are provided in trans, i.e. by snRNPs. This limits the structural constraints 
on the intron to short conserved sequences, a situation which would greatly facilitate 
"exon shuffling" (see below). 
The possible origin of introns has given rise to considerable debate, resulting in 
the postulation of two conflicting theories. The first holds that genes originally evolved 
with discontinuous structures, i.e. introns were present, and that they have been lost 
from certain organisms, especially prokaryotes, as their genomes have become more 
streamlined for rapid DNA replication (Doolittle, 1978). The second theory suggests 
that introns have become added to genes after the divergence of eukaryotes and 
prokaryotes and, therefore, that prokaryotic genes resemble ancestral genes (Orgel and 
Crick, 1980). 
The revelation that RNA molecules act to catalyse certain reactions (reviewed 
in Cech and Bass, 1986; Cech, 1987) has led to the proposal that, prior to the evolution 
of protein synthesis, RNA served as both functional and informational molecule, i.e. the 
so-called "RNA world" (Gilbert, 1986). This theory states that self-splicing introns were 
an important component of such a world, acting, by 	-splicing, to allow RNA 
recombination. The discovery that the excised intron of Tetrahymena thermophila 
rRNA has enzymatic activity as a poly(C) polymerase (Zaug and Cech, 1986) led to the 
postulation of a scheme for RNA-catalysed replication of RNA (Cech, 1986) which 
lends considerable weight to the RNA-world theory. This model for pre-biotic evolution 
holds that genes originally evolved with discontinuous structures and that introns were 
subsequently eliminated. 
Evidence that introns pre-dated the divergence of prokaryotes and eukaryotes 
has been provided by the discovery of introns in prokaryotic genes (reviewed in Schmidt, 
1985) and from studies of chloroplast genes (Shih et al., 1988), while the elimination 
of introns has been well-documented (e.g. Perler et al., 1980). However, it is clear that 
certain introns can spread by DNA recombination (reviewed in Lambowitz, 1989) 
suggesting that the pattern of introns which exists today is the result of conflicting 
processes of insertion and elimination. 
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Several direct selective pressures may have played roles in the retention of 
introns in eukaryotic genes. Firstly, as discussed in Section 1.9, gene expression can be 
controlled at the level of splicing. Secondly, other steps in mRNA biogenesis, e.g. 
nuclear-cytoplasmic transport, have co-evolved with splicing and may, in some instances, 
be dependent upon it. Thirdly, certain introns may be retained because they contain 
important functional elements at the DNA level, e.g. enhancers or promoters (e.g. 
Bornstein and McKay, 1988). However, although the expression of some genes requires 
the presence of an intron (e.g. Buchman and Berg, 1988), the expression of others 
does not (Treisman et al., 1981; Ng et al., 1985). 
One further postulated selective pressure to retain introns is the scope for 
assortment of exons provided by non-homologous recombination within introns which 
could serve to generate diversity during evolution (Gilbert, 1978; 1985). Support for 
such an "exon-shuffling" evolutionary mechanism is provided by the discovery that many 
exons correspond to functional or structural protein domains or modules (Gilbert et al., 
1986) and that exons encoding related domains can be found in genes encoding 
unrelated proteins (Sudhof et al., 1985). 
1.11 THIS THESIS 
The PRP8 gene was cloned in this laboratory and the generation of antisera to 
J9-galactosidase-PRP8 fusion proteins allowed identification of the protein gene product 
(Jackson et al., 1987). In this thesis, I present the following: 
generation and characterisation of antisera to further /3-galactosidase-PRP8 
fusion proteins. 
demonstration that the full-length PRP8 protein is a component of the yeast U5 
snRNP particle and that a U4/U5/U6 snRNP complex forms in yeast splicing 
extracts in an ATP-dependent manner. 
analysis of the molecular interactions of the PRP8 protein, demonstrating 
putative RNA-binding properties. 
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(iv) identification of a PRP8 analogue in HeLa cell extracts, which is associated with 
the human U5 snRNP and also possesses RNA-binding properties. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Suppliers of Laboratory Reagents 
Restriction enzymes and other DNA modifying enzymes: 
Amersham International, Bethesda Research Laboratories, Boehringer Mannheim, New 
England Biolabs and Pharmacia. 
Deoxyribonucleotides and dideoxyribonucleotides: 
Pharmacia. 
Ribonucleotides; 
Sigma and Pharmacia. 
Acrylamide and NN'-methylene bisacrylamide: 
BDH Chemicals, "Electran" grade. 
Agarose, Ultra-Pure Agarose and Low Melting-Point Agarose: 
SeaKem and BRL. 
Media reagents: 
Difco Labs. 
Standard laboratory reagents (analytical grade, or better): 
BDH, Fisons, Sigma, May and Baker, Koch-Light, Bio-Rad and Serva. 
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2.1.2 Growth Media 
All quantities listed are for 1 litre, unless otherwise stated. 	Solutions are 
autoclaved (see Section 2.2.2) and stored at room temperature. Antibiotic and amino 
acid stock solutions were added to media immediately before use. 
2.1.2.1 E. coli Media 
Luria broth (LB): 	 lOg Bacto-Tryptone (Difco), 
5g yeast extract (Difco), lOg NaCl, adjusted to 
pH7.2 with NaOH. 
Luria-agar (LB-agar): 	LB plus 15g agar (Difco). 
LB/ampicillin: 	 LB plus 0.1mg/mI ampicillin. 
Spizizen minimal agar: 	2g (NH4)SO4, 14g K2HPO4, 6g KH2P041  ig Na3  
citratc.31120, 0.2g MgS049  2g glucose, 2mg vitamin 
Bi, 15g agar (Difco). 
M9+CA medium: 	6g Na2HPO4.H20, 3g KH2PO4, 0.5g NaCl, ig 
NH4CI, 5g casamino acids (Difco), 2g glucose, 
10mg vitamin Bi, 0.25g MgSO4.7H20, 22mg 
CaC12.7H20. 
M9+CA+W medium: 	M9+CA medium plus 20mg tryptophan. 
Ampicillin stock: 	 0.1g/ml; stored at -20°C. 
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2.1.2.2 Yeast Media 
lOg Bacto-Tryptone (Difco), 20g Bacto-Peptone 





YPDA plus 20g agar (Difco). 
YPDA plus 216g sorbitol. 
6.7g yeast nitrogen base without amino acids 
(Difco), 20g glucose (supplemented with amino 
acids to 20mg/I as required). 
YMM plus 20g agar (Difco). 
amino acid stocks: 	4mg/ml in dH20; filter sterilised and stored at 4°C. 
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2.1.3 Bacterial Strains 
All strains were derivatives of E. coli K-12. 
TABLE 2.1 Bacterial Strai 
Strain 	Genotype 
HB101 	F, hsdS20((B,mB), recA13 
Ara-14, proA2, lacYl, gjjç 
rpsL2O(Sm'), 	mtl-1, 
supE44. 
DH5 	F, recAl, endAl, gyrA96, 
thil, hsdR17(rK,mK), 
supE44. 
BMH71-18 	A(lac, pm), thi, supE, 
F'(lacI ,  lacZ !!M15, p) 
pop2136 	endA, thi, hsdR1,XcI 7. 







Messing et al. (1977) 
K. Stanley (pers. comm.) 
33 
2.1.4 Yeast Strains 
TABLE 2.2 Yeast Strains 
Strain 	Genotype 	 Source 
BJ2412 	 , 	, 	 E. Jones (Pittsburgh) 
jLrpl, g, pep4-3, 
prbl-1 122, prcl-407. 
SPJ8.31 	al  prp8-1, ura3-52, 	S. Jackson (this laboratory) 
i, bi. 
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2.1.5 Plasmid Vectors and Constructs 
TABLE 2.3 Plasmid and Phagemid Vectors 
Vector 	Description 	 Source 	Reference 
pEX-1 	E. coli plasmids; multiple 	- 	 Stanley and 
pEX-2 cloning sites in 3' end of Luzio (1984). 
pEX-3 	lacZ gene, ampA.  For 
synthesis heat-inducible 
,6-gal fusion proteins in 
strain pop2136. 
pUR278 E. coli plasmids; D. Lane Ruther and 
pUR288 multiple cloning sites (ICRF, Muller-Hill 
pUR289 in 3' end of lacZ gene, Clare Hall) (1983). 
pUR290 amp A.  For synthesis of 
pUR291 IPTG-inducible 13-gal 
pUR292 fusion proteins in 
strain BMH71-18 or NM522. 
pATH-i E.coli plasmids; D.Finnegan Dieckmann 
pATH-2 multiple cloning sites in 3' (Edinburgh) and 
pATH-3 end of !ME gene, ampA. Tzogaloff 
for synthesis of IAA-inducible (1985) 
TrpE fusion proteins. 
pEMBL8(+) E. coli phagemids; N. Murray Dente et al. 
pEMBL9(+) multiple cloning sites (Edinburgh) (1983) 
in segment of lacZ gene 
coding for a-peptide of 13-gal; 
amp R. 	Fl bacteriophage origin, 
allows synthesis of single-stranded 
phagemid DNA. Propagated in strain NM522. 
YEp24 intermediate copy number D. Botstein Botstein 
yeast plasmid; URA3; 2jtm (M.I.T.) (1979) 
replication origin. E. coli 
plasmid; 	ampR.  
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pSP64-HBt6 pSP64 with human /3-globin A.Krainer Kramer et al. 
gene downstream of 	(Harvard) (1984) 
SP6 promoter. 
pSPrp5lApA pSP62 with yeast RP51A 	C.Pikielny Pikielny et al. 
gene (with region 	(Brandeis) (1986) 
encoding poly-A tail) 
downstream of SP6 promoter. 
pY8000 YEp24 with 9.0kb insert 	S.Jackson Jackson et al. 
containing entire PRP8 	(this lab) (1988). 
gene. 
pY85888 YCp50 with 7.6kb insert 	" 
containing all but last 3 
codons of PRP8 gene. 
pY8712 pSPT18 with 1.3kb S.Jackson 
HindIII-BamHI fragment from (PhD thesis). 
5' end of PRP8 gene. 
pFP8.1 pUR290 with 1.3kb 	" Jackson et al. 
BglII fragment of PRP8 gene. (1988). 
pFP8.2 pUR290 with 2.4kb 
BglII fragment of PRP8 gene. 
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2.1.6 Miscellaneous Materials 
2.1.6.1 Antisera 
Antisera against FP8.1 (rabbits 46 and 47) and FP8.2 (rabbits 42 and 43) were 
raised by S. Jackson in this laboratory (Jackson et al., 1988). 
Antibodies (purified by ammonium sulphate precipitation) against the m3G cap 
structure were a gift from R. LUhrmann (Marburg). 
Human Sm-sera were provided by I. Mattaj (Heidelberg; Sm- "Kung"), D. Black 
(Yale; Sm-JE) and M. Dalrymple (this lab; Sm #24). 
2.1.6.2 DNA Oligonucleotides 
Yeast U2: 5'-CTACACTFGATCFAAGCCAAAAGGC-3' 
Yeast U4: 5'-TTTCAACCAGCAAA-3' 
Yeast U6: 5'-TC(T/A)TCTCTGTATFG-3' 
Human U4: 5'-GGAAAAGTITICAATFAG-3' 
Human U5: 5'-GACTCAGAGTTGTTC-3' 
Human U6: 5'-GGCYJ'CACGAA1TFGCGT-3' 
DNA oligonucleotides were custom synthesised by the OSWEL DNA Service 
(Department of Chemistry, Edinburgh) or by the ICRF (Clare Hall) oligonucleotide 
synthesis service, except the oligonucleotide complementary to yeast U6 snRNA which 
was a gift from D.Brow (UCSF) and that complementary to yeast U2 snRNA which was 
a gift from D.Field (Toronto). 
2.1.6.3 Others 
Purified yeast polyadenylate-binding protein was a gift of A.Sachs (Stanford 
Medical School). 
HeLa cell nuclear extract was provided by P. Sharp (MIT.). 
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2.2 	GENERAL METHODS 
2.2.1 General Guidelines 
Unless otherwise stated all small-scale procedures were performed in 1.5m1 
polypropylene microfuge tubes (handled only with gloved hands and sterilised by 
autoclaving at 120°C, 15psi for 15 minutes), while large-scale procedures were performed 
in 15ml or 30m1 Corex tubes (sterilised by baking at 250°C for 16 hours) or 10m1 or 
50m1 Falcon tubes (sterile when purchased). Liquids were dispensed using Gilson 
Pipetman P-20, P-200 and P-bOO automatic pipettors and tips (sterilised as for 
microfuge tubes) or glass pipettes (sterilised as for Corex tubes). All procedures were 
performed at room temperature unless otherwise stated. 
Centrifugation of volumes less than 1.5ml was performed in an Eppendorf 
microfuge at 13,000rpm (13,800g), centrifugation of volumes up to 50m1 was performed 
in an IEC Centra-4X bench-top centrifuge with swing-out rotor, a MSE Minor 'S' 
bench-top centrifuge with fixed-angle rotor or a Sorvall RC-5B centrifuge with HB-4 
swing-out rotor or SS-34 fixed-angle rotor (all at speeds specified for particular 
methods), while larger volumes were centrifuged in a Sorvall RC-5B centrifuge with 
GS-A or GS-3 rotors (speeds again as specified for particular methods). A Beckman 
OTD55B ultracentrifuge with a Ti50 rotor was used for ultracentrifugation. 
2.2.2 Preparation and Sterilisation of Solutions 
All solutions were prepared using distilled or double-distilled water and (for 
stock solutions) were filtered through Whatman No.1 filter-paper. Most solutions were 
sterilised, either by autoclaving at 120°C, 15psi for 15 minutes or by filtration through 
Acrodisc filter-sterilisation units (0.45gm pore-size; Gelman Sciences). Solutions were 
stored at room temperature unless otherwise stated. 
2.2.3 Deionisation of Solutions 
Solutions were deionised where necessary (as stated in particular methods) by 
treatment with 0.1 volume of mixed-bed ion-exchange resin (20-50 mesh, Bio-Rad 
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Laboratories) for 30 minutes at room temperature with stirring. The resin was then 
removed by filtration through Whatman No.1 filter-paper. 
2.2.4 Autoradiography 
[32P]-labelled nucleic acids, in gels or on filters, were detected by exposure of 
X-ray film (Du Pont Cronex or Amersham Hyperfilm-MP) in light-proof lead-shielded 
cassettes by one of the following methods, depending on the amount of radioactivity in 
the gel or on the filter: (in order of increasing sensitivity) (i) at room temperature; (ii) 
at -70°C with a calcium-tungstate intensifying screen; (iii) with pre-flashed film at -70°C 
with an intensifying screen (Laskey, 1984). 
[35S]-labelled nucleic acids, in a fixed and dried gel, were detected by exposure 
of X-ray film (Cronex) at room temperature, without an intensifying screen. 
[35S]-labelled proteins, in a dried gel impregnated with Amplify, were detected 
by exposure to pre-flashed X-ray film (Cronex or Hyperfilm) at -70°C, without an 
intensifying screen. 
2.2.5 Dialysis Tubing 
Dialysis tubing (Medicell International Ltd.) was prepared by boiling in a large 
volume of 2% (w/v) sodium bicarbonate, 1mM EDTA for 10 minutes, rinsing thoroughly 
in dH20 and boiling for 10 minutes in dH20 and was stored at 4°C in 50% (vlv) 
ethanol. Before use, the tubing (which was always handled with gloved hands) was 
washed, inside and out, with dH20. 
2.2.6 Buffers 
TE buffer: 	10mM Tris-HCl (pH7.5), 1mM EDTA; autoclaved. 
lOx TBE buffer: 	0.9M Tris-borate (pH8.3), 20mM EDTA; unsterilised. 
lOx TAE: 	 0.4M Tris-acetate (pH7.5), 20mM EDTA; unsterilised. 
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20x SSC: 	 3M NaCl, 0.3M Na3citrate, adjusted to pH7.0 with NaOH: 
unsterilised. 
lOx PBS: 	 15mM KH2PO4, 80mM K2HP041  1.5M NaCl, pH7.2; 
autoclaved. 
IN TBS: 	 0.5M Tris-HCl, 1.5M NaCl, pH7.5; autoclaved. 
2.3 	MICROBIOLOGICAL METHODS 
All procedures were performed under conditions of "Good Microbiological 
Practice" as recommended by the U.K. Genetic Manipulation Advisory Group. 
23.1 Growth and Storage of E. coli 
E. coli cells were grown at 37°C, except for transformed cells of strain pop2 136 
which were grown at 30°C. Untransformed strains HB101, DH5 and pop2136 were 
maintained on LB-agar plates and strains NM522 and BMH71-18 on Spizizen minimal 
agar plates. Transformed strains were maintained on LB/ampicillin-agar plates to select 
for plasmid-conferred resistance. Liquid cultures in LB or LB/ampicillin medium were 
continuously shaken and growth monitored by determination of the OD 6nm• Cells 
in colonies on the surface of inverted agar medium plates remained viable at 4°C for 
up to 1 month, while long-term storage was achieved by making a saturated liquid 
culture 15% (v/v) in glycerol and freezing at -70°C. 
2.3.2 Growth and Storage of Yeast 
Yeast cells were propagated as described by Sherman et al. (1983). 
Temperature-sensitive pr98-1 strains were grown at 23°C, while all other strains were 
grown at 30°C. Untransformed strains were maintained on YPDA-agar plates, 
transformed strains on YMM-agar supplemented with the appropriate amino acids to 
allow growth and to select for retention of the plasmid. Liquid cultures in 'YPDA or 
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supplemented YMM medium were continuously shaken and growth monitored by 
determination of the OD.nm.  Cells in colonies on the surface of inverted agar 
medium plates remained viable for at least 1 month at 4°C, while long-term storage was 
achieved by making a saturated liquid culture 15% (v/v) in glycerol and freezing at 
-70°C. 
2.4 	NUCLEIC ACID METHODS 
2.4.1 Storage of Nucleic Acids 
Double-stranded plasmid DNA was stored at 4°C, while single-stranded template 
DNA and DNA oligonucleotides were stored at -20°C. 
2.4.2 Quantitation of Nucleic Acids 
The OD.nm  of the nucleic acid solution was determined in a Perkin-Elmer 320 
spectrophotometer and its concentration calculated by assuming that an OD.6flm  of 1.0 
corresponds to 50jgJml of double-stranded DNA and to 40igIml of single-stranded 
DNA or RNA. Alternatively, the concentration of a double-stranded DNA solution 
was estimated by comparing the intensity of fluorescence of the unknown DNA with 
that of standard DNA solutions in an agarose mini-gel (see Section 2.4.6). 
2.4.3 Deproteinisation of Nucleic Acid Solutions 
Aqueous nucleic acid solutions were deproteinised by extraction with phenol and 
chloroform. An equal volume of phenol/chloroform was added to the nucleic acid 
solution and the phases mixed by vortexing (or, for larger DNAs, by gentle shaking). 
The phases were separated by centrifugation in a microfuge (13,800g) or Sorvall SS-34 
rotor at 10,000rpm (12,000g) for 2-5 minutes and the upper (aqueous) phase transferred 
to a fresh tube. Extraction with phenol/chloroform was repeated as necessary (until no 
material was observed at the phase interface following centrifugation) and the procedure 
was then repeated with chloroform to remove any residual phenol. The nucleic acid 
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was subsequently ethanol precipitated (see Section 2.4.4) to remove any residual 
chloroform. 
Phenol was redistilled and stored under dH20 at -20°C. For extractions of 
DNA solutions phenol was pre-equilibrated with 1M Tris-HCl (p118.0) and stored under 
TE buffer at 4°C. For extraction of RNA solutions phenol equilibrated with dH20 was 
used. 	Chloroform was mixed 24:1 (v/v) with isoamyl alcohol and stored at room 
temperature. 
2.4.4 Ethanol Precipitation of Nucleic Acids 
To precipitate nucleic acid from an aqueous solution, 0.1 volumes of 3M sodium 
acetate (pH5.2) or 0.025 volumes of 4M NaCl and 2.5 volumes of ethanol were added 
and the mixture incubated at 4°C for >10 minutes or at -20°C for >1 hour. The 
precipitated nucleic acid was recovered by centrifugation in a microfuge (13,800g) or 
Sorvall HB-4 rotor at 10,000rpm (16,000g) for >15 minutes at 4°C. The pellet was 
washed by resuspending it in 70% ethanol and recovering by centrifugation as above. 
Following the wash step as much of the supernate as possible was drained off and the 
pellet was dried under vacuum. The nucleic acid could then be re-dissolved in the 
desired volume of the appropriate buffer. 
2.4.5 Restriction Endonuclease Digestion of DNA 
DNA was incubated with a greater than 2-fold excess of restriction endonuclease 
in the buffer recommended by the enzyme's manufacturer with the volume of the 
enzyme stock solution added not exceeding 10% of the total volume. Incubations were 
continued for at least one hour at the temperature recommended by the manufacturer. 
Reactions were terminated by heat-inactivation of the enzyme at 65°C for 10 minutes 
and/or by phenol/chloroform extraction. 
2.4.6 Agarose Gel Electrophoresis of DNA 
Horizontal 0.7-1.5% agarose slab gels were prepared by heating the agarose in 
TAB buffer to dissolve it, allowing it to cool to approximately 50°C and adding ethidium 
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bromide to 0.5 jig/mi before casting the gel. 20x20x0.7cm submerged gels were used for 
preparative and most analytical purposes while 9x13x0.4cm gels with filter paper wicks 
were used for some analytical purposes. Before loading, 0.2 volumes of 30% glycerol, 
0.25% bromophenol blue was added to the sample and the gel was run in TAE buffer 
at 5-20 V/cm. DNA was visualised on a 254nm (short wavelength) UV transilluminator 
and, if required, photographed through a red filter using Ilford HP5 5x4 inch negative 
or Polaroid 667 positive film. 
2.4.7 Recovery of DNA Fragments from Agarose Gels 
2.4.7.1 Electroelution 
The following method is based on one described in Maniatis et al., (1982). For 
preparative gels, Ultra-Pure Agarose was used in order to reduce impurities which, if 
carried over in the recovered DNA, might impair subsequent reactions, e.g. ligation. 
For the purpose of this method, ethidium bromide was added to the electrophoresis 
buffer at 0.5pglml. After electrophoresis, DNA bands were visualised under a 
long-wavelength UV lamp (300-360nm) in order to minimise damage to the DNA. 
When the required fragment was well enough separated from any other fragments, the 
current was switched off and the buffer removed until it was below the level of the gel 
surface. Directly in front of the band of interest, a trough was cut in the gel, 5mm 
wider than the band on either side. A piece of dialysis tubing was inserted and pushed 
underneath the gel such that it formed a floor to the trough and a wall at the side 
furthest from the DNA band. The trough was filled with buffer from the tank and the 
current switched on. Under the UV light it was possible to observe the band eluting 
out of the gel into the trough and, when this was complete, the current was reversed 
briefly to release the DNA from the dialysis tubing. The current was switched off and 
the buffer from the trough recovered. This buffer, containing the eluted DNA, was 
phenol/chloroform extracted, ethanol precipitated and the purified fragment redissolved 
in TE buffer. 
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2.4.7.2 Ground Glass Method 
DNA fragments were recovered from excised agarose gel pieces using the 
"GENECLEAN" kit (BlO 101 Inc.) precisely as dictated in the manufacturer's 
instructions. 
2.4.8 Denaturing Acrylamide Gel Electrophoresis 
Denaturing (sequencing-type) acrylamide gel electrophoresis of DNA and RNA 
was performed as described by Sanger and Coulson (1978). To give gels of the desired 
percentage polyacrylamide/7M urea in 1xT13E buffer, 9/10 volume stock solutions were 
prepared (e.g. 6.67% (w/v) aciylamide:bisacrylamide (20:1), 7.78M urea for a final gel 
of 6% polyacrylamide/7M urea), deionised, filtered and stored at 4°C. 	Gels were 
prepared by mixing 45m1 of the stock solution with 5m1 10xTBE buffer, 0.4m1 10% (w/v) 
ammonium persulphate (freshly prepared) and 40l of TEMED and pouring between 
two 42x23cm glass plates separated along their edges by 1x42cm strips of 0.4mm-thick 
modeller's Plastikard (Slater's Plastikard, Matlock, U.K) and sealed with PVC tape. A 
Plastikard slot-forming comb (cut to give 1cm-wide wells) was inserted in the top of the 
gel and polymerisation was allowed to proceed for at least 1 hour. To run the gel, the 
PVC tape sealing the bottom edge of the plates was removed, the slot-forming comb 
withdrawn and the gel placed in the electrophoresis tank filled with 1xTBE buffer. 
After the gel was pre-electrophoresed for 30-60 minutes, the samples were denatured 
by heating to 90°C for 2 minutes in urea load buffer (10M urea, 1xTBE buffer, 0.1% 
(w/v) bromophenol blue, 0.1% (w/v) xylene cyanol; the urea was deionised before the 
addition of the other components and the final mixture was filter sterilised and stored 
at -20°C) and loaded, using a drawn-out glass capillary. Electrophoresis was continued 
at 30-35W until the bromophenol blue and xylene cyanol marker dyes had migrated an 
appropriate distance. 
2.4.9 Purification of DNA Oligonucleotides 
DNA oligonucleotides were purified from denaturing polyacrylamide gels by 
electroelution. An aliquot of the crude oligonucleotide preparation containing 1.5-2.5 
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OD. nm  units of DNA was dried down in a vacuum desiccator. The DNA was 
redissolved in 1jl of ddH20, 2il of urea load buffer was added and the sample 
denatured and loaded onto a 1cm-wide well in a 0.8mm-thick 12% polyacrylamide/urea 
gel (see Section 2.4.8, the double thickness being achieved by the use of double 
side-spacers and comb). Electrophoresis was carried out at 30W until the bromophenol 
dye had run approx. 30cm, the gel plates were removed and the gel placed, on Saran 
Wrap, on a fluorescent thin-layer chromatography (t.l.c.) plate. 	Under a 
short-wavelength UV light, the DNA was visualised as dark shadows against the 
fluorescent background and the full-length species was excised using a scalpel. The 
DNA was recovered from the gel piece by elution in the "BioTrap" equipment 
(Schleicher & Schuell) in 1xTBE buffer at 200V for >1 hour. The sample was 
collected from the "trap", diluted to lml with dH20 and desalted over a Sephadex G-25 
column (NAP-b, Pharmacia). This involved pre-equilibrating the column with 2 bed 
volumes of 10mM potassium phosphate (pH7.5) followed by 2 bed volumes of dH20. 
The sample was loaded in a volume of lml, eluted in a volume of 1.5m1 of dH20 and 
dried down in the vacuum desiccator. The purified oligonucleotide was dissolved in 
l°Ml of dH20 and stored at -20°C. 
2.4.10 Filling-in of Recessed 3'-termini of DNA 
Recessed 3'-termini were filled using the DNA polymerising activity of the 
Klenow fragment of E. coli DNA polymerase I. The reaction was performed on the 
restriction fragment (up to 1jg of DNA) in 251.il of buffer as follows; 50mM Tris-HCI 
(pH7.5), 10mM MgSO4, 0.1mM DT!', 50jig/ml BSA, 80/.LM of each of dATP, dCTP, 
dGTP and dTTP. 2 units of Klenow fragment were added before the reaction was 
incubated at 22°C for 15-30 minutes and terminated by heating to 70°C for 5 minutes 
to inactivate the enzyme. 
2.4.11 Ligation of DNA 
Vector and insert DNA fragments were mixed in the molar ratio 1:3 with the 
vector DNA at a concentration of approx. lOugIml for cohesive ends and in excess of 
100jg/ml for blunt ends. This DNA mixture was ethanol precipitated and redissolved 
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in 10l of ligation buffer (20mM Tris-HCI (pH7.6), 10mM MgC121  10mM D11T and 
0.6mM ATP with the addition of 15% PEG 6000 for blunt end ligations [Pheiffer and 
Zimmermann ,1983]). T4 DNA ligase (1-5 units) was added and the reaction incubated 
at 15°C overnight (for cohesive ends) or 22°C for 1 hour (blunt ends). A portion of 
the reaction mix was used directly for transformation of E. coli cells (see Section 2.4.12). 
2.4.12 Transformation of E. coli Cells 
2.4.12.1 Preparation of Competent Cells (except strain pop2136) 
Transformation of E. coli strains, other than pop2 136, was performed by a 
method based on that of Hanahan (1985). Cells were streaked onto a LB-.agar plate 
and grown overnight at 37°C and a single colony was picked into 7m1 of LB. This 
culture was grown with vigorous shaking at 37°C until it reached an OD.6flm  of 
approx. 0.3 and 5ml was then used to inoculate lOOml of LB and this second culture 
grown as above to an OD. nm  of approx. 0.45 before being transferred to a pre-chilled 
50m1 Falcon tube and left on ice for 15 minutes. 	Cells were harvested by 
centrifugation in a IEC Minor 'S' bench-top centrifuge at 3,000rpm (1,000g) for 5 
minutes at 4°C and washed once, by resuspension and centrifugation (as above), with 
TFBI (100mM RbCl, 50mM MnC12, 35mM sodium acetate, 10mM CaCl2, 15% (vlv) 
glycerol (pH5.8); filter sterilised). 	The cells were collected by centrifugation, 
resuspended in 30m1 of ice-cold TFBI, incubated on ice for 20 minutes, collected once 
more by centrifugation and resuspended in 4ml of TFBII (10mM MOPS (p116.8, 
adjusted with KOH), 10mM RbC1, 75mM CaCl2, 15% (vlv) glycerol; filter sterilised). 
After a further 20 minute incubation on ice the cells were competent for DNA uptake 
and were either used immediately or were snap-frozen in N20) and stored for future 
use at -70°C. 
2.4.12.2 Preparation of Competent Cells of Strain pop2136 
Cultures were grown and harvested as for other strains (Section 2.4.12.1) and 
then resuspended in 30m1 of ice-cold 100mM CaCl2 and incubated for 1 hour on ice. 
The cells were collected by centrifugation, resuspended in lml of ice-cold 100mM CaCl2 
and used immediately or stored for up to 24 hours on ice (but not frozen). 
2.4.12.3 Transformation of Strains HB101, DH5, NM522 and BMH71-18 
Aliquots of competent cells (0.2m1) prepared as above (Section 2.4.12.1) were 
mixed with 20-100ng of DNA, either ligation reaction mix (Section 2.4.11) or plasmid 
preparation (Section 2.4.14), and incubated on ice for 30 minutes. The mixture was 
transferred to a small glass test-tube and heated to 42°C in a water-bath with shaking 
for 2 minutes before being returned to ice for 1 minute. The mixture was diluted with 
0.8m1 of LB and incubated at 37°C on a rotating wheel for 1 hour. Aliquots of this 
transformed cell suspension were spread onto LB-agar/ampicillin plates and incubated 
overnight at 37°C. 104 to 107  transformants were obtained per 1g of supercoiled 
pBR322 plasmid DNA used. 
2.4.12.4 Transformation of Strain pop2136 
DNA (20-100ng) was added to 0.1ml aliquots of competent cells prepared as 
above (Section 2.4.12.2) and incubated at 4°C for 10 minutes. The cells were 
heat-shocked at 34°C for 5 minutes before 0.9m1 of LB was added. Incubation at 34°C 
was continued for 20 minutes before aliquots of the transformed cell suspension were 
streaked out on LB-agar/ampicillin plates and incubated overnight at 30°C. Up to 106 
transformants were obtained per lj.tg of supercoiled pBR322 plasmid DNA used. 
2.4.13 Transformation of Yeast Cells 
Yeast cells were transformed by the method of Ito et al. (1983). Cells were 
grown overnight in YPDA to stationary phase, at 23°C for temperature sensitive strains 
and at 30°C for others. 0.5m1 of this culture was used to inoculate 50m1 of YPDA and 
the culture grown at the appropriate temperature until the OD.nm  reached approx. 
0.4 (about 8.5x106 cells/ml). The cells were harvested by centrifugation in a 50m1 
Falcon tube in a Centra 4-X bench-top centrifuge at 3,000rpm (1,600g) for 5 minutes 
at room temperature. The cell pellet was resuspended in 5ml of TE buffer, 
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re-centrifuged as above, resuspended in a further 5m1 of TE buffer, 0.208m1 of 2.5M 
Li acetate was added to give a final concentration of 0.1M and the cells were incubated 
at the appropriate temperature (23°C or 30°C) for 1 hour with gentle shaking. DNA 
(1-10j.ig in 0.lml) was added to 0.2m1 aliquots of the cells and the incubation continued, 
without shaking, for 30 minutes before 0.7ml of 50% (w/v) PEG 4000 was added (to 
give a concentration of 35% (w/v)). The mixture was incubated for a further 1 hour 
at the same temperature as before and then heated to 42°C for 5 minutes. The cells 
were collected by centrifugation in a microfuge (13,800g) for 30 seconds at room 
temperature, resuspended in sterile H20, spun down again, resuspended in 0.1ml of 
sterile 1120 and streaked out on a YMM-agar plate supplemented to select 
transformants. 	The plates were incubated at 23°C or 30°C as appropriate and 
transformants were usually visible after 3 days. 
2.4.14 Preparation of Plasmid DNA from E.coli Cells 
2.4.14.1 Small-scale Rapid Alkaline Extraction of Plasmid DNA 
This was performed by a method slightly modified from that of Birnboim and 
Doly (1980). Plasmid-carrying E.coli cells were grown overnight in 2ml of LB/ampicillin 
medium, 1.5m1 of the culture was transferred to an Eppendorf tube and the cells spun 
down by centrifugation in a microfuge (13,800g) for 30 seconds at room temperature. 
The cell pellet was resuspended in 0.1ml of lysis solution (2mg/mi lysozyme, 10% (w/v) 
glucose, 25mM Tris-HCI (pH8), 10mM EDTA; freshly prepared) and incubated on ice 
for 30 minutes. 	The cells were then lysed by addition of 0.2m1 of alkaline SDS 
solution (1% (w/v) SDS, 0.2M NaOH; freshly prepared) followed by incubation on ice 
for 5 minutes, then 0.15m1 of 3M sodium acetate (pH4.8) was added and the incubation 
continued for a further 60 minutes on ice. Centrifugation in a microfuge (13,800g) for 
5 minutes at room temperature was performed in order to spin out the cell debris and 
chromosomal DNA and the supernate was subsequently subjected to a 
phenol/chloroform extraction and ethanol precipitation. 	The DNA pellet was 
redissolved in 40jil of TE buffer containing 100g/ml RNase A (lmgIml stock solution 
prepared by boiling for 15 minutes to inactivate DNases and stored at -20°C) and 
incubated at 37°C for 30 minutes to digest RNA present in the preparation. This 
procedure routinely yielded in excess of 1tg of plasmid DNA which was suitable for 
restriction analysis or cloning procedures. 
2.4.14.2 Intermediate-Scale Alkaline Extraction of Plasmid DNA 
This method constitutes a scaled-up version of that described for the small-scale 
preparation in Section 2.4.14.1. Cells were grown overnight as before but in a volume 
of 40m1 and harvested by centrifugation in a Sorvall SS-34 rotor at 5,000rpm (3,000g) 
for 5 minutes. The procedure followed that described above except that the following 
volumes were used; 0.8m1 lysis solution, 1.6m1 alkaline SDS solution and 1.2m1 sodium 
acetate (p114.8). The cleared supernate (after centrifugation in a Sorvall SS-34 rotor 
at 12,000rpm [17,000g] for 5 minutes) was phenol/chloroform extracted, ethanol 
precipitated, the nucleic acid pellet redissolved in 0.4m1 of TE buffer and 10l of 
lmg/ml RNase A added. After 30 minutes incubation at 37°C, 40il of 3M sodium 
acetate (pH4.8) was added and the solution phenol/chloroform extracted and ethanol 
precipitated (centrifugation steps now being performed in a microfuge [13,800g]). The 
DNA pellet was finally dissolved in 0.1ml of TE buffer. This procedure yielded in 
excess of 20jg of plasmid DNA. 
2.4.14.3 Large-scale CsCl Preparation of Plasmid DNA 
This method was based upon that described by Guerry et al. (1973). Cells were 
grown overnight in LB/ampicillin medium and harvested in 200m1 plastic bottles in a 
GS-A rotor at 5,000rpm (4,000g) for 5 minutes before being resuspended in 6ml of 
sucrose mix (25% (w/v) sucrose, 50mM Tris-HCl (pH8))  and transferred to 30m1 
polypropylene tubes. To this was added imi of lysozyme solution (10 mg/ml lysozyme 
in sucrose mix; freshly prepared) and the mixture was left at room temperature for 5 
minutes before lml of 0.5M EDTA (pH8) was added. The tube was inverted several 
times, to allow mixing, then incubated at room temperature for a further 10 minutes. 
Cell lysis was achieved by the addition (by slow bubbling through the mix) of lOml of 
ice-cold Triton mix (0.1% (v/v) Triton X-100, 50mM Tris-HCl (pH8), 62.5 mM EDTA 
(pH8)), standing on ice for 10 minutes and mixing gently. The lysate was cleared by 
centrifugation in a SS-34 rotor at 18,000rpm (39,000g) for 45 minutes at 4°C. Closed 
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circular plasmid DNA purification was achieved by equilibrium centrifugation in 
CsCl/ethidium bromide gradients as described by Maniatis et at. (1982). For each lml 
of cleared lysate, 0.95g of CsCl and 50p1 of 10mg/mI ethidium bromide were added and 
the solution transferred to a Beckman 12m1 polyallomer tube which was sealed and 
centrifuged in a Ti50 rotor at 37,000rpm (95,000g) for 48-60 hours at 18°C. The DNA 
was visualised using a long-wavelength UV lamp and the lower of the two bands 
(corresponding to closed circular plasmid DNA) was recovered by piercing the side of 
the tube with a 19-guage needle and syringe. Ethidium bromide was removed by 
repeated extractions with butan-1-ol (pre-equilibrated with CsCl-saturated TE buffer) 
and CsCl removed by dialysis against several changes of 2 litres of TE buffer over 16-20 
hours at 4°C. The dialysate was subsequently phenol/chloroform extracted, ethanol 
precipitated and redissolved in 0.5-1.0ml of TE buffer. This procedure yielded anything 
from 0.1-1.0mg of plasmid DNA, depending on the particular plasmid and strain used. 
2.4.15 Measurement of Radioactivity in Nucleic Acids 
The incorporation of radiolabel into nucleic acids (see Sections 2.4.16 and 2.4.22) 
was determined by precipitation with trichioroacetic acid (TCA). A 1:10 dilution (in 
dH20) of the labelling reaction was made and 1/.Ll of this was spotted onto a Whatman 
GF/C glass-fibre disc (2.1cm diameter), while a further lil was added to an Eppendorf 
tube containing 50jil of 0.5mglml E.coli tRNA. To this was added 131I of 50% (w/v) 
TCA and the mixture was incubated on ice for 15 minutes before the precipitate was 
collected by filtering through a GF/C filter under a gentle vacuum. The filter was 
washed with 15m1 of ice-cold 10% (w/v) TCA, followed by 15ml of ice-cold ethanol and 
then the radioactivity on each of the filters was determined by scintillation counting. 
The first filter measured the total radioactivity in the sample, while the second measured 
the radioactivity incorporated into nucleic acid, so comparison of the two values gave 
the percentage efficiency of the labelling reaction. Oligonucleotides less than 20 
nucleotides in length are not quantitatively precipitated by this procedure. 
2.4.16 Labelling of DNA Probes by Random-Priming 
DNA isolated in a number of ways can be labelled for use as probes by the 
method of Feinberg and Vogelstein (1983). The method applies to the labelling of 
entire plasmid sequences (provided they were first linearised with a restriction 
endonuclease), purified DNA fragments, or, indeed, to DNA fragments separated from 
a mixture of fragments in a low melting-point (LMP) agarose gel (without the need for 
purification). 
2.4.16.1 Purification of DNA Fragments from LMP Agarose Gels 
A slab gel was prepared as described in Section 2.4.6, but using LMP agarose 
(BRL), and the DNA was electrophoresed with the running voltage not exceeding 
7.5V/cm (to avoid smearing). The DNA was visualised on a UV transilluminator and 
the band containing the required fragment was excised. The gel piece was weighed, 
H20 added (3m1 per gram of gel) and the tube placed in a boiling water bath for 7 
minutes to dissolve the agarose and denature the DNA. This solution can either be 
used immediately for the labelling reaction or stored at -20°C. 
2.4.16.2 Labelling Reaction 
Prior to commencing the labelling reaction the DNA must be completely 
denatured. This was achieved for DNA in LMP agarose by boiling as described above 
(but, if it had subsequently been stored, it was boiled for a further 3 minutes following 
thawing) while purified DNA fragment or linearised plasmid was boiled for 5 minutes. 
Reagents were added in the following order: dH20 (to total volume of 50.l), 10l 
oligo-labelling buffer (for preparation see below), ljtl of 20mg/mi BSA, DNA solution 
(up to 32.5l containing 20-10ng of DNA). At this point, the mixture was heated to 
37°C for 10 minutes to allow oligonucleotide primers to anneal to the DNA. 
Subsequently, 10-20jCi of a-[32P]-dCTP and 2 units of Klenow enzyme were added. 
The mixture was incubated at room temperature for 2.5-18 hours, to allow 
polymerisation to occur, and the reaction terminated by the addition of 0.2ml of 
"oligo-stop solution" (20mM NaCl, 20mM Tris-HCI (pH7.5), 2mM EDTA, 0.25% SDS, 
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1mM dCTP). Incorporation was assayed by TCA precipitation and was usually in excess 
of 50%. 
Oligo-labelling buffer was prepared by the mixing of three solutions, A:B:C, in 
the ratio 100:250:150 and could be stored at -20°C with freeze-thawing over many 
months. 
Solution 0: 1.25M Tris-HC1 (pH8.0), 125mM MgCl2; stored at 4°C. 
Solution A: 1.0mI solution 0 + 18l 2-mercaptoethanol + 5j.d dATP + 5d 
dGTP + 5il dlTP (each at 0.1M in 3mM Tris-HCI (pH7.0), 0.2mM EDTA); stored 
at -20°C. 
Solution B: 2M HEPES-Na (pH6.6); stored at 4°C. 
Solution C: Hexadeoxynucleotides dissolved in TE buffer at 90 OD nm  units 
per ml; stored at -20°C. 
2.4.17 Labelling of DNA Oligonucleotide Probes 
Oligonucleotide DNA was 5'-end labelled for use as a probe by a slight 
modification of the method of Maxam and Gilbert (1980). The labelling reaction was 
performed in a total volume of lOpl containing 20 pmoles of oligonucleotide, 1l of lOx 
kinase buffer (700mM Tris-HCl (pH7.6), 100mM MgCl2, 1mM KC1, 50mM DTT; stored 
at -20°C), 10iCi of ' -[32P]-A1P and at least 2 units of T4 polynucleotide kinase (in 
not more than ljil). The kinase reaction was allowed to proceed for 30 minutes at 
37°C and was terminated by dilution to lml with 10mM potassium phosphate (pH7.0). 
Unincorporated nucleotide was then removed by passage over Sephadex G-25 (NAP-10  
column, Pharmacia) as follows; the column was pre-equilibrated with 4 bed volumes of 
10mM potassium phosphate (p1117.0), the diluted labelling reaction (imi) loaded and the 
oligonucleotide eluted with 1.5m1 of the same buffer. 
2.4.18 Southern Blotting from Agarose Gels 
The transfer of DNA from agarose gels to nitrocellulose membranes was 
performed by the method of Southern (1975). The DNA sample was electrophoresed 
through an agarose gel and photographed as described in Section 2.4.6. After any 
unused parts of the gel were cut off, it was soaked in several volumes of Southern 
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denaturation buffer (1.5M NaCl, 0.5M NaOH) for 1 hour at room temperature with 
shaking to denature the DNA. The gel was neutralised by soaking in several volumes 
of Southern neutralisation buffer (1M Tris-HCI (p118.0), 1.5M NaCl) for 1 hour at room 
temperature with shaking. A double sheet of Whatman 3MM paper (pre-wetted with 
10xSSC buffer) was placed over a glass plate with the ends dipping into a reservoir filled 
with 10xSSC buffer and the gel was placed, with the original underside uppermost, on 
the damp 3MM paper. A piece of nitrocellulose membrane (Schleicher and Schuell 
BA85) was cut slightly larger than the gel, pre-wetted in 2xSSC buffer and placed over 
the gel. Two pieces of 3MM paper, pre-wetted in 2xSSC, buffer were placed over the 
nitrocellulose, then a 5-8cm stack of paper towels was placed on top. Finally a glass 
plate was placed on top of the stack and weighed down with a 500g weight. Transfer 
of DNA was allowed to proceed for 12-20 hours after which the nitrocellulose was 
removed, rinsed in 6xSSC for 5 minutes and baked for 2 hours at 80°C under vacuum. 
The membrane was used immediately for hybridisation experiments (see Section 2.4.20). 
2.4.19 Colony Blotting 
Colony screening to identify recombinant clones was performed by the method 
of Grunstein and Hogness (1975) as described by Maniatis et al. (1982). Transformed 
E.coli colonies were picked, using sterile toothpicks, and streaked in a grid pattern on 
duplicate LB-agar (plus ampicillin) plates and grown overnight. One of the duplicate 
plates was stored at 4°C as the master plate (colonies which carried the desired 
recombinant DNA sequences were later recovered from this) while the bacterial streaks 
on the other were transferred to a nitrocellulose membrane. This was achieved by 
gently laying the membrane (Schleicher and Schuell BA85) on top of the agar, causing 
the bacteria to stick to it. The membrane was then removed and laid, colony side 
uppermost, on Whatman 3MM paper soaked with Southern denaturation buffer (see 
Section 2.4.18) for 5 minutes. This step was repeated with 3MM paper soaked in 
Southern neutralisation buffer (see Section 2.4.18) for 5-10 minutes and 3MM paper 
soaked in 2xSSC. The membrane was air-dried, baked at 80°C under vacuum for 2 
hours and used immediately for hybridisation experiments (see Section 2.4.20). 
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2.4.20 Hybridisation of Southern and Colony Blots 
Nitrocellose membranes carrying DNA blotted from an agarose gel (Section 
2.4.18) or DNA liberated from blotted bacterial colonies (Section 2.4.19) were hybridised 
with radiolabelled DNA probes synthesised as described in Section 2.4.16. The 
membrane was sealed in a plastic bag with 10-30m1 of pre-hybridisation buffer (2xSSC, 
lOx Denhardt's solution [see below], 0.1mg/mi heat-denatured salmon-sperm DNA) and 
incubated at 65°C for at least 2 hours with constant shaking. The probe was denatured 
by heating to 100°C for 5 minutes and added to the bag and hybridisation was 
continued for 12-20 hours at 65°C with shaking. Probe which had bound to the 
membrane non-specifically was removed by a series of washes as follows; three 5 minute 
washes in 2xSSC at room temperature, two 30 minute washes in 2xSSC, 0.5% SDS at 
65°C and two 10 minute washes in 0.1xSSC at room temperature. The membrane was 
blotted dry on Whatman 3MM paper, covered with Saran Wrap and autoradiographed. 
Denhardt's solution was prepared at 50x concentration (1% (w/v) Ficoll, 1% 
(w/v) BSA, 10% (w/v) SDS, 1% (w/v) polyvinyl pyrroiidine; stored at room temperature). 
2.4.21 Northern Blotting from Polyacrylamide Gels 
Total yeast RNA or RNA recovered from an immunoprecipitation reaction (see 
Section 2.7.12) was electrophoresed through a denaturing polyacrylamide gel (Section 
2.4.8) and transferred to a nylon membrane for hybridisation experiments. The gel 
plates were dismantled and the area of interest of the gel (estimated from the position 
of the marker dyes) was cut from the remainder, while still attached to one of the gel 
plates. The gel piece was transferred onto a piece of Whatman 3MM paper and this 
was placed, gel side uppermost, on several sheets of 3MM paper soaked in 0.5xTBE to 
wet the 3MM paper. Two Scotchbrite pads, three further pieces of 3MM paper and 
a piece of nylon membrane (Hybond N, Amersham) were also soaked in 0.5xTBE 
buffer. 	This was then assembled into the cassette of a Bio-Rad Trans-Blot 
electroblotting unit as follows; on top of one Scothbrite pad was placed one piece of 
3MM paper, followed by the piece carrying the gel (gel side uppermost), the nylon 
membrane, the remaining two pieces of 3MM paper and, finally, the second Scotchbrite 
pad. Extreme care was taken at each stage to ensure that all air bubbles were excluded 
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from the assembly. The cassette was inserted in the Trans-Blot electroblotting tank 
(with the gel side oriented toward the cathode), the tank filled with 0.5xTBE buffer and 
transfer performed at 60V for 1-1.5 hours, with cooling supplied by a water-cooling 
system. After transfer, the cassette was disassembled and the membrane dried at 37°C 
for 10 minutes. The RNA was fixed on the membrane by wrapping in Saran Wrap and 
irradiating, RNA side down, on a UV transilluminator for 5 minutes. The membrane 
was used immediately in hybridisation experiments to detect snRNAs (see Section 
2.4.22). 
2.4.22 Hybridisation of Northern Blots 
Hybridisation of Northern blots (Section 2.4.21) with oligonucleotide probes was 
performed by a method based on that of Church and Gilbert (1984). The membrane 
was re-wetted in dH20 and sealed in a plastic bag with 10-20ml pre-hybridisation buffer 
(0.5M sodium phosphate (pH7.0), 7% SDS, 1mM EDTA). After incubation at 28°C 
for 1 hour, with constant agitation, the 5'-end labelled oligonucleotide probe (see 
Section 2.4.17) was added in the 1.5m1 volume in which it was eluted from the NAP-10  
column. Hybridisation was continued for 18-22 hours at 28°C with constant agitation, 
after which the membrane was washed in 0.5M sodium phosphate (pH7.0), 5% SDS, 
1mM EDTA for 20 minutes at 28°C with shaking. The membrane was blotted dry and 
autoradiographed. 
2.4.23 In Vitro Transcription Reaction 
Radiolabelled RNA, for use in in vitro splicing reactions (see Section 2.5.2) and 
for probing protein blots (see Section 2.7.10), was synthesised in vitro from DNA cloned 
downstream from of their cognate promoters by SP6 (Melton et al., 1984) or Ti 
(Davanloo et al., 1984) RNA polymerases. The reaction was performed in 20.1 volume 
containing the following; 0.2g of linearised template DNA (there was no requirement 
to purify this from the restriction digestion reaction mix), 2j1 lOx transcription buffer 
(400mM Tris-HCl (pH7.5), 60mM MgC12, 100mM DTT, 1mg/mi BSA; stored at -20°C), 
10 units RNAsin (Promega), 25j.M UTP, 0.5mM each of ATP, CTP and GTP, 20/LCi 
of a-[32P}-UTP, 2-5 units of the appropriate RNA polymerase. If the RNA was to be 
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capped, 2l of 10mM G(5')ppp(5')G cap analogue (Pharmacia) was included in the 
reaction mix and the GTP concentration was reduced to 0.1mM. The polymerisation 
reaction was carried out at 37°C for 30-60 minutes and stopped on ice. Incorporation 
of radiolabel was generally in the range of 30-60%, depending on the particular 
template. Labelled RNA synthesised in this way was stored at -20°C for 1-2 weeks. 
2.4.24 3'-End Labelling of RNA 
RNA purified from an immunoprecipitation reaction was 3'-end labelled by the 
method of England et al. (1980). The dried RNA pellet from the ethanol precipitation 
was resuspended directly in lOjiCi of cytidine 3',5'-[5'-32P]-bisphosphate (ljil) and 21 
of reaction mix was added to give final conditions of; 50mM HEPES-NaOH (pH7.5), 
10mM MgC12, 3mM DT!', 10% (v/v) deionised DMSO, lOigIml BSA, 25iM ATP, 5 
units of RNAsin (Promega), 2 units T4 RNA ligase (BRL). The reaction was allowed 
to proceed for 16-20 hours at 4°C and was terminated by the addition of 57jil of 0.3M 
sodium acetate (pH5.2) and phenol/chloroform extraction. Labelled RNA was ethanol 
precipitated and analysed by electrophoresis through a 6% polyacrylamide gel (see 
Section 2.4.8) until the xylene cyanol dye had migrated approx. 30cm 	and 
autoradiography. 
2.5 	IN VITRO SPLICING 
2.5.1 Preparation of Yeast Splicing Extract 
Yeast whole cell extract competent for in vitro splicing was prepared by a 
method slightly modified from that of Lin et al. (1985). Cells of strain BJ2412 were 
grown overnight at 30°C in 500m1 of YPDA medium to an OD.6nm  of 0.4-0.5 and 
harvested by centrifugation in a Sorvall GS-3 rotor at 5,000rpm (4,200g) for 10 minutes 
at room temperature. 	The cells were resuspended in 50ml of 50mM potassium 
phosphate (pH7.5), transferred to a 50ml Falcon tube and spun down in a Centra-4X 
bench-top centrifuge at 3,000rpm (1,600g) for 5 minutes at room temperature. The 
cells were resuspended in 40m1 of lyticase buffer (1.2M sorbitol, 50mM potassium 
phosphate (pH7.5), 30mM DTI) and 2,500 units of lyticase (Sigma; dissolved in 1120 
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at 2,500 units/ml and stored at 4°C) were added. Cell wall digestion was allowed to 
proceed for 30 minutes at 30°C with gentle agitation and the spheroplasts thus 
generated were washed twice with 1.2M sorbitol by gentle resuspension and 
centrifugation as before. The spheroplasts were transferred to an Erlenmeyer flask 
with 200ml of YPDAS medium and incubated for 2 hours at 30°C with gentle agitation 
to allow metabolic recovery. The spheroplasts were harvested by centrifugation in a 
Sorvall GS-A rotor at 5,000rpm (4,000g) for 10 minutes at room temperature, 
resuspended in 50m1 of SB buffer (1.2M sorbitol, 50mM Tris-HC1 (pH7.5), 10mM 
MgC12, 3mM DTT) and transferred to a SOml Falcon tube, then spun down in a 
bench-top centrifuge as before and weighed. All subsequent steps were performed 
in the cold-room at 4°C. For each gram of spheroplasts, lml of ice-cold buffer A 
(10mM HEPES-KOH (pH7.0), 10mM KC1, 1.5mM MgC12, 0.5mM D1T) was added, the 
spheroplasts resuspended and transferred to the receptacle of a 30ml Dounce tissue 
homogeniser and incubated on ice for 5 minutes. After this incubation to allow the 
spheroplasts to swell osmotically, they were lysed by 10-12 strokes of a tight-fitting 
Teflon pestle and the lysate transferred to a lOml beaker on ice. Exactly 1/9th volume 
of 2M KCI was added drop-wise, with gentle stirring, to give a final concentration of 
0.2M. 	The lysate was left, stirring gently on ice, for 30 minutes before being 
transferred to a 30m1 polycarbonate tube and centrifuged in a Sorvall SS-34 rotor at 
17,000rpm (35,000g) for 30 minutes at 4°C. The supernate was transferred to a 12ml 
screw-top polycarbonate tube (avoiding the floating, cloudy lipid layer) and centrifuged 
in a Beckman Ti50 rotor at 37,000rpm (95,000g) for 1 hour at 4°C. This high-speed 
supernate was collected (again avoiding any residual lipid) and dialysed against 2 changes 
of 1 litre of buffer D (50mM KC1, 20mM HEPES-KOH (pH7.0), 0.2mM EDTA, 0.5mM 
DTT, 20% (v/v) glycerol) for 3 hours at 4°C and any protein which precipitated during 
dialysis was cleared by centrifugation in a microfuge (13,800g) for 10 minutes at 4°C. 
The protein concentration of the extract was determined (see Section 2.7.1) and was 
usually in the range 10-25 mg/ml. The extract was snap-frozen in N2(I) in small aliquots 
and stored at -70°C. 
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2.5.2 Yeast In Vitro Splicing 
Yeast in vitro splicing reactions were performed essentially as described by Lin 
et at. (1985). The components of the reaction, other than whole-cell extract, were 
mixed as follows; 1jl of a dilution of a 17 or SP6 transcription reaction (see Section 
2.4.23) containing 20,000 dpm of uncapped, labelled substrate RNA, lpi 30% (w/v) PEG 
8000, ljil 25mM MgCl2, 0.6l 1M potassium phosphate (pH7.5), 0.6iil 40mM ATP and 
0.8j.il "IgG buffer" (prepared by mixing 0.5M potassium phosphate (pH7.5): glycerol: 
0.1M citric acid (pH3.0; adjusted with 0.1M sodium citrate) in the ratios 3:1:2 to give 
a final pH value of approx. 7.0). Then 5jil of splicing extract (thawed and allowed to 
warm to room temperature) was added. The final reaction therefore contained 10mM 
HEPES-KOH, 25mM KCI, 0.1mM EDTA, 0.25mM DTIT, 11.33% (v/v) glycerol, 3% 
(w/v) PEG 8000, 2.5mM MgCl2, 80mM potassium phosphate, 2.4mM ATP, 2.64mM 
citric acid and was allowed to proceed at 24°C for 2-30 minutes. After the reaction 
was stopped by the addition of 31 of stop solution (lmg/ml proteinase K, 50mM 
EDTA, 1% SDS) and incubation at 37°C for 15 minutes, 0.2ml of splicing cocktail 
(50mM sodium acetate (pH5.3), 1mM EDTA, 0.1% SDS, 25 j.g/ml tRNA) was added, 
the mixture phenol/chloroform extracted and the RNA ethanol precipitated. The pellet 
was redissolved in 1l of ddH20 and 2l of urea load buffer was added before heating 
to 90°C for 2 minutes to denature the RNA and electrophoresing through a 6% 
polyacrylamide/7Murea gel (see Section 2.4.8). 	When the xylene cyanol dye had 
migrated approx. 30cm, electrophoresis was halted and the gel plates separated. The 
gel was transferred to Whatman 3MM paper, covered with Saran Wrap and subjected 
to autoradiography. 
2.5.3 In Vitro Splicing in a HeLa Cell Nuclear Extract 
In vitro splicing reactions in HeLa cell nuclear extracts were performed by a 
slight modification of the method described by Kramer et at. (1984). The components, 
other than the nuclear extract, were mixed at room temperature as follows; ljil of a 
dilution of a SP6 transcription reaction (Section 2.4.23) containing 20,000 dpm of 
capped, labelled substrate RNA. 2.5l 200mM KC1, 2p1 40mM MgC12, 2il 0.1M creatine 
phosphate (Tris salt), 0.4j.1 0.1M ATP and 7.1i1 of ddH20. Then 10j.1 of nuclear 
extract (which had been thawed and allowed to warm to room temperature) was added. 
The final reaction therefore contained 8mM HEPES-KOH (pH7.6), 60mM KCI, 3.2mM 
MgCl2, 8mM creatine phosphate, 1.6mM ATP, 8% (v/v) glycerol, 0.08mM EDTA, 
0.2mM PMSF. The was reaction allowed to proceed at 30°C for 0.3-3 hours before 
being stopped by the addition of 751l of ddH20 and 0.lml of 2xPK buffer (0.2mM 
Tris-I-ICl (pH7.5), 25mM EDTA, 0.3M NaCl, 2% SDS, 4mg/ml protcinase K) and 
further incubation at 30°C for 30 minutes. The mixture was subjected to two rounds 
of phenol/chloroform extraction and the RNA was ethanol precipitated. The pellet was 
redissolved in lj.tl of ddH20, 2il of urea load buffer was added and the RNA 
denatured by heating to 90°C for 2 minutes. The RNA was electrophoresed through 
a denaturing 10% polyacrylamide/7M urea gel (see Section 2.4.8) at 30W until the 
xylene cyanol dye had migrated approx. 30cm and the gel was processed for 
autoradiography as for yeast splicing gels (Section 2.5.2). 
2.6 	DNA SEQUENCING 
2.6.1 Preparation of Single-Stranded Phagemid DNA 
An overnight culture of cells containing phagemid DNA was prepared by picking 
an individual ampicillin colony into 2m1 of LB/ampicillin medium and incubating at 
37°C and 40i1 of this was used to inoculate 2m1 of LB medium. This was incubated 
at 37°C with vigorous shaking for 30 minutes before being infected with helper phage 
M13K07 at an m.o.i. of 20 (i.e. there are approx. 4x107 bacteria present in the culture, 
so 8x108 phage particles were added). The infected culture was shaken vigorously for 
a further 6-8 hours at 37°C before the cells were spun out by centrifugation in a 
microfuge (13,800g) for 15 minutes at room temperature and lml of the supernate 
transferred to a fresh 1.5m1 Eppendorf tube. Secreted phage particles were precipitated 
by the addition of 0.25ml of ice-cold 20% (w/v) PEG 6000, 3.75M ammonium acetate, 
incubation on ice for 30 minutes and centrifugation in a microfuge (13,800g) for 15 
minutes at room temperature. All traces of the supernate were removed, the pellet 
resuspended in 0.4ml TE buffer and chloroform extracted (with vortexing for a full 
minute). The aqueous phase was subjected to two phenol/chloroform extractions and 
one further chloroform extraction before 0.5 volumes of 7.5M ammonium acetate and 
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2 volumes of ethanol were added. The mixture was incubated at -20°C for 20 minutes 
to allow precipitation, and the phagemid DNA was pelleted by centrifugation in a 
microfuge (13,800g) for 15 minutes at 4°C. After a 70% ethanol wash and drying, the 
pellet was dissolved in 20pI of ddH20 and stored at -20°C. A small aliquot of the 
preparation was analysed on an agarose gel (Section 2.4.6) when single-stranded 
phagemid DNA was clearly visible in greater abundance than M13K07 helper phage 
DNA (8.7kb). 
2.6.2 Sequencing Reactions 
Sequencing of DNA was performed by the dideoxy-chain terminator method as 
described by Sanger et al. (1977). To 8jl of template DNA preparation (see Section 
2.6.1) was added 2l of annealing mix (freshly prepared by mixing 0.1M Tris-HCI 
(pH7.5), 0.1M MgCl2 and 4g/ml universal sequencing primer in the ratio 3:2). The 
mixture was heated to 85°C for 10 minutes and allowed to cool at room temperature 
for a further 10 minutes to permit annealing of the primer to the template DNA. 
Meanwhile, 2.51il aliquots of sequencing solutions A, C, G and T (see Table 2.5) were 
dispensed into Eppendorf tubes. 	To the annealed template-primer mix, 8j.Ci of 
a-[35S]-dATP and 2.5 units of Kienow were added and mixed gently and then 2.5.il 
aliquots of this were transferred to the side-walls of the tubes containing the A, C, G 
and T solutions. The tubes were spun in a microfuge for 1 second to mix the contents 
and thus start the reaction. After 15 minutes incubation at room temperature, 2.541 
of chase solution (see Table 2.5) was added to each of the four tubes and incubation 
continued at room temperature for a further 15 minutes. The reaction was terminated 
by the addition of 31il of formamide load dye (deionised formamide, 20mM EDTA, 
0.3% (w/v) xylene cyanol, 0.3% (w/v) bromophenol blue; stored at -20°C) and heating 
to 100°C for 2-5 minutes and was subsequently electrophoresed through a 6% 
polyacrylamide/7M urea gel as described in Section 2.4.8 (except that a BRL 
5.7mm-Sharkstooth Comb was used instead of a conventional well comb) until the 
bromophenol dye had migrated approx. 40cm. Following electrophoresis, the gel plates 
were separated and the gel (still attached to one of the plates) immersed in 2 litres of 
fixing solution (10% (v/v) acetic acid) for 15 minutes. The gel was then removed from 
the fixing solution, thoroughly drained and transferred from the glass plate to a piece 
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of Whatman 3MM paper (achieved by pressing the 3MM paper firmly onto the gel and 
lifting carefully off). The gel was covered with Saran Wrap, dried under vacuum at 
80°C for 2 hours and autoradiographed (after removal of the Saran Wrap). 
TABLE 2.5 Composition of Sequencing Solutions 
(all concentrations in jIM) 
Solution 
A C G T chase 
dATP - - - - 1000 
dCTP 110 4 82 82 1000 
dGTP 110 82 4 82 1000 
dTTP 110 82 82 4 1000 
ddATP 33.3 - - - - 
ddCfP - 67.5 - - - 
ddGTP - - 150 - - 
ddTTP - - - 250 - 
(all solutions in TB buffer and stored at -70°C) 
2.7 	PROTEIN METHODS 
2.7.1 Quantitation of Proteins 
Dilutions of the test sample were prepared and 2il of each were spotted onto 
a piece of Whatman No.1 filter paper alongside 2jl aliquots of protein concentration 
standards (BSA, 50-1000g/ml; stored at -20°C) and dried at 65°C for a few minutes. 
The filter was then incubated in ESAU stain (25% (v/v) propan-2-ol, 10% (v/si) acetic 
acid, 1% (w/v) Coomassie Brilliant Blue (R250); stored at room temperature and can 
be re-used many times) for 15 minutes at room temperature and destained with tapwater 
until the background staining was low. The protein concentration in the test sample 
was then estimated by comparison with the standards of known concentration. 
2.7.2 SDS-Polyacrylamide Gel Electrophoresis of Proteins 
TABLE 2.6 Composition of SDS-Polyacrylamide Gel Mixes 
Stock Soins. 	 8.5% Separating Gel 	5% Stacking Gel 
30% (w/v) acrylamide* 
1.25% (w/v) bisacrylamide* 
1M Tris-HCI (pH8.8) 
1M Tris-HCI (pH6.8) 
dH2O 
20% (w/v) SDS 










(*Stock acrylamide and bisacrylamide solutions were deionised, filtered and stored at 
4°C) 
Proteins were separated by SDS-discontinuous polyacrylamide gel electrophoresis 
(SDS-PAGE) as described by Laemmli (1970). An 8.5% separating gel mix (Table 2.6) 
was prepared and poured between two 16xl6cm glass plates (separated at their edges 
by 1.5mm spacers, sealed with a piece of rubber tubing and clamped into an AlTO 
gel-casting apparatus, model SJ-1060) to within 5cm of the top of the notched plate. 
Water was gently layered over the gel mix and the assembly left in an upright position 
at room temperature for 1 hour to allow polymerisation. The water was poured off 
the surface, stacking gel mix (Table 2.6) was poured onto the separating gel up to the 
top of the notched plate and a Teflon slot-forming comb (12x0.5cm wells or 200.3cm 
wells) was inserted. After at least 30 minutes, the stacking gel was fully polymerised 
and the comb and sealing rubber tubing were removed. The gel assembly was 
transferred to an AlTO electrophoresis tank (model SJ-1060) which was filled with 
SDS-PAGE buffer (25mM Tris- base, 192mM glycine, 1% (w/v) SDS (pH8.8); prepared 
as a lOx stock). Samples were prepared by mixing with an equal volme of 2x protein 
load buffer (125mM Tris-HCI (pH6.8), 200mM DYF, 4% (w/v) SDS, 40% (v/v) glycerol, 
0.02% (w/v) bromophenol blue; stored at 4°C for up to 3 weeks) and heating to 100°C 
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for 5 minutes before being loaded on the gel. Electrophoresis was performed at 
50-200V for 3-16 hours. Size markers in the range 29-205kD were from Sigma. 
2.7.3 Staining of Protein Gels 
2.7.3.1 Coomassie Staining 
After SDS-PAGE (see Section 2.7.2) was completed, the gel plates were 
separated and the gel transferred to a plastic container where it was incubated at 37°C 
for 30-60 minutes in sufficient staining solution (25% (v/v) propan-2-ol, 10% (v/v) acetic 
acid, 0.05% (w/v) bromophenol blue) to submerge the gel. The staining solution was 
then removed, the gel washed briefly with water and 100-200ml of destaining solution 
(25% (v/v) methanol, 10% (v/v) acetic acid) added. The gel was destained at 37°C until 
the background was low, i.e. 2-16 hours. For storage the gel was transferred onto a 
sheet of Whatman 3MM paper, covered with Saran Wrap and dried for 2 hours at 80°C 
on a vacuum gel drier. 
2.7.3.2 Silver Staining 
Detection of very small amounts of protein in SDS-polyacrylamide gels was 
achieved by the method of Morrisey (1981). Following SDS-PAGE, the gel was 
transferred to a plastic container (kept exclusively for this purpose) and incubated at 
room temperature with constant agitation in the following: lOOmi 50% (v/v) methanol, 
10% (v/v) acetic acid for 30 minutes; lOOmI 5% (v/v) methanol, 7% (v/v) acetic acid for 
30 minutes; 50m1 10% (v/v) glutaraldehyde for 30 minutes; several changes of lOOml 
dH20 over 2 hours; 5ag/mI DIT for 30 minutes; 0.1% (w/v) silver nitrate for 30 
minutes. The gel was then rinsed twice rapidly in dH20 and once rapidly in developer 
solution (3% (w/v) sodium carbonate, 0.02% (v/v) formaldehyde) before being incubated 
in lOOml of developer solution until staining reached the desired intensity. Development 
was halted by the addition of 5m1 of 2.3M citric acid and incubation for 10 minutes and 
the gel was then rinsed in several changes of lOOmI dH20 over 30 minutes. Finally 
the gel was incubated in lOOmI 0.03% (w/v) sodium carbonate for 30 minutes and was 
stored sealed in a plastic bag at 4°C. It was possible to silver stain a gel which had 
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previously been Coomassie stained with the omission of the first step, i.e. incubation in 
50% (v/v) methanol, 10% (v/v) acetic acid. 
2.7.4 Extraction of Total Cellular Protein for Electrophoresis 
2.7.4.1 Escherichia coli Protein 
An overnight culture of E.coli cells was diluted 1:100 into fresh medium and 
grown to the desired cell density with induction of fusion protein expression as required 
(see Section 2.7.5). The culture was cooled on ice for 15 minutes and the cells from 
lml were harvested by centrifugation in the bench-top Centra-4X centrifuge at 3,000rpm 
(1,600g) for 5 minutes. The cells were resuspended in 50l of dH20, by vortexing, 
50Ml of 2x protein load buffer (see Section 2.7.2) was added and the cells lysed by 
heating to 100°C for 5 minutes. The lysed culture was centrifuged in a microfuge 
(13,800g) for 5 minutes to clear insoluble material and 15-20/4l of the supernate was 
loaded on a 0.5cm well for SDS-PAGE. 	The remainder of the supernate was 
snap-frozen in N2(l) and stored at -70°C if necessary. 
2.7.4.2 Yeast Protein 
A lOOml yeast cell culture (in YPDA or supplemented YMM medium as 
appropriate) was grown overnight to late logarithmic phase, i.e. until the OD.6flm  was 
in the range 0.6-1.0, transferred to 50ml Falcon tubes and the cells harvested by 
centrifugation in a Centra-4X centrifuge at 3,000rpm (1,600g) for 10 minutes at room 
temperature. 	The cells were washed by resuspension in SOmI 1xPBS buffer and 
centrifugation as before and were then resuspended in 2m1 of 1xPBS. 	The cell 
suspension was transferred to microfuge tubes and the cells spun down by centrifugation 
in a microfuge (13,800g) for 30 seconds at room temperature. To each cell pellet was 
added an equal volume of sonication buffer (1xPBS, 0.1% NP40, 1mM PMSF, 1mM 
DIT and (optionally) 5g/ml each of pepstatin A and leupeptin; freshly prepared) and 
each was sonicated at full power for four bursts of 30 seconds each (with 2 minutes on 
ice between bursts). The lysate was centrifuged in a microfuge (13,800g) for 2 minutes 
at 4°C and the supernate was collected and centrifuged in a microfuge (13,800g) for 15 
minutes at 4°C. An equal voume of 2x protein load buffer (see Section 2.7.2) was 
added to the supernate and the protein denatured by heating to 100°C for 5 minutes. 
Aliquots of this extract (5-25jil) were subjected to SDS-PAGE while the remainder was 
snap-frozen in N20) and stored at -70°C. Alternatively the supernate from the second 
spin was used directly for immunoprecipitation reactions (see Section 2.7.12) without 
denaturation in protein load buffer. 
2.7.4.3 Drosophila melanoaster Protein 
The cells from a culture of Drosophila melanogaster cells were resuspended in 
5 volumes of lx protein load buffer (see Section 2.7.2) and heated to 100°C for 5 
minutes before being centrifuged in a microfuge (13,800g) for 2 minutes at room 
temperature. Aliquots of the supernate (10-15d) were subjected to SDS-PAGE while 
the remainder was snap-frozen in N2(l) and stored at -70°C. 
2.7.5 Induction of Fusion Protein Synthesis in E.coli 
2.7.5.1 pUR Vector System 
E. coli BMH71-18 or NM522 cells carrying pUR construct or parent vector 
plasmid were grown overnight at 37°C in 5m1 of LB/ampicillin medium and and this was 
diluted 1:100 into fresh LB/ampicillin medium (5ml for analytical purposes (Section 
2.7.4.1) and 200m1 for preparative purposes (Section 2.7.6)). The culture was incubated 
at 37°C with shaking until the OD.nm reached 0.4 and then 0.004 volume of 24mg/mI 
IPTG was added and the incubation continued for a further 1 hour. 
2.7.5.2 pEX Vector System 
E. coli pop2136 cells carrying pEX construct or parent vector plasmid were 
grown overnight in Sml LB/ampicillin medium at 30°C and this was diluted 1:100 into 
fresh LB/ampicillin medium (volumes as in Section 2.7.5.1). The culture was incubated 
at 30°C with shaking until the OD.nm reached 0.4, when it was shifted to a water 
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bath at 42°C for a few minutes. Incubation was continued at 42°C with vigorous 
shaking for 1 hour. 
2.7.5.3 pATH Vector System 
Induction of trpE fusion polypeptide synthesis in E. coli HB101 cells carrying 
pATH construct or parent vector plasmid was performed by the method of Spindler et 
(1984). Cells were grown overnight in 5m1 M9+CA+W/ampicillin medium at 37°C 
and this was diluted 1:10 into M9+CA/ampicillin (volumes as in Section 2.7.5.1). This 
culture was incubated at 37°C with vigorous shaking for 1 hour before 0.005 volume of 
1mg/mI indoleacrylic acid (in ethanol; stored at -20°C) was added and incubation 
continued for a further 2 hours with vigorous shaking at 37°C. 
2.7.6 Purification of Fusion Proteins from E.coli 
2.7.6.1 Purification by SDS-PAGE 
A 200m1 culture was induced for fusion protein synthesis (see Section 2.7.5) and 
a 15m1 crude SDS-lysate was prepared as described in Section 2.7.4.1. A preparative 
8.5% SDS-polyacrylamide gel was poured as described in Section 2.7.2 except that, 
instead of inserting a Teflon comb to form individual wells, dH20 was layered on top 
of the stacking gel to allow it to set level, effectively forming one large well spanning 
the entire width of the gel. Crude SDS-lysate (0.5-1.0ml per gel) was electrophoresed 
through the gel and vertical reference strips (0.3-0.5mm wide) were cut from either edge 
and from the middle of the gel and Coomassie stained (Section 2.7.3.1). By lining up 
these strips with the remainder of the gel it was possible to excise the horizontal strip 
of gel containing the fusion protein. The strips were placed in a section of dialysis 
tubing which was then filled with 3-5m1 SDS-PAGE buffer (Section 2.7.2) and clipped 
at either end to form a bag. This assembly was placed in a BRL horizontal gel 
electrophoresis tank and submerged in SDS-PAGE buffer and the protein was eluted 
from the gel pieces at 150V for 4 hours. The current was reversed for 15 seconds to 
detach the eluted protein from the dialysis tubing and the liquid was recovered from the 
bag. The fusion protein solution was concentrated by centrifugation in a MSE Minor 
'S' fixed-angle rotor bench-top centrifuge at 3,000rpm (1,000g) in a Centricon 30 
microconcentrator (Amicon Corporation) at 4°C to a volume of imi. An aliquot of 
purified protein was subjected to SDS-PAGE (Section 2.7.2) to assess the recovery, 
which was generally in the range 50-100jg per gel. The protein was stored frozen at 
-70°C. 
2.7.6.2 Purification in Insoluble Protein Fraction 
A 200m1 E. coil culture was induced for fusion protein synthesis (see Section 
2.7.5) and the insoluble protein fraction prepared by a modification of the method of 
Hall et al. (1984). Following induction, the cells are harvested by centrifugation in a 
Sorvall GS-A rotor at 3,000rpm (1,500g) for 5 minutes at 4°C, resuspended in 4m1 of 
15% (w/v) sucrose, 50mM Tris-HC1 (pH8.0), 50mM EDTA, and transferred to a 30m1 
polycarbonate tube before 0.4m1 of 10mg/mi lysozyme was added. After thorough 
mixing the tube was left on ice for 40 minutes, with intermittent gentle agitation, and 
5.6m1 of 0.2% (v/v) Triton X-100 in TE buffer was added. After 5 minutes incubation 
on ice, the mixture was spun in a Sorvall SS-34 rotor at 19,000rpm (43,000g) for 10 
minutes at 4°C and the supernate was discarded. The insoluble protein pellet was 
either resuspended in lx protein load buffer (see Section 2.7.2) and heated to 100°C 
for 5 minutes, for SDS-PAGE, or was solubilised to give renatured protein as follows; 
2-5ml of 6M urea was added, the pellet sonicated at full power for 3x15 seconds on ice 
and the mixture recentrifuged in a Sorvall SS-34 rotor as above. The supernate was 
dialysed against three changes of 1 litre each of 1xPBS buffer at 4°C. The protein 
preparation was concentrated in a Centricon 30 microconcentrator (see Section 2.7.6.1) 
and stored at -70°C. 
2.7.7 Immunisation of Rabbits 
All experiments on live animals were performed in compliance with the Cruelty 
to Animals Act (1986) under licence number 63181. Rabbits were females of the 
half-lop variety and were obtained from Froxfieid Rabbits, Hampshire. 
The volume of fusion protein preparation (see Section 2.7.6) containing the 
required amount (50-100,4g for the first injection and 20-50jg for all subsequent 
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injections) was diluted to imi with dH20. To this was added imi of Freund's complete 
adjuvant (for the first injection) or Freund's incomplete adjuvant (for all subsequent 
injections), the mixture was vortexed until a stable emulsion had been formed and this 
was injected into the rabbit at several subcutaneous sites using a 25-guage needle. 
Immunisation was repeated at monthly intervals. 
Blood was collected from the ear vein (lOmi) prior to the first injection 
(pre-immune) and 10-12 days after the second and all subsequent injections (immune). 
Ten days after the final injection the rabbit was anaesthetised with Sagatal (May and 
Baker Ltd., Dagenham), blood (75-125m1) was withdrawn directly from the heart, using 
a 19-guage needle and syringe, and the rabbit was finally killed with a further injection 
of Sagatal. 
2.7.8 Serum Preparation and Storage 
Blood collected as described (see Section 2.7.7) was allowed to clot for 1 hour 
at room temperature and the clot freed from the walls of the container using a glass 
rod. The blood was left at 4°C overnight to allow the clot to retract, the serum was 
withdrawn to a lOmI or 50ml Falcon tube and centrifuged in a bench-top centrifuge 
at 3,000rpm (1,600g) for 2 minutes to remove red cells. Some (or all, for smaller 
bleeds) of the serum was aliquoted into Eppendorf tubes and snap-frozen in N20) for 
storage at -70°C, while the remainder was snap-frozen in the Falcon tube and stored 
at -70°C. When serum was required, an aliquot was thawed on ice, the desired volume 
withdrawn and the remainder immediately snap-frozen as above. Each individual aliquot 
was subjected to no more than six freeze-thaw cycles. 
2.7.9 Western Blotting 
Electrophoretic transfer of proteins from SDS-polyacrylamide gels to 
nitrocellulose membrane was performed by a modification of the method of Towbin et 
(1979). 	Following SDS-PAGE (see Section 2.7.2), the gel and a piece of 
nitrocellulose membrane, cut to the same size as the gel, were soaked in lx Western 
transfer buffer (20mM Tris base, 150mM glycine) for 30 minutes at room temperature. 
Two Scotchbrite pads and four pieces of Whatman 3MM paper, cut to the size of the 
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Scotchbrite pads, were wetted in the same buffer and the following was assembled in 
the cassette of a BioRad TransBlot electroblotting unit; on top of the first Scotchbrite 
pad was placed two pieces of 3MM paper, then the gel, the nitrocellulose membrane, 
the other two pieces of 3MM paper and finally the second Scotchbrite pad. The 
cassette was inserted (gel oriented toward the anode) into the TransBlot electroblotting 
tank which was filled with lx Western transfer buffer. Proteins were transferred to the 
membrane at 65V for 3 hours or at 25V for 16 hours, with cooling supplied by a 
water-cooling system. Following transfer, the nitrocellulose membrane was dried at 
37°C for 15 minutes, re-wetted in dH20, stained for 2 minutes in Ponceau S (Sigma) 
and destained by washing with dH20 several times. This allowed visualisation of the 
proteins on the membrane and, therefore, the transfer could be verified and the 
membrane cut to strips if required. The membrane was incubated in 20-30m1 blocking 
solution (see Table 2.7) for 2-4 hours at 37°C with agitation and then incubated for 
16-20 hours at 4°C with agitation in primary antibody diluted (1:500-1:2000 of polyclonal 
serum) in the appropriate antibody solution (Table 2.7, approx. lml per 10cm2 of 
membrane). The membrane was washed in 5 changes of wash buffer (SOml 1xTBS, 
0.1% (v/v) NP40) for 5 minutes each at room temperature with shaking and then 
incubated at room temperature for 1 hour, with agitation, in lOml of a dilution of 
alkaline phosphatase-conjugated goat anti-rabbit IgG antibodies (Promega Biotec, 1:7,500 
in the appropriate antibody solution; see Table 2.7). The membrane was then washed 
as above and was placed in 5-10mI of freshly prepared development solution (0.1M 
Tris-HC1 (pH9.5), 0.15M NaCl, 5mM MgCl2, 0.33mg/mI BCIP*,  0.165mg/mI  NBT*;  
*both supplied at SOmg/ml in the Promega development substrate kit) until the staining 
of the bands reached the desired intensity. Development was terminated by washing 
the membrane in an excess of dH20 and the membrane was blotted dry, covered with 
Saran Wrap and stored in the dark at room temperature. 
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TABLE 2.7 Composition of Immunoblotting Solutions 
Blocking Solution 
5% (w/v) BSA., 1xTBS, 
0.1% (w/v) NaN3  
1xTBS, 0.2% (v/v) Tween 20 
1xTBS, 1% (w/v) ovalbumin, 
0.1% (w/v) NaN3  
Antibody Solution 
1% (w/v) BSA, 1xTBS, 
0.1% (w/v) NaN3  
as blocking solution 
as blocking solution 
(all solutions freshly prepared) 
2.7.10 North-Western Blotting 
Proteins fractionated by SDS-PAGE and transferred to a nitrocellulose filter 
were probed for RNA binding properties by the method of Gerke and Steitz (1986). 
Western blotting was performed as described in Section 2.7.9 but, after the Ponceau 
S staining step, the membrane was incubated for at least 1 hour with several changes 
of 50m1 binding buffer (10mM Tris-HC1 (pH7.5), 50mM NaCl, 1mM EDTA, 0.02% 
(w/v) BSA, 0.02% (w/v) polyvinyl pyrrolidine, 0.02% (w/v) Ficoll; freshly prepared) at 
room temperature with agitation. The membrane was then sealed in a plastic bag and 
incubated in binding buffer (2m1 per 10cm2) containing 20,000 dpm/ml of [32P]-labelled 
RNA probe (from an in vitro transcription reaction; see Section 2.4.23) and 1O/hg/ml 
tRNA for 1 hour at room temperature with shaking. After binding, the membrane was 
washed with 2-4 changes of 50m1 binding buffer, for 5 minutes each, at room 
temperature with agitation, blotted dry, covered with Saran Wrap and autoradiographed. 
2.7.11 Affinity Purification of Antibodies 
Antibodies were purified from crude serum using antigen immobilised on 
nitrocellulose membrane by the method of Robinson et al. (1988). Preparative 
SDS-PAGE of a crude lysate of E. coli cells induced for fusion protein synthesis was 
performed as described in Section 2.7.6.1 and protein was Western blotted to a 
nitrocellulose membrane as described in Section 2.7.9. The membrane was Ponceau 
S stained to visualise the protein pattern and the horizontal strip containing the fusion 
protein was excised and blocked as in Section 2.7.9 (blocking solution III). The 
membrane strip was then incubated with lOmi of the blocking solution containing a 
1:100 to 1:300 dilution of polyclonal serum for 2-3 hours at room temperature or 
overnight at 4°C with agitation. The membrane was washed, as described in Section 
2.7.9, and the bound antibodies were eluted by incubation in 2m1 of 0.1M glycine-HCI 
(pH2.5), 0.1% (w/v) ovalbumin for 5 minutes followed by a second 2m1 of the same 
buffer for 10 minutes, both at room temperature. 	Each batch of eluant was 
immediately neutralised by the addition of 0.5ml 1M Tris-HC1 (pH7.5), the two batches 
were pooled and dialysed against three changes of 1 litre each of 1xT13S at 4°C over 
16-20 hours. The affinity purified antibody solution was stored at 4°C in the presence 
of 0.1% (w/v) NaN3. 
2.7.12 Immunoprecipitation Reactions 
2.7.12.1 High Stringency Immunoprecipitation from Labelled Extracts 
In vivo labelling of yeast proteins, preparation of extracts and immuno-
precipitation reactions were performed as described by Lee et al. (1986). 
In vivo labelling of proteins was achieved by adding 0.5mCi of L-[ 35  S]-methionine 
to 400ml of supplemented YMM medium containing approx. 5x106 yeast cells/ml and 
continuing incubation until the cell density was approx. 1x108 cells/ml. Yeast total cell 
protein was extracted as described in Section 2.7.4.2, except that following the second 
clearing spin in the microfuge, 7 volumes of immunoprecipitation buffer (1xPBS, 1% 
(v/v) NP40, 10% (v/v) foetal calf serum, 1mM PMSF) was added. 
For immunoprecipitation reactions, the diluted [S]-labelled extract was divided 
into 6-12 Eppendorf tubes (as required), to each aliquot was added 101il of the 
appropriate polyclonal serum and the tube incubated at 4°C with mixing for 3-16 hours 
to allow antibody-antigen binding. To this was added a 1:1 slurry of swollen Protein 
A-Sepharose beads:NET buffer (50mM Tris-HCl (pH7.5), 0.15M NaCl, 5mM EDTA) 
and incubation continued for a further 1 hour to allow the immune-complexes to bind 
to the beads. The beads were then washed as follows (all at room temperature, each 
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wash being terminated by spinning out the beads in a microfuge (13,800g) for 30 
seconds); 2x30 minutes in HEN buffer (0.1M HEPES-NaOH (pH7.9), 1M NaCl, 1% 
(v/v) NP40, 10mM EDTA, 1mM PMSF), 2x30 minutes in LIT buffer (0.5M LiC1, 0.1M 
Tris-HCl (pH8.8), 0.1% (w/v) SIDS, 1% (v/v) NP40), and 10 minutes in HEN buffer 
again, all with constant mixing. After the final wash the beads were resuspended in 
35pA of 1.33x protein load buffer (see Section 2.7.2), heated to 100°C for 5 minutes, 
spun in a microfuge (13,800g) for 2 minutes and the supernate electrophoresed through 
an 8.5% SDS-polyacrylamide gel (see Section 2.7.2). The gel was Coomassie stained 
(see Section 2.7.3.1), incubated in 50m1 Amplify (Amersham) for 30 minutes at room 
temperature with agitation, covered with Saran Wrap and dried in a vacuum drier at 
80°C for 2 hours. Immunoprecipitated proteins were visualised by autoradiography after 
removal of the Saran Wrap. 
2.7.12.2 Low Stringency Immunoprecipitation from Yeast Extracts 
Immunoprecipitation from protein extracts under conditions of low stringency 
was performed by a procedure developed in this laboratory by M. Lossky and described 
in Lossky et al. (1987). 
Protein A-Sepharose (PAS) beads were swollen by incubation in NTN buffer 
(50mM Tris-HCl (pH7.5), 0.15M NaCl, 0.1% (v/v) NP40) for 10 minutes and were then 
washed 4 times in the same buffer (these, and all subsequent washes, were performed 
by resuspending the beads in imI of buffer and then recovering them by centrifugation 
in a microfuge (13,800g) for 15 seconds). For each reaction, 20il of swollen PAS was 
incubated with 3-15j1 of the appropriate serum or 15jig of anti-m3G antibody for 1 
hour in 0.1ml total volume of NTN buffer with mixing. The PAS-IgG complexes 
formed were spun down and washed 4-5 times with imI of NTN buffer. For controls, 
IgG was adsorbed to PAS beads in the presence of purified fusion proteins (see Section 
2.7.6), at a concentration of lug per lul of serum used, to form PAS-IgG-fusion protein 
complexes and thus block antigen binding sites on the IgG. 
Splicing extract (see Section 2.5.1) or yeast total cell protein extract (see Section 
2.7.4.2) was diluted with an equal volume of buffer such that final conditions were 
10mM HEPES-KOH (pH7.0), 150mM Na'/K' ions, 2.5mM MgCl2, 0.1% (v/v) NP40 
amd then added to the beads. Alternatively, splicing extract was assembled into a 
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mock-splicing reaction (as described in Section 2.5.2, but with no RNA substrate added, 
-1+ ATP), then diluted with an equal volume of buffer, such that the final conditions 
were as above, and added to the beads. The tube was incubated at 4°C for 2 hours, 
with mixing, to allow the IgG to bind its antigen and the beads were washed 4-5 times 
with NTN buffer and once with NT buffer (50mM Tris-HC1 (pH7.5), 0.15M NaCl). At 
this point the beads were treated for SDS-PAGE as described in Section 2.7.12.1, 
electrophoresed and Western blotted (see Section 2.7.9) or the precipitated RNA was 
purified for analysis as described below. 
The beads were incubated in 50jil of proteinase K solution (50mM Tris-HCI 
(pH7.5), 0.3M NaCl, 5mM EDTA, 1.5% (w/v) SDS, 2mg/ml proteinase K; stored at 
-20°C) for 30 minutes at 37°C and then 50l dH20 was added. The mixture was 
extracted 3 times with phenol/chloroform, to release the RNA and remove the beads 
and protein, and ethanol precipitated (0.2-0.5.Lg of sonicated salmon sperm DNA, 
extensively deproteinised and treated overnight at room temperature with 0.3M NaOH, 
was added as carrier). The purified RNA was then 3'-end labelled and analysed 
directly by polyacrylamide gel electrophoresis (as described in Section 2.4.23) or was 
electrophoresed through a 6% polyacrylamide gel (Section 2.4.8) for Northern blot 
analysis (as described in Sections 2.4.21 and 2.4.22). 
2.7.12.3 Low Stringency Immunoprecipitations from HeLa Cell Nuclear Extracts 
Immunoprecipitation reactions from mock-splicing reactions in HeLa cell nuclear 
extracts (see Section 2.5.3), were performed as described for yeast extracts (Section 
2.7.12.2), except that, in place of NTN and NT buffers, all washes were with HKMN 
buffer (20mM HEPES-KOH (pH7.6), 60mM KCI, 3.2mM MgC12, 0.1% (v/v) NP40) and 
the mock-splicing reaction mix was not diluted prior to incubation with the PAS-IgG. 
2.7.13 Non-denaturing Gel Electrophoresis 
Non-denaturing gel electrophoresis of yeast cell extracts was performed by the 
method of Pikielny et al. (1986). A vertical, 15cmxl5cmxl.5mm gel was cast from 3% 
(w/v) acrylamide (60:1, acrylamide : bisacrylamide), 0.5% (w/v) agarose, 0.5X TBE. To 
each sample was added 1/5th volume of load buffer (50% (v/v) glycerol, 2.5xTBE, 0.05% 
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(w/v) each xylene cyanol and bromophenol blue; stored at -20°C), the mix was loaded 
on 1cm wells in the gel and electrophoresis was carried out in 0.5xTBE at 150V for 
approximately 3 hours at 4°C. 
For Northern hybridisation analysis, the fractionated sample was transferred from 
the gel to Hybond N membrane by electroblotting in 0.5xTBE at 60V and probed 
exactly as described for denaturing polyacrylamide gels (Sections 2.4.21 and 2.4.22). 
Non-denaturing gel electrophoresis of HeLa cell extracts was performed as 
described by Konarska and Sharp (1987). This is essentially as described above for yeast 
extracts, except; (i) a 4% (w/v) acrylamide (80:1 acrylamide : bisacrylamide), 50mM 
Tris-glycine (50mM Tris base, 50mM glycine: pH8.8) gel was cast and run in Tris-glycine 
buffer, (ii) 1/10th volume load buffer (97% (v/v) glycerol, 1% (w/v) each xylene cyanol 
and bromophenol blue) was added to the sample, and (iii) the gel was pre-run for 15-30 
minutes. For Northern hybridisation analysis, this was electroblotted to GeneScreen in 




RAISING ANTISERA TO THE PRP8 PROTEIN 
3.1 INTRODUCTION 
Following the cloning of the PRP8 gene in this laboratory, an immunological 
approach was employed to identify the putative protein product and to commence 
analysis of its function (S.Jackson, in Jackson et al., 1988). Two regions from the centre 
of the PRP8 gene (8.1 and 8.2, see Figure 3.1A) were cloned into the 3' end of the 
E.coli lacZ gene of the pUR series of vectors to allow synthesis of /3-galactosidase--PRP8 
fusion proteins (FP8.1 and FP8.2) and these were used to raise antisera in rabbits 
(S.Jackson, in Jackson et al., 1988). The fusion constructs were made before the 
sequence of the PRP8 gene had been determined, and was achieved by cloning each 
fragment into the lacZ gene in all three reading frames and screening for fusion protein 
synthesis. 
At the outset of this project, the sequence of almost the entire gene had been 
determined (S.Jackson; Ph.D. thesis, University of Edinburgh) and a protein of larger 
than 200kD, predicted from the long open reading frame, had been identified in 
immunoprecipitation experiments. The aim of this project was to raise antisera to 
those regions of the PRP8 protein not represented in FP8.1 or FP8.2 and to use the 
new sera, in combination with anti-8.1 and anti-8.2, to analyse the protein. 	The 
possession of antisera to all regions of the protein was important for two reasons; (i) 
the large species may represent a precursor molecule which is cleaved to smaller 
functional molecule(s) which may not be recognised by antisera raised against FP8.1 or 
FP8.2, or (ii) even if the large species is the active molecule, it is potentially, due to its 
size, a multi-domain protein and antisera to all such domains would facilitate functional 
analysis. 
More recently, further sequencing of the 5' end of the PRP8 gene (S.Dunbar, 
personal communication) has revealed that the start codon lies 351bp upstream from the 
point predicted by the previous sequence. This means that the protein contains 2413 
amino acid residues and has a predicted molecular weight of 28OkD. 
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3.2 	RAISING ANTISERA TO PRP8 FUSION PROTEINS 
3.2.1 Construction of Plasmids to Synthesise Fusion Proteins 
The availability of the full sequence of the PRP8 gene made it possible to 
determine the regions of predicted coding sequence which were not represented in 
pFP8.1 and pFP8.2 and, therefore, to construct plasmids to direct synthesis of 
/3-galactosidase fusion proteins containing most of the remainder of the predicted coding 
sequence. The vectors used for this construction were from the pEX series (Stanley 
and Luzio, 1984). These contain several unique restriction sites in each of the three 
reading frames in the 3' end of the lacz gene which is under the control of the lambda 
1r promoter. Therefore, when these plasmids are present in an E. coli strain bearing 
a lambda c1857 prophage which encodes a temperature-sensitive ci repressor protein, 
synthesis of the 13-galactosidase protein, or of the 13-galactosidase fusion protein, can be 
induced by inactivating the ci repressor at 42°C. 
Figure 3.1A shows the two regions of the PRP8 gene used to make such 
constructs; the 1.26kb BamHI-BgIII fragment of pY85888 was cloned into the BamHI 
site of pEX-3 to make pFP8.3 and the 4.15kb BglII fragment of pY85888 was cloned 
into the BamHI site of pEX-1 to make pFP8.4. The "8.3" fragment consists entirely 
of PRP8 coding sequence, while the "8.4" fragment consists of 1.46kb of PRP8 coding 
sequence from the BglII site to the Clal site, 9bp upstream of the stop codon, and 
2.69kb of YCp50 vector sequence. The first in-frame stop codon in the YCp50-derived 
sequence is 48bp from the ClaI site and, therefore, the plasmid pFP8.4 would be 
predicted to encode a fusion protein with an extra 16 amino acid residues derived from 
YCp50 sequence at its C-terminus. The appropriate pEX vectors were selected to 
maintain the reading frame of the lacZ gene through the PRP8 gene fragment. 
E. coli cells carrying plasmids with the correct insert were identified by colony 
hybridisation, and those with the insert in the desired orientation were identified by 
screening for fusion protein synthesis. Small-scale protein preparations from such cells 
were analysed by SDS-PAGE followed by Coomassie Blue staining of the gel. Figure 
3.113 shows the results of a screen for FP8.3 synthesis and it is clear that the cell 
extracts in lanes 1 and 2 contain j3-galactosidase (116kD) while that in lane 3 contains 
a fusion protein with an apparent molecular weight of approximately 175kD. This is 
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FIGURE 3.1: CONSTRUCTION AND EXPRESSION OF bcZ-PRP8 GENE 
FUSIONS (8.3 AND 8.4) 
Physical map of the PRP8 gene showing the position and orientation of the 
open reading frame (ORF) and restriction enzyme sites: B, BamHI; Bg, BglII; C, Clal; 
X, XbaI. Brackets show the regions used to construct lacZ-PRP8 fusions and the 
predicted molecular weights of the f3-galactosidase-PRP8 fusion proteins are indicated. 
Screening for FP8.3 synthesis. Extracts from heat-induced E.coli pop2136 cells 
containing possible pFP8.3 recombinant plasmids were fractionated on an 8.5% 
SDS-polyacrylamide gel and stained with Coomassie Blue. Sizes of protein molecular 
weight markers (M) are indicated (kD). 
Screening for FP8.4 synthesis. Extracts from heat-induced E.coli pop2136 cells 
containing possible pFP8.4 recombinant plasmids were fractionated on an 8.5% 
SDS-polyacrylamide gel and stained with Coomassie Blue. Markers as in (B). 
Coomassie Blue-stained 8.5% SDS-polyacrylamide gel showing extracts from 
cells of following: pop2136 host strain, uninduced (lane 1) and induced (lane 2); host 
strain containing pEX-1 vector, uninduced (lane 3) and induced (lane 4); host strain 
containing pFP8.3, induced (lane 5); host strain containing pFP8.4, induced (lane 6). 
Markers as in (B). 
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slightly higher than the 165kD predicted by the coding sequence of the PRP8 fragment, 
but restriction analysis of the plasmid carried in these cells supported the correct 
structure (data not shown), suggesting that the migration of the fusion protein in 
SDS-PAGE is aberrantly slow. Figure 3.1C shows a screen for FP8.4 synthesis in which 
the cell extracts in lanes 2, 6-12, and 14 contain 13-galactosidase, while those in lanes 
1, 5, 13 and 15 contain a fusion protein with an apparent M.W. of 170kD, which is the 
size predicted by the coding sequence of the PRP8 fragment. Restriction analysis of 
the plasmid carried in these cells supported the correct structure (data not shown). 
Figure 3.113, by way of summary, shows no change in the protein spectrum in cells of 
the pop2136 host strain upon incubation at 42°C (compare lanes 1 and 2) while 
13-galactosidase is synthesised in cells containing the vector pEX-1 upon induction 
(compare lanes 3 and 4) and the fusion proteins FP8.3 (lane 5) and FP8.4 (lane 6) are 
synthesised in cells containing the constructs pFP8.3 and pFP8.4, respectively, upon 
induction. 
With the discovery that the region at the N-terminus of the PRP8 protein not 
represented in any of FP8.1-FP8.4 sequences was larger than at first thought (see 
Section 3.1), it was decided to construct a plasmid which would synthesise a fusion 
protein containing the rest of the PRP8 protein sequence. In. this case, the vector used 
was from the pUR series (Ruther and Muller-Hill, 1984) which, like the pEX series, 
have several unique restriction sites in the 3' end of the E. coli lacZ gene, but under 
the control of its own promoter. These plasmids are propagated in cells carrying the 
1jq allele, on a F' episome, which overproduces the lac repressor protein. Synthesis 
of the /3-galactosidase protein, or the /3-galactosidase fusion protein, is induced by 
growing the cells in the presence of IPTG. 
Figure 3.2A depicts the construction of this plasmid. The 0.75kb DdeI-SmaI 
fragment of pY8712 was subjected to an end-filling reaction and blunt-end ligated into 
the Hincli site in the polylinker of pEMBL9(+). This fragment contains 735bp of 
PRP8 coding sequence from the DdeI site, 16 codons downstream of the N-terminus 
of the PRP8 protein, to the BamHI site. Plasmids with the correct insert were 
identified by restriction analysis of small-scale plasmid preparations, and one of those 
with the desired orientation of the insert, i.e. with the 5' end of the PRP8 gene 
fragment oriented toward the EcoRI end of the vector polylinker, was sequenced to 
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FIGURE 3.2: CONSTRUCTION AND EXPRESSION OF lacZ-PRP8 GENE 
FUSIONS (8F AND 8.5) 
Construction of gene fusions. Restriction enzyme sites: B, BamHI; Bg, BglII; 
C, dal; X, XbaI. The filled box represents PRP8 coding sequence. 
Screening for FP8.5 synthesis. Extracts from IPTG-induced E.coli NM522 cells 
containing pUR278 (lane 1) or pFP8.5 (lanes 2-7) were fractionated in an 8.5% 
SDS-polyacrylamide gel and stained with Coomassie Blue. Sizes of protein molecular 
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verify the accuracy of the end-filling and blunt-end ligation reactions (data not shown). 
This plasmid construct was called pEM8.5. 
To make the fusion protein construct, the 0.75kb BamHI fragment of pEM8.5 
was cloned into the BamHI site of pUR288 and E.coli cells carrying plasmids with the 
correct insert were identified by colony hybridisation. However, when 26 of such clones 
were screened for fusion protein synthesis, they all produced large amounts of 
13-galactosidase, although several larger proteins, the largest of which had an apparent 
molecular weight of about 145kD, were faintly detected in some cases (data not shown). 
This was, in fact, the size predicted by the coding sequence of the PRP8 fragment. 
When the plasmids in such cells were analysed by restriction digestion, all those which 
gave faint, large proteins, upon induction, proved to have the correct structure (data not 
shown). It was concluded that this fusion protein was unstable in E.coli cells and, upon 
synthesis, the PRP8 portion was rapidly degraded to leave /3-galactosidase. This was not 
altogether surprising, since the N-terminal region of PRP8, which was included in this 
fusion protein, contains several runs of proline residues, each 6-8 amino acids in length, 
which would be predicted to confer a very open conformation upon the region and, 
thus, render it very accessible to proteolytic attack. 
As an alternative, a smaller region of the PRP8 gene was used to make a 
further fusion construct (Fig. 3.2A). The 0.6kb XbaI-HindIII fragment of pEM8.5 was 
cloned into pUR278, cut with XbaI and Hindlil. This fragment contains 546bp of 
PRP8 coding sequence from the XbaI site, immediately downstream of the last of the 
runs of proline residues, to the BamHI site. E.coli cells carrying the correct constructs 
were identified by restriction analysis of small-scale plasmid preparations and screened 
for fusion protein synthesis. Figure 3.2B shows that all such cells synthesise two major 
fusion protein species, the larger of which has an apparent molecular weight of 
approximately 136kD, as predicted from the PRP8 coding sequence. The smaller of the 
two bands probably represents a species created by the partial degradation of the larger 
at its C-terminus. This fusion construct was called pFP8.5 and the fusion protein whose 
synthesis it directs was called FP8.5. 
3.2.2 Raising Antisera to the 13-Galactosidase Fusion Proteins 
Fusion proteins were partially purified from SDS-polyacrylamide gels, or from 
the insoluble protein fraction, and injected into rabbits. Two rabbits, numbers 56 and 
57, were immunised with FP8.3 and two, numbers 58 and 59, with FP8.4. For each 
immunisation, at least 20jg of the gel-purified fusion protein (denatured) and varying 
amounts of fusion protein resolubilised from the insoluble fraction (at least partly 
renatured) were used. Blood withdrawn after the third immunisations of rabbits 56 and 
58 yielded sera which detected PRP8 on Western blots (see Section 3.3.2) and so 
terminal bleeds were collected from these animals after the fourth immunisations. 
Rabbits 57 and 59 gave significantly poorer responses. 
Attempts to raise antisera to FP8.5 in two rabbits failed to produce sera with 
a significant response against the PRP8 portion of the fusion protein. 
3.2.3 Construction of Plasmids to Synthesise TrpE Fusion Proteins 
The generation of TrpE fusion proteins, incorporating the same regions of PRP8 
as are present in FP8.1-8.5, was undertaken in order to provide large quantities of 
antigen for affinity purification of PRP8-specific antibodies from the corresponding 
antisera. The vectors used for these constructions were from the pATH series 
(Dieckmann and Tzagoloff, 1985), which contain several unique restriction sites, in each 
of the three reading frames, in the 3' end of the E.coli IME gene under the control of 
its own promoter. When these plasmids are present in cells grown in the presence of 
tryptophan, synthesis of the TrpE protein or TrpE fusion protein is repressed, but 
lowering the concentration of tryptophan by dilution and the addition of indole acrylic 
acid leads to induction of synthesis of the protein. 
The regions of the PRP8 gene fused to the !ME gene were exactly as for 
FP8.1-8.5 and are shown in Figure 3.3A. The fusion construct pTRP8.1 consists of the 
1.3kb BglII fragment cloned into the BamHI site of pATH-2; pTRP8.2 is the 2.4kb 
BglII fragment of PRP8 cloned into the BamHI site of pATH-2; pTRP8.3 is the 1.3kb 
BamHI-HindIII fragment of pFP8.3 (containing the 1.26kb BamHI-BglII fragment of 
PRP8) cloned between the BamHI and Hindu! sites of pATH-2; pTRP8.4 is the 1.5kb 
BgIII-ClaI fragment of PRP8 cloned between the BamHI and Clal sites of pATH-3; 
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FIGURE 3.3: CONSTRUCI1ON AND EXPRESSION OF p-PRP8 GENE 
FUSIONS 
Physical map of the PRP8 gene showing the position and orientation of the 
open reading frame (ORF) and restriction enzyme sites: B, BamHI; Bg, Bp-III; C, Clal; 
X, XbaI. Brackets show the regions used to construct the p-PRP8 gene fusions and 
the predicted molecular weights of the TrpE-PRP8 fusion proteins are indicated. 
Screening for TRP8.5 synthesis. Extracts from E.coli HB101 cells carrying 
pATH-2, uninduced (lane 1) or IAA-induced (lane 2), and carrying pTRP8.1, uninduced 
(lane 3) or IAA-induced (lane 4), were fractionated on a 8.5% SDS-polyacrylamide gel 
and stained with Coomassie Blue. Sizes of protein molecular weight markers (M) are 
indicated (kD). 
Extraction of TrpE-PRP8 fusion proteins in insoluble protein fractions. 
Insoluble protein fractions were prepared from IAA- induced E.coli HB101 cells carrying 
fl-PRP8 gene fusion constucts and samples were fractionated on an 8.5% SDS-
polyacrylamide gel as follows: pTRP8.1 (lane 1), pTRP8.2 (lane 2), pTRP8.3 (lane 3), 
pTRP8.4 (lane 4), pTRP8.5 (lane 5). Markers as in (B). 
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pTRP8.5 is the 0.6kb XbaI-HindIII fragment of pEM8.6 (containing the 0.55kb 
XbaI-BamHI fragment of PRP8) cloned between the Xbal and Hindill sites of pATI-I-2. 
E. coli cells carrying plasmids with the correct inserts in the desired orientation 
were identified by colony hybridisation, by analysis of small-scale protein preparations 
of induced cultures and by restriction analysis of plasmid DNA preparations (data not 
shown). Figure 3.313 shows a typical result when total protein from cells containing 
pATH vector or pTRP8.1, with or without induction, was analysed by SDS-PAGE and 
Coomassie staining. Upon induction of cells containing vector alone, a protein of 
approximately 37kD, corresponding to TrpE, was synthesised (compare lanes 1 and 2), 
while induction of cells containing pTRP8.1 leads to synthesis of a protein of 
approximately 87kD, as predicted for the TRP8.1 fusion protein (compare lanes 3 and 
4). 
Figure 3.3C shows a Coomassie-stained SDS-polyacrylamide gel with insoluble 
protein preparations from E.coli cells induced for synthesis of all five TrpE fusion 
proteins. TRP8.5 appears as a doublet, with a size difference of approximately 5kD 
(lane 5), matching the pattern seen with its corresponding -galactosidase fusion protein. 
The larger of the two TRP8.5 species and the TRP8.1 (lane 1), TRP8.2 (lane 2) and 
TRP8.4 (lane 4) proteins all gave apparent molecular weights on .SDS-PAGE which 
were consistent with the sizes predicted from the coding regions of the respective PRP8 
fragments. TRP8.3, like the corresponding /3-galactosidase fusion protein, migrates 
aberrantly slowly (lane 3, see Section 3.2.1). 
33 	PROPERTIES OF THE ANTISERA 
3.3.1 Immunoprecipitation of PRP8 Protein 
A protein larger than 200kD, corresponding to the PRP8 gene product had been 
immunoprecipitated from L-[35S]-methionine labelled yeast extracts by anti-8.1 serum, 
but anti-8.2 serum precipitated this protein with a very much lower efficiency (S.Jackson, 
in Jackson et al., 1988). Figure 3.4 shows such an immunoprecipitation experiment 
performed with pre-immune and immune 8.3 and 8.4 sera and with immune 8.1 and 8.2 
sera. Anti-8.1 serum has precipitated the large PRP8 protein (lane 6) but, in this 
instance, this protein was not detected in the immunoprecipitation with anti-8.2 serum 
EJ 
FIGURE 3.4: IMMUNOPRECIPITATION OF THE PRP8 PROTEIN 
Immunoprecipitation of proteins from L-[S]-methionine- labelled extract of 
yeast strain BJ2412 was performed with 10il of each of the following sera: pre-immune 
8.3 (lane 1), immune anti-8.3 (lane 2), pre-immune 8.4 (lane 3), immune anti-8.4 (lane 
4), immune anti-8.2 (lane 5), immune anti-8.1 (lane 6). Immunoprecipitates were 
fractionated in an 8.5% SDS-polyacrylamide gel. Sizes of protein molecular weight 
markers (M) are indicated (kD). 
FIGURE 3.5: DETECTION OF THE PRP8 PROTEIN ON AN IMMUNOBLOT 
Extracts were prepared from yeast strain SPJ8.31 containing YEp24 (lanes 1, 3, 
5 and 7) or pY8000 (lanes 2, 4, 6 and 8) and samples (approximately 100g total 
protein per 0.5cm lane) were electrophoresed through an 8.5% SDS-polyacrylamide gel 
and electroblotted to nitrocellulose. The blot was probed with antisera as follows; 
anti-8.3 (lane 1), anti-8.1 (lane 2), anti8.2 (lane 3), anti-8.4 (lane 4). Sizes of protein 
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(lane 5). Pre-immune 8.3 and 8.4 (lanes 1 and 3) and immune 8.3 (lane 2) sera fail to 
precipitate any labelled proteins of high molecular weight, while immune 8.4 serum 
immunoprecitates a species which co-migrates with the large PRP8 protein (lane 4). 
Therefore, both anti-8.1 and anti-8.4 sera are capable of recognising the protein which 
represents the full-length, primary PRP8 gene product in native protein extracts, 
whereas anti-8.2 and anti-8.3 cannot do so efficiently. 	Anti-8.4 serum also 
immunoprecipitates a protein species of approximately llOkD which co-migrates with 
that immunoprecipitated by anti-8.1 serum in quantities proportional to the copy number 
of the cloned PRP8 gene in transformed yeast cells (Jackson et al., 1988). However, 
this species is not immunoprecipitated with anti-8.4 serum from rabbit no.59, which does 
immunoprecipitate the full-length PRP8 protein, albeit less efficiently than that from 
rabbit no.58 (data not shown), and is, therefore, probably not immunologically related 
to the PRP8 protein. 
3.3.2 Detection of the PRP8 Protein by Immunoblotting 
Immunoblotting experiments were performed on whole cell extracts from strain 
SPJ8.31 harbouring the plasmid pY8000 (carrying the PRP8 gene; expected copy 
number of approximately 5-10 per cell) or the parent vector of pY8000, i.e. YEp24. 
Figure 3.5 shows the results from an experiment in which such extracts were probed 
with antisera against the four PRP8 fusion proteins and, clearly, all four detect the 
280kD PRP8 protein when it is in the denatured form on a Western blot. The 
pre-immune sera do not detect this protein (data not shown). The weakness of the 
signals at 28OkD in the extracts from cells carrying YEp24 alone (lanes 1,3,5 and 7) 
shows that the level of full-length PRP8 protein present in yeast cells is very close to 
the lower limit of detection by this method (the maximum possible amount of extract 
was loaded on each lane). The only signal which is enhanced in extracts from cells 
with the higher copy number of the PRP8 gene is that at 28OkD (compare lanes 2, 4, 
6 and 8 with lanes 1, 3, 5, and 7 respectively). Therefore, the llOkD protein which is 
seen in immunoprecipitations (see Section 3.2.3.1) is not detected by any of the antisera 
on immunoblots, since it, also, was overproduced in cells carrying pY8000. 
[a' 
3.4 	DISCUSSION 
This chapter has described the generation of antisera against 13-galactosidase 
fusion proteins containing two regions of the PRP8 protein (FP8.3 and FP8.4). These 
have been characterised by their ability to recognise the 28OkD primary product of the 
PRP8 gene, both by immunoprecipitation and immunoblotting procedures and their 
properties were compared with those of previously characterised antisera against 
different PRP8 fusion proteins (FP8i. and FP8.2). 
Anti-8.4 serum was able to precipitate the PRP8 protein, while anti-8.3 serum 
was not. However, anti-8.3 serum was able to detect the PRP8 protein on immunoblots 
which suggests that, either the PRP8-specific antibodies in anti-8.3 serum can only 
recognise denatured epitopes, or that such epitopes are inaccessible to the antibodies 
in the native protein. This second possibility could be due to the folding of the PRP8 
protein itself or to its association with other molecules in complexes. 	The same 
phenomenon was seen with anti-8.1 and anti- 8.2 sera, whereby both antisera detect the 
28OkD PRP8 protein on immunoblots but only anti-8.1 serum immunoprecipitates it 
efficiently from native extracts (S.Jackson, Ph.D. thesis). 
The generation of anti-8.3 and anti-8.4 sera meant that antisera against 90% of 
the full 28OkD PRP8 protein were available to commence a functional analysis of the 
protein. 
CHAPTER 4 
THE PRP8 PROTEIN IS A snRNP COMPONENT 
4.1 INTRODUCTION 
The combination of the anti-PRP8 sera, as described in Chapter 3, and the yeast 
in vitro splicing system (Lin et al., 1985) provided the means to analyse the function of 
the PRP8 protein in the splicing reaction. That functional PRP8 protein is required for 
the pre-mRNA splicing reaction in vitro has been established in two ways: (i) prior 
immunodepletion of the protein using anti-8.1 and anti-8.2 sera results in a diminution 
of splicing activity (M.Lossky, in Jackson et al., 1988), (ii) the in vitro splicing activity 
of extracts from cells carrying the prp8-1 mutation is more heat-labile than that of 
extracts from wild-type cells (Lustig et al., 1986). This chapter describes the analysis of 
the interactions of the PRP8 protein with other components of the yeast splicing 
machinery. 
4.2 	THE 28OkD PRP8 PROTEIN IS ASSOCIATED WITH U5 snRNA 
The yeast spliceosome, like its mammalian counterpart, is a large complex 
containing snRNAs and, presumably, many proteins (see Section 1.7.2). By analogy with 
the mammalian system, it seems likely that the yeast snRNAs exist outside the 
spliceosome complexed with proteins as snRNP particles, rather than as naked RNA 
molecules. To detect any interactions between the PRP8 protein and snRNAs, 
immunoprecipitation reactions were performed, under low stringency conditions, from 
in vitro splicing extracts using antibodies from all four anti-PRP8 sera, and any co-
precipitated RNA species were purified and 3'-end labelled. By this means, the two 
forms of U5 snRNA (214 and 179 nucleotides in length) were shown to be 
co-precipitated when using anti-8.1 or anti-8.4, but not with anti-8.2 or anti-8.3 
(M.Lossky, in Lossky et al., 1987). Significantly, US snRNA was only precipitated using 
antibodies from sera which were able to immunoprecipitate the PRP8 protein itself (see 
Section 3.3.1). 
FIGURE 4.1: U5 snRNA CO-PRECIPITATES WITH THE PRP8 PROTEIN 
Sonicated extract (lane 1) or splicing extract (lane 2) from yeast strain BJ2412 
was subjected to immunoprecipitation with anti-8.1 antibodies, RNA was recovered from 
the immune complexes, 3'-end labelled and analysed on a 6% polyacrylamidel7M urea 
gel. DNA size markers (M) were an end labelled MspI digest of pBR322 plasmid DNA 
(sizes in nucleotides). 
Immunoprecipitation 
Antigen competition.xperiments were performed as in (A), but with anti-8.1 
antibodies which had been pre-incubated in the presence of an excess of 3-galactosidase 
(lane 1) or of FP8.1 (lane 2). 
FIGURE 4.2: THE FULL-LENGTH PRP8 PROTEIN CO-PRECIPITATES WITH 
snRNAs 
Immunoprecipitation from yeast splicing extract was performed using anti-m3G 
(lanes 1-4) and anti-8.4 (lane 5) antibodies. Precipitated material was fractionated in 
a 8.5% SDS-polyacrylamide gel, electroblotted to nitrocellulose and probed with the 
following antisera; anti-8.3 (lane 1), anti-8.1 (lane 2), anti-8.2 (lane 3), anti-8.4 (lane 4), 
anti-8.1 (lane 5). Sizes of protein molecular weight markers (M) are indicated (kD). 
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To establish that co-precipitation of the US snRNA species was due to 
association with the PRP8 protein and not with other proteins recognised by the 
antisera, antigen competition experiments were performed. For these, crude, sonicated 
yeast cell extracts were used, and Figure 4.1A shows that the same two US snRNA 
species were precipitated from this extract (lane 2) as from a splicing extract (lane 1) 
using anti-8.1 serum. Figure 4.213 shows a competition experiment in which the anti-8.1 
antibodies, bound to protein A-Sepharose (PAS), were pre-incubated in the presence 
of a vast excess of either /3-galactosidase (lane 1) or of FP8.1 (lane 2). The difference 
between these two reactions was that, when competed by /3-galactosidase, the 
PRP8-specific antibodies were still available to bind their epitopes, while competition 
with FP8.1 blocked these antibodies. It is clear that U5 snRNA was precipitated upon 
competition with /3-galactosidase but not upon competition with FP8.1, while all other 
labelled RNA species were precipitated to the same extent in both cases, i.e. they 
represent non-specific background precipitation. This experiment confirmed that the U5 
snRNA was precipitated due to an association with the PRP8 protein and similar results 
were subsequently obtained when antigen competition experiments were performed on 
splicing extracts (see Section 4.3.1). 
Antibodies against the m3G cap structure can be used to precipitate the full 
range of snRNAs from yeast cell extracts, including the two forms of U5 (Riedel et al., 
1986). Therefore, the proteins which were co-precipitated with snRNAs from a splicing 
extract were analysed by SDS-PAGE and Western blotting. The results are shown in 
Figure 4.2, where lane 5 shows detection of the 28OkD PRP8 protein when probed with 
anti-8.1 serum following precipitation with anti-8.4 antibodies and lanes 1-4 show 
material precipitated with anti-m3G antibodies and probed with each of the four 
anti-PRP8 sera. The asterisks indicate signals which are due to the antibodies in the 
gel, i.e. these were detected in controls where the IgG-PAS complexes were denatured 
and run on the SDS-gel without incubation with splicing extract (data not shown). The 
only specific signal detected in the anti-m3G precipitate corresponds to a protein of 
28OkD detected by all four anti-PRP8 sera and which co-migrates with that precipitated 
by anti-8.4 antibodies. It appears, then, that it is only the full-length, 28OkD PRP8 
protein which is associated with the U5 snRNA and not a smaller processed product, 
since no other PRP8-specific band is detected on the Western blots. 
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43 	EFFECTS OF ATP ON snRNP PRECIPITATION 
4.3.1 Incubation with ATP Has Two Effects on snRNP Precipitation 
M. Lossky (in Lossky et al., 1987) was able to show two distinct effects on the 
pattern of snRNAs associated with the PRP8 protein upon incubation of splicing extract 
under in vitro splicing conditions, without added substrate pre-mRNA ("mock-splicing" 
conditions), in the presence of ATP compared to when ATP was absent. Figure 4.3 
shows such an experiment with anti-8.4 antibodies. Firstly, there was an increase in the 
amount of the two forms of U5 snRNA which was precipitated and, secondly, there 
was additional precipitation of U4 snRNA when ATP was present (compare lanes 1 and 
2). The additional precipitation of U4 snRNA was shown to be specific to anti-PRP8 
antibodies by a competition experiment in which it is abolished by pre-saturation of the 
antibodies with FP8.4 (lane 4), but not by pre-saturation with /3-galactosidase (lane 3). 
With anti-8.1 antibodies, the increased precipitation of U5 snRNA is observed, but not 
the additional precipitation of U4 snRNA (M.Lossky, in Lossky et al., 1987). 
4.3.2 Increased U5 snRNP Precipitation 
The increased precipitability of U5 snRNA upon incubation under mock-splicing 
conditions in the presence of ATP could be due to either; (i) de novo association of 
PRP8 protein with U5 snRNAs, or (ii) increased precipitability of PRP8-U5 snRNP 
complexes which already exist in the extract. To test this, the efficiency of precipitation 
of the PRP8 protein with anti-8.4 antibodies was compared before and after incubation 
of a splicing extract in the presence of ATP. Figure 4.4A shows that precipitation of 
the PRP8 protein, detected by Western blotting, was increased approximately 3-fold 
after incubation with ATP, reflecting the increased precipitation of the U5 snRNA 
species after incubation of the same extract with ATP (Figure 4.4B). In similar 
experiments, the amount of PRP8 protein precipitated from an extract which had been 
incubated under mock-splicing conditions in the absence of ATP was increased relative 
to that precipitated from extract which had not been pre-incubated, but was less than 
that precipitated from extract incubated in the presence of ATP (data not shown). 
This, once again paralleled the increased precipitability of the U5 snRNA species and, 
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FIGURE 4.3: EFFECT OF INCUBATION WITH ATP ON snRNA PRECIPITATION 
Splicing extract was incubated at 25°C for 20 minutes in splicing buffer without 
ATP (lane 1) or in the presence of 2mM ATP (lanes 2-4), before being subjected to 
immunoprecipitation with anti-8.4 antibodies and RNA was purified and 3'-end labelled. 
Antigen competition was performed by pre-treatment of the antibodies with an excess 
of -gaIactosidase (lane 3) or FP8.4 (lane 4). 
FIGURE 4.4: INCUBATION WITH ATP INCREASES THE PRECIPITABILITY OF 
Splicing extract was subjected to immunoprecipitation with anti-8.4 antibodies 
directly (lanes 2, 4, 6 and 8) or after incubation in splicing buffer with 2mM ATP (lanes 
3, 5, 7 and 9). Precipitated material was fractionated in an 8.5% SDS-polyacrylamide 
gel and blotted to nitrocellulose. Mock immunoprecipitation was performed in the 
absence of extract (lane 1). The blot was probed with antisera as follows; anti-8.3 
(lanes 1-3), anti-8.1 (lanes 4 and 5), anti-8.2 (lanes 6 and 7) and anti-8.4 (lanes 8 and 
9). Sizes of protein molecular weight markers (M) are indicated (kD). 
Splicing extract was subjected to immunoprecipitation with anti-8.4 antibodies 
directly (lane 1) or after incubation at 25°C for 20 minutes in splicing buffer with 2mM 
ATP (lane 2) and precipitated RNA was purified and analysed as described in Figure 
4.1. 
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presumably, reflected the presence of endogenous ATP in the splicing extract. Indeed, 
the increase in U5 snRNA precipitability upon incubation without additional ATP 
varies greatly between different extracts, suggesting that the amount of endogenous ATP 
present is highly variable. 
These results indicate, then, that the increased precipitability of the U5 snRNA 
species, upon incubation in the presence of ATP, reflects an increased precipitability of 
U5 snRNP particles which contain the 28OkD PRP8 protein. 
4.3.3 Precipitation of U4 and U6 snRNAs 
It was shown that incubation of splicing extract under mock-splicing conditions 
in the presence of ATP leads to precipitation of U4 snRNA with anti-8.4 antibodies 
(Section 4.3.1) and that this represented U4 and U5 snRNPs precipitating as a complex 
rather than as separate snRNPs independently associated with the PRP8 protein 
(M.Lossky, in Lossky et al., 1987). In metazoan cells, the U4 and U6 snRNAs are 
found base-paired to one another in a single snRNP particle (Bringmann et al., 1984; 
Hashimoto and Steitz, 1984; Rinke et al., 1985) while the yeast species have also been 
shown to be associated by base-pairing (Siliciano et al., 1987; Brow and Guthrie, 1988). 
This suggested that U6 snRNA may also be associated with PRP8 after incubation in 
the presence of ATP, yet no species of the appropriate size was detected in 3'-end 
labelling experiments. However, it was possible that this was due to the U6 snRNA 
being a poor substrate for the 3'-end labelling reaction, since its 3' terminus contains 
a run of uridine residues and is predicted to be sequestered in secondary structure 
(England et al., 1980). 
Possible precipitation of U6 snRNA was investigated by Northern blot analysis. 
RNA, precipitated from a splicing extract with antibodies from anti-8.4 serum, was 
purified. Half was 3'-end labelled and analysed as usual, while the other half was 
electrophoresed, unlabelled, through a denaturing polyacrylamide gel, electroblotted to 
a nylon membrane and probed with a radiolabelled oligonucleotide complementary to 
U6 snRNA. Figure 4.5 depicts the result of such an experiment in which panel A 
shows the Northern blot probed for U6 and panel B shows the 3'-end labelled RNA 
from the same reactions. Clearly, U6 snRNA (112-115nt) was precipitated by anti-8.4 
antibodies after incubation in the presence of ATP (compare lanes 2 and 3). The 
FIGURE 4.5: U6 snRNA CO-PRECIPITATES WITH THE PRP8 PROTEIN 
Splicing extract was incubated at 25°C for 20 minutes in splicing buffer without 
ATP (lane 2) or in the presence of 2mM ATP (lanes 3-5) before being subjected to 
immunoprecipitation with anti-8.4 antibodies and RNA was purified from the immune 
complexes. The samples were split and half of each was fractionated in a 6% 
polyacrylamidel7M urea gel. Total RNA (T) extracted from from a half volume of 
splicing extract was directly analysed (lane 1). RNA was electroblotted to Hybond N 
nylon membrane and probed with a 5'-end labelled U6 snRNA- specific oligonucleotide. 
Antigen competition was performed by pre-incubation of the antibodies with an excess 
of -galactosidase (lane 4) or FP8.4 (lane 5). 
The other half of the purified RNA from each of the reactions described in (A) 
was 3'-end labelled and analysed on a 6% polyacrylamidc/7M urea gel. 
FIGURE 4.6: EFFECT OF HEPARIN ON snRNA PRECIPITATION 
Splicing extract was incubated at 25°C for 20 minutes in splicing buffer without 
ATP (lanes 1 and 3) or in the presence of 2mM ATP (lanes 2 and 4). Distilled H20 
(1/10th volume; lanes 1 and 2) or heparin (1/10th volume of 40mg/mi; lanes 3 and 4) 
was added and incubation continued for a further 5 minutes. The reaction mixes were 
subjected to immunoprecipitation with anti-8.4 antibodies and the precipitated RNA was 
analysed as described in Figure 41. 
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abolition of U6 snRNA precipitation by pre-incubation of the antibodies with an excess 
of FP8.4 (lane 5), but not by pre-incubation with an excess of 13-galactosidase (lane 
4), shows that the precipitation of U6 snRNA is mediated by the PRP8 protein. 
Antibodies from anti-8.1 serum do not precipitate U6 snRNA (data not shown), and so 
the pattern of precipitation of this species exactly parallels that of the U4 snRNA. 
	
4.4 	EFFECTS OF HEPARIN ON snRNP PRECIPITATION 
The association of U4/U6 and US snRNPs upon incubation in the presence of 
ATP (as described in Section 4.3) appeared to be in direct contradiction to the results 
of Cheng and Abelson (1987), who report an ATP-dependent dissociation of an 
endogenous U4/U5/U6 snRNP complex, as analysed by electrophoresis on 
non-denaturing polyacrylamide gels. However, it was possible that the addition of 
heparin to the samples, prior to loading on the gel, was having an effect on the 
complexes. To test this, immunoprecipitations with anti-8.4 antibodies were performed 
in the presence of an equivalent amount of heparin (final concentration of 4mg/mi). 
The result is shown in Figure 4.6, and, although some of the sample has been lost from 
lane 3 (compare background signals with those in other lanes), it is clear that the 
presence of heparin has dramatic effects on the precipitation of snRNAs. Firstly, in the 
presence of ATP, the amount of US snRNA precipitated is greatly decreased (compare 
lanes 2 and 4) and, secondly, U4 snRNA is precipitated in the absence of ATP (lane 
1), but not in its presence (lane 2). It appears that the presence of heparin disrupts 
the U5 snRNP, such that it is only poorly precipitated with anti-8.4 antibodies, and 
causes it to associate with U4 snRNA (presumably as part of the U4/1J6 snRNP) in a 
complex which is dissociated in the presence of ATP. These results, in the presence 
of heparin, are entirely consistent with those obtained with the non-denaturing gel 
system (Cheng and Abelson, 1987). 
4.5 	IS PRP8 AN Sm-ANTIGEN? 
The finding that PRP8 is a stable component of the yeast U5 snRNP raises the 
possibility that the precipitability of the U5 snRNP by antibodies from various Sm-sera 
(see Section 1.5.2.2) occurs via a direct recognition of this particular protein. To test 
Rb 
this, Western blots of total yeast splicing extract were probed with various Sm-sera 
(Kung, JE and #24) but, while they all detected a variety of smaller species, none 
detected a protein of greater than 200kD (data not shown). In addition, when blots of 
material precipitated from splicing extracts by anti-8.4 antibodies were probed, no signals 
were detected (data not shown). These results seem to indicate that PRP8 is not an 
Sm-antigen, but could also mean that the Sm-antibodies do not recognise the epitopes 
in a denatured form or, indeed, that insufficient PRP8 is present on the blots to be 
detected. 
4.6 	DISCUSSION 
In this chapter, it has been demonstrated that the full-length, 28OkD, PRP8 
protein is a component of the U5 snRNP. Under a variety of conditions which affect 
the precipitability of U5 snRNA species, the long (214nt) and short (179nt) forms are 
always precipitated in approximately equal amounts (M.Lossky, personal communication). 
This suggests that the two forms exist within a single snRNP particle, or that there are 
two forms of the U5 snRNP which are present in approximately equal amounts, both 
containing the PRP8 protein (for further discussion, see below). Variations in the 
precipitability of the PRP8 protein appear to be reflected in the precipitability of the 
U5 snRNA species, indicating that the PRP8 protein is a stable component of the 
snRNP particle. This is further supported by the finding that the association is observed 
in crude, sonicated cell extracts which are not competent for the in vitro splicing 
reaction. 
The failure of anti-8.2 and anti-8.3 antibodies to precipitate the U5 snRNA 
species reflects their inability to precipitate the PRP8 protein from [ 35  S]-labelled cell 
extracts (see Section 3.3.1). As was suggested in Section 3.4, this could be due to an 
inability to recognise their epitopes in the native protein or to the inaccessibility of their 
epitopes. Neither possibility can be discounted, although the finding that the PRP8 
protein is a stable snRNP component, complexed with snRNA and, presumably, other 
proteins, might suggest that certain regions of the protein would be masked by these 
other components and rendered inaccessible to antibody binding. 
The increased precipitability of the U5 snRNP following incubation of splicing 
extract in the presence of ATP can be explained in either of two ways. Firstly, it may 
be due to a conformational change in the PRP8 protein, or in the snRNP particle, such 
that the anti-8.1 and anti-8.4 epitopes are rendered more accessible to antibody binding. 
Alternatively, the ATP incubation may result in the release of the US snRNP from 
higher order complexes in which these epitopes are inaccessible to antibody binding. 
Given that the increased precipitability is observed with both anti-8.1 and anti-8.4 
antibodies, which recognise large and widely separated (in the primary sequence) regions 
of the PRP8 protein, any conformational change would need to be very substantial and, 
therefore, the second explanation would seem more plausible. 
The additional co-precipitation of U4 and U6 snRNAs, by anti-8.4 antibodies, 
upon incubation in the presence of ATP, would appear to represent the association of 
U5 and U4/U6 snRNPs to form a multi-snRNP complex. Anti-8.1 antibodies do not 
precipitate U4 and U6 snRNAs from extracts incubated with ATP, even though 
precipitation of U5 snRNA is very efficient. Immunodepletion of U5 snRNPs from an 
ATP-treated extract using anti-8.1 antibodies prevents the subsequent precipitation of 
both US and U4 snRNAs by anti-8.4 antibodies (M.Lossky, personal communication). 
This result suggests that the binding of anti-8.1 antibodies disrupts the U4/U5/U6 snRNP 
complex and precipitates all the released US snRNP and that anti-8.4 antibodies do not 
recognise the U4/1J6 snRNP directly. 
Recently, antibodies against the yeast PRP4 protein have been shown to 
precipitate complexes containing U4, US, and U6 snRNAs from splicing extracts 
(Peterson-Bjorn et al., 1989; Banroques and Abelson, 1989). Such complexes are 
precipitated in the absence of exogenous ATP, although at higher salt concentrations 
U4 and U6 are preferentially precipitated and in the presence of heparin and ATP only 
U4 and U6 snRNAs are precipitated (Banroques and Abelson, 1989), suggesting that 
the PRP4 protein is associated with the U4/U6 snRNP. It may be that endogenous 
complexes containing U4, US and U6 snRNPs are precipitable by antibodies against the 
PRP4 protein, but not by those against the PRP8 protein. These results, and those 
described in this chapter, can be drawn together into a model wherein endogenous 
snRNP complexes dissociate upon incubation in the presence of ATP, freeing the 
U4/U6 and US snRNPs to interact with each other in a distinct complex, precipitable 
by anti-8.4 antibodies. 	The results with anti-PRP4 antibodies in the presence of 
heparin are similar to those obtained with anti-PRP8 antibodies, i.e. complexes 
containing U4, U5, and U6 snRNA are present in the absence of ATP, but are 
disrupted in its presence. 
Studies have been carried out on the formation of snRNP complexes, in the 
absence of heparin, in HeLa cell extracts. Konarska and Sharp (1987, 1988) detected 
an endogenous U4/U5/U6 multi-snRNP particle in HeLa cell nuclear extracts, as assayed 
by nondenaturing gel electrophoresis. However, upon incubation in the presence of 
ATP, more free U4, U6 and U4/U6 snRNP particles were detected and U411J51U6 
multi-snRNP particles accumulated. The endogenous complex may not be functionally 
equivalent to the U4/U5/U6 multi-snRNP particle. Possibly, upon incubation with ATP, 
snRNPs are released from such an endogenous complex and become free to form into 
U4/1J5/U6 multi-snRNP complexes. Such a model would be consistent with the results 
described in this chapter for yeast extracts. D. Black (personal communication) analysed 
snRNP complex formation in HeLa cell extracts by means of glycerol gradient 
centrifugation and his data clearly indicate the ATP-dependent formation of a U4/U5/U6 
snRNP complex. Endogenous multi-snRNP complexes were not detected by this 
method. 
The ATP-dependent U4/U51U6 snRNP complex, detected in immunoprecipitation 
reactions, may represent an intermediate in spliceosome formation, a pathway for which 
has been deduced from the analysis of snRNA components of complexes separated on 
non-denaturing gels (Pikielny et al., 1986; Konarska and Sharp, 1987). The first 
splicing-specific complex which forms on the pre-mRNA contains U2 snRNA and this 
is converted to one which contains U2, U4, U5, and U6 snRNAs. Therefore, the 
formation of the U4/U5/U6 multi-snRNP complex is entirely compatible with these 
snRNPs entering the spliceosome simultaneously. That the level of the U4/U5/U6 
snRNP complex in HeLa cell extracts declines as active spliceosomes are formed 
(Konarska and Sharp, 1987), lends support to the idea that this complex represents an 
intermediate in spliceosome assembly. 
Since the PRP8 protein is a stable component of the U4/U5/U6 multi-snRNP 
complex, it seems likely that this protein, also, is incorporated into the spliceosome. 
Indeed, it was shown that anti-8.4 antibodies, but none of those against other fusion 
proteins, were able to precipitate splicing intermediates (free exon 1 and lariat 
intron-exon 2) and one of the products (lariat intron) from a yeast in vitro splicing 
reaction (M.Lossky, personal communication). This indicates that the PRP8 protein is, 
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indeed, present in the functional spliceosome and that, following partial dissociation of 
the complex after the reaction, it remains associated with the lariat intron product and 
not with the spliced mRNA. 
As mentioned above, both forms of the yeast U5 snRNA were always 
precipitated in approximately equal amounts using anti-PRP8 antibodies. Analysis of 
the snRNA components of the yeast spliceosome yielded similar results, i.e. both forms 
were detected in approximately equal amounts (Pikielny et al., 1987). Taken together 
with the results presented in this chapter, several possible models for the existence of 
two forms of this species can be postulated; (i) each U5 snRNP contains equal amounts 
of each form, (ii) each U5 snRNP contains either one form or another, but each 
multi-snRNP complex or spliceosome contains equal amounts of each form of U5 
snRNP, or (iii) as for (ii), but each multi-snRNP complex spliceosome contains either 
a U5 snRNP with the long form of snRNA or one with the short form, i.e. the two 
forms are functionally interchangeable. Patterson and Guthrie (personal communication) 
have shown that yeast cells carrying a mutated SNR7 gene, capable only of transcribing 
the short form of U5 snRNA, are viable. This result supports the idea that the two 
forms are functionally interchangeable, although it cannot be discounted that such cells 
would be disadvantaged under certain growth conditions. 
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CHAPTER 5 
INTERACTIONS OF THE PRP8 PROTEIN 
5.1 INTRODUCTION 
In Chapter 4, it was established that the PRP8 protein is a stable component 
of the U5 snRNP and that it enters the spliceosome, possibly via a U4/U5/U6 
multi-snRNP complex. With the antibodies against /3-galactosidase-PRP8 fusion 
proteins, several routes to the investigation of interactions of the PRP8 protein within 
these complexes are available. In this chapter, attempts to reconstitute the US snRNP 
are described, the success of which would allow identification of the protein components 
of the particle and analysis of RNA-protein interactions. In addition, the RNA-binding 
properties of the PRP8 protein, and of fusion proteins containing regions of the PRP8 
protein, are investigated. 
5.2 	IN VITRO RECONSTITUTION OF THE US snRNP 
5.2.1 Synthesis of SNR7 Gene 
In vitro assembly of functional Ui snRNPs on in vitro transcribed, radiolabelled 
Ui snRNA has been achieved in Xenopus oocyte extract (Hamm et al., 1987) and in 
HeLa cell S100 extract (Patton et al., 1987). This led to a detailed analysis of the 
RNA-protein interactions in this complex, and to structural models for the snRNP 
(Hamm et al., 1988; Patton and Pederson, 1988). 
To perform analogous experiments for the yeast US snRNP, it was necessary to 
generate yeast US snRNA transcripts in vitro. However, the cloned SNR7 gene 
(Patterson and Guthrie, 1987) has no convenient restriction sites at its 5' or 3' ends to 
allow its insertion downstream of a bacteriophage promoter (SP6 or Ti). To circumvent 
this problem, it was decided to synthesise the gene de novo. Six oligonucleotides, as 
shown in Figure 5.1A, were synthesised and the full-length products were gel-purified. 
These were designed to produce, when ligated together, the SNR7 gene with the 
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FIGURE 5.1: ATTEMPTED IN VITRO RECONSTITUTION OF THE U5 snRNP 
Construction of the synthetic SNR7 gene. The six oligonucleotides used to 
construct the gene are indicated, showing their sizes and the positions of the phage T7 
gene 10 promoter, the HpaI restriction enzyme site and the BamHI and PstI restriction 
enzyme site compatible termini. 
In vitro transcription of the SNR7 gene. The plasmid pFN-1 was linearised with 
HpaI and transcribed by T7 RNA polymerase and an aliquot of the reaction mix was 
electrophoresed through a 6% polyacrylamidel7M urea gel. Sizes of markers are 
indicated in nucleotides (MspI digest of pBR322 plasmid DNA). 
Gel retardation assay for protein binding to U5 snRNA. Radiolabelled, in vitro 
transcribed US snRNA was incubated for 15 minutes at room temperature in the 
presence of 75mM monovalent cations, 5mM MgC12, 2mg/mi tRNA in the absence (lane 
1) or presence (lane 2) of Sjil of yeast splicing extract. The reaction mixes were 
electrophoresed through non-denaturing composite polyacrylamide/agarose gels. 
Analysis of US snRNA-containing complexes in a yeast splicing extract. Extract 
was incubated at 25°C for 20 minutes in splicing buffer in the absence of ATP (lane 
1) or in the presence of 2mM ATP (lane 2). The reaction mixes were electrophoresed 
through a non-denaturing gel, as in (C), blotted to Hybond N nylon membrane and 
probed with a 5'-end labelled oligonucleotide specific for U5 snRNA. 
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bacteriophage 77 gene 10 promoter at its 5' end and a HpaI restriction site at its 3' end 
in a BglII-I cassette. This was cloned into the BamHI and PstI sites of pEMBL8(+) 
and single-stranded DNA was prepared and sequenced. This verified that the construct 
had the desired sequence, and the plasmid was named pFN-l. 
When pFN-1 plasmid DNA was linearised by digestion with HpaI, it could be 
used as a template for in vitro transcription using T7 RNA polymerase. The 217nt 
run-off transcript synthesised in this way was identical to the long-form of US snRNA 
except that it possessed 2 additional G residues at the 5' end and an additional U 
residue at the 3' end. Figure 5.113 shows the [32P}-labelled transcript obtained in such 
a reaction, where essentially all of the RNA synthesised is full-length. 
5.2.2 Attempted Reconstitution of U5 snRNP 
Radiolabelled, in vitro synthesised U5 snRNA was incubated in the presence of 
cold, competitor tRNA and yeast cell extract and binding of proteins was analysed by 
gel retardation assay on non-denaturing polyacrylamide-agarose composite gels. Figure 
5.1C shows the result of a typical experiment where lane 1 contained RNA in the 
absence of extract and lane 2 contained RNA after incubation with splicing extract. 
Clearly, the migration of the RNA was retarded after incubation in the splicing extract, 
indicating that it was bound by proteins. The pattern obtained in this experiment, i.e. 
that of two retarded complexes, was repeatedly seen under a variety of conditions, i.e. 
different concentrations of MgCl2, presence or absence of ATP, presence or absence 
of a GpppG cap structure on the US snRNA, in the presence of varying amounts of 
competitor tRNA, and also when performed with sonicated yeast extract (data not 
shown). In an attempt to disrupt endogenous snRNP particles and, possibly, increase 
the concentration of free snRNP proteins available to bind exogenous snRNA, extracts 
were pre-treated with micrococcal nuclease, but this had no effect on the retardation 
pattern obtained (data not shown). When, for comparison, splicing extract was run on 
such a non-denaturing gel, blotted to a nylon membrane and probed with a US-specific 
oligonucleotide probe, U5 snRNA was seen to be present in several complexes (Figure 
5.2D). The fastest migrating of these, presumably the free U5 snRNP, co-migrated with 
the slowest migrating complex observed in the reconstitutuion experiment. It was 
possible, therefore, that this represented a reconstituted US snRNP particle. 
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To test whether the U5 snRNA was indeed being sequestered into snRNP 
complexes, immunoprecipitations were performed on reconstitution mixes using anti-8.4 
antibodies and anti-Sm antibodies (from serum #24, M.Daliymple, this laboratory), both 
of which would precipitate genuine U5 snRNP particles. The results of these 
experiments indicated that a tiny proportion (less than 1%) of the U5 snRNA was 
precipitable with anti-Sm antibodies after incubation in splicing extract, whereas none 
was precipitable with anti-8.4 antibodies (data not shown). This strongly suggests that 
the gel retardation of the U5 snRNA does not represent the formation of snRNP 
complexes, but rather is due to the non-specific RNA-binding activity of proteins in the 
extracts. 
53 	RNA-BINDING PROPERTIES OF THE PRP8 PROTEIN 
Since the PRP8 protein is a component of the U5 snRNP and of the 
spliceosome, it is possible that it directly binds RNA, either the U5 snRNA or the 
substrate pre-mRNA, in these complexes. This was investigated using the technique of 
"North-Western blotting" whereby proteins are transferred to nitrocellulose membranes 
from SDS-polyacrylamide gels and probed for RNA-binding properties with radiolabelled 
RNA. 
When total yeast splicing extract, or proteins precipitated with anti-8.4 antibodies, 
were probed with either pre-mRNA or U5 snRNA, no binding to a 28OkD protein was 
detected (data not shown). This may suggest that the PRP8 protein does not bind 
RNA, but it is also possible that the amount of PRP8 protein present on such blots was 
too small to be detected by this method. 
Fusion proteins, however, provide a ready source of plentiful amounts of 
particular regions of the PRP8 protein, so TRP8.1 to TRP8.5 (see Section 3.2.3) were 
tested for their ability to bind RNA and Figure 5.2 shows the result of such an 
experiment. Figure 5.2A depicts a Coomassie-stained SDS-polyacrylamide gel displaying 
insoluble E.coli protein preparations containing each of the five TrpE-PRP8 fusion 
proteins (lanes 1-5). Figure 5.213 depicts the result of probing a blot, corresponding to 
the gel in Figure 5.2A, plus purified poly(A)-binding protein in lane 6, with a 
polyadenylated pre-mRNA (rp5lApA, transcribed in vitro from pSPrp5lApA). As 
expected, the poly(A)-binding protein binds the transcript through an interaction with 
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FIGURE 5.2: TRP8.5 FUSION PROTEIN BINDS RNA 
Insoluble protein fractions from induced E.coli HB101 cells containing 
pTRP8.1-8.5. Samples from insoluble protein fractions were fractionated and analysed 
as described in Figure 3.3C: TRP8.1 (lane 1), TRP8.2 (lane 2), TRP8.3 (lane 3), TRP8.4 
(lane 4), TRP8.5 (lane 5). Sizes of protein molecular weight markers (M) are indicated 
(kD). 
Blot assay for RNA binding. Samples of insoluble protein fractions containing 
TRP8.1-8.5 were subjected to electrophoresis as in (A), but with an additional track 
containing 2g of purified polyadenylate-binding protein (lane 6). Proteins were 
electroblotted to nitrocellulose and probed with radiolabelled rp51ApA transcript. 
Amino acid sequence of a portion of the PRP8 protein represented in TRP8.5. 
Basic residues are indicated by underlining. 
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its poly(A) tail (lane 6) and, of the TrpE fusion proteins, only TRP8.5 binds the RNA 
(lane 5). The failure of TRP8.1-TRP8.4 to bind the transcript to any significant extent 
shows that the TrpE portion of the fusion proteins does not possess RNA-binding 
activity. The binding of RNA by TRP8.5 is therefore due to the PRP8 portion of the 
fusion protein. 
To test whether this binding is specific for intron-containing pre-mRNA species, 
further experiments were performed in which TRP8.5 was probed with U5 snRNA and 
anti-sense transcript from exon 2 of the yeast CYH2 gene. In both cases, TRP8.5 
bound to the RNA species as strongly as to the rp5lApA transcript, indicating that the 
binding activity of the region of the PRP8 protein present in TRP8.5 is not 
sequence-specific (data not shown). 
5.4 	DISCUSSION 
In this chapter, it was shown that exogenous US snRNA was not reconstituted 
into snRNP particles when incubated in yeast whole cell extracts, as assayed by 
precipitability by antibodies which precipitate endogenous US snRNP particles. Many 
possible reasons for this can be envisaged, a few of which are outlined below. 
In the reconstitution of the Ui snRNP (Hamm et al., 1987; Patton et al., 1987), 
extracts which are known to be rich in free snRNP proteins were used and this is 
probably not true of yeast splicing extract. Attempts to disrupt endogenous U5 snRNPs 
with micrococcal nuclease may have been unsuccessful on two counts; (i) although 
micrococcal nuclease digestion leads to degradation of full-length U5 snRNA in splicing 
extracts, smaller fragments remain uncleaved, presumably protected by proteins (data not 
shown), (ii) snRNP proteins may have been rendered insoluble on disruption of the 
complexes. It may be that the extracts used in the Ui snRNP studies contain more 
snRNP proteins than non-specific RNA-binding proteins. This is unlikely to be the 
case in yeast whole cell extracts, given the low abundance of snRNPs. Therefore, upon 
addition of the snRNA, there may be competition between the snRNP-specific proteins 
and non-specific RNA-binding proteins for binding, with the former predominating in 
Xenopus oocyte and HeLa S100 extracts and the latter predominating in yeast cell 
extracts. This would explain the sequestering of exogenous U5 snRNA into complexes 
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which are retarded on non-denaturing gels. It is not clear, though, why such binding 
would not be competed by the addition of an excess of tRNA. 
The TRP8.5 fusion protein was found to possess a non-specific RNA-binding 
property. Although it is possible that the interface between the TrpE and the PRP8 
portions of the fusion protein generate a novel RNA-binding site, this interaction is 
probably mediated by the PRP8 portion alone. The region of the PRP8 protein present 
in this fusion protein (Figure 53C) contains a segment between amino acids 85 and 124 
in which 19 out of 39 are basic residues (S.Jackson, Ph.D. thesis, University of 
Edinburgh; S.Dunbar, personal communication). This represents a strong candidate for 
a RNA-binding site within the PRP8 component of TRP8.5. It has been shown that 
the PRP8 protein can be cross-linked, by UV-irradiation, to pre-mRNA in the 
spliceosome, which strongly implies a direct binding to the splicing substrate 
(E.Whittaker, personal communication). It is tempting to speculate, in this light, that 
the basic region between residues 85 and 124 constitutes the substrate-binding site. 
There are several possible reasons why TRP8.5 does not show binding specificity 
for pre-mRNA. The PRP8 protein may not have a sequence-specific binding capacity, 
but rather may function to bind a non-conserved region of the substrate in the 
spliceosome, e.g. exon 1. Alternatively, the specificity of RNA-binding may be conferred 
by regions of the PRP8 protein not represented in TRP8.5, or, indeed, by other proteins 
in the U5 snRNP, or in the spliceosome. 
The finding that PRP8 protein directly contacts the pre-mRNA, combined with 
its presence in the U5 snRNP, leads to speculation on its relationship to the 
intron-binding protein of HeLa cells (Gerke and Steitz, 1986; Tazi et al., 1986). This 
protein, of 70kD (Gerke and Steitz, 1986) or lOOkD (Tazi et al., 1986), binds 
specifically to the polypyrimidine tract upstream of the 3' splice site and, under certain 
conditions, co-purifies with the U5 snRNP. The possibility that the PRP8 protein 
represents a yeast homologue of this protein is considered in Chapter 6. 
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CHAPTER 6 
IDENTIFICATION OF A PRP8 HOMOLOGUE IN HELA CELLS 
6.1 INTRODUCTION 
In most respects, the process of pre-mRNA splicing in yeast cells closely 
resembles that in higher eukaryotic cells. As discussed in Chapter 1, the basic two-step 
pathway is conserved and, in both cases, this takes place in a large complex, the 
spliceosome. By non-denaturing gel electrophoresis, three splicing specific complexes can 
be separated in yeast and HeLa cell in vitro splicing reactions, and these are equivalent 
on the basis of snRNA and splicing substrate, intermediate and product content (see 
Section 1.7). In Chapter 4, it was shown that a U4IU5ItJ6 multi-snRNP complex forms 
in yeast extracts under similar conditions to those which promote formation of an 
equivalent complex in HeLa cell extracts. 
In this light, it might be predicted that at least some of the protein splicing 
factors will be conserved between yeast and human cells, as, indeed, are the 
spliceosomal snRNAs to varying extents (see Section 1.5.2.1). Evidence for this is 
provided by the finding that certain patient anti-Sm sera can precipitate both human and 
yeast snRNPs, indicating conservation between the species of the Sm-epitope(s) on at 
least one protein in each snRNP (see Section 1.5.2.2). The generation of antibodies 
against the /3-galactosidase-PRP8 fusion proteins provided an opportunity to investigate 
whether HeLa cells contain a homologue of the yeast PRP8 protein. However, snRNAs 
were not precipitated from HeLa cell nuclear extracts by antibodies against FP8.1-FP8.4 
(M.Lossky; Ph.D. thesis, Imperial College, London). 
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6.2 	IDENTIFICATION BY IMMUNOBLOTING OF A HUMAN HOMOLOGUE 
OF PRP8 
6.2.1 Antibodies Against PRP8 Detect a Large HeLa Protein 
The inability of anti-PRP8 antibodies to precipitate snRNAs from HeLa cell 
extracts (see Section 6.1) does not preclude the existence of a human homologue of the 
PRP8 protein. It is possible, for instance, that the antibodies do not recognise the 
native form of such a homologue, or that the homologue is not stably associated with 
any snRNAs under the conditions tested. Assaying for the precipitation of snRNAs by 
anti-PRP8 antibodies did not, therefore, constitute a very rigorous test for the existence 
of a homologous protein in human cells. 
HeLa cell nuclear extract (a gift from P. Sharp, M.I.T) was tested for the 
presence of proteins which are recognised by anti-PRP8 sera (anti-8.1 to anti-8.4) in 
immunoblotting experiments, and the results are shown in Figure 6.1A. Clearly, a large 
number of HeLa cell nuclear proteins cross-reacted with each of the anti-PRP8 sera and 
few firm conclusions could be drawn from such an experiment. However, it is 
interesting to note the detection of a species of approximately 220kD by anti-8.1 (lane 
2), anti-8.2 (lane 3), and anti-8.4 (lane 4) sera, but not by anti-8.3 serum (lane 1). As 
an initial test for which of these signals is due to antibodies against the PRP8 portion 
of the fusion proteins, antibodies from anti-8.2 serum were affinity purified against 
/3-galactosidase or FP8.2 and used to probe blots of HeLa cell nuclear extract (Figure 
As before, crude anti-8.2 serum detected a large number of proteins (lane 1), 
many of which were detected by antibodies purified against FP8.2 (lane 3). Antibodies 
purified against f3-galactosidase gave the same pattern, but with the exception of the 
220kD species (lane 2), clearly indicating that only the 220kD signal results from 
antibodies specific to the PRP8 portion of FP8.2. Similar results were obtained using 
affinity purified antibodies from anti-8.1 serum (data not shown). 
To confirm that antibodies to three different regions of the PRP8 protein 
recognise a 220kD HeLa cell protein, immunoblotting experiments were repeated with 
antibodies affinity purified against the corresponding TrpE-PRP8 fusion proteins (Figure 
This experiment showed that affinity purified anti-8.1 (lane 1), anti-8.2 (lane 2), 
and anti-8.4 (lane 3) antibodies detect the 220kD species in HeLa cell nuclear extract. 
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FIGURE 6.1: DETECTION OF A 220kD HELA PROTEIN IMMUNOLOGICALLY 
RELATED TO PRP8 
Probing HeLa cell nuclear extract with whole antisera. Aliquots (6p1) of nuclear 
extract were fractionated in an 8.5% SDS-polyacrylamide gel. electroblotted to 
nitrocellulose and probed with antisera as follows; anti-8.3 (lane 1), anti-8.1 (lane 2), 
anti-8.2 (lane 3), anti-8.4 (lane 4). Sizes of protein molecular weight markers (M) are 
indicated (kD). 
Aliquots of HeLa cell nuclear extract were subjected to electrophoresis and 
electroblotted as in (A) and then probed as follows; anti-8.2 serum (lane 1), IgG from 
anti-8.2 serum affinity purified against /3-galactosidase (lane 2), or against FP8.2 (lane 
3). Markers as in (A). 
Aliquots of HeLa cell nuclear extract were subjected to electrophoresis and 
electroblotted as in (A) and probed as follows; IgG from anti-8.1 serum affinity purified 
against TRP8.1 (lane 1), IgG from anti-8.2 serum affinity purified against TRP8.2 (lane 
2), IgG from anti-8.4 serum affinity purified against TRP8.4 (lane 3). Markers as in 
(A). 
FIGURE 6.2: PRP8-SPECIFIC ANTISERA DETECT A LARGE PROTEIN(S) IN 
A PURIFIED U5 snRNP FRACTION 
Aliquots of 20S U5 snRNP fraction, purified as described in Bach et al. (1989), 
were fractionated in a 4-20% gradient SDS- polyacrylamide gel. The total protein 
content was visualised by staining with Coomassie Blue (lane 1). Protein from the 
remainder of the samples was electroblotted to nitrocellulose and probed as follows; 
pre-immune 8.4 serum (lane 2), immune anti-8.4 serum (lane 3), pre-immune 8.2 serum 
(lane 4), immune anti-8.2 (lane 5), IgG from anti-8.4 serum affinity purified against 
TRP8.4 (lane 6), IgG from anti-8.2 serum affinity purified against TRP8.2 (lane 7). 
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As for crude anti-8.3 serum, affinity purified anti-8.3 antibodies did not detect this 
species (data not shown). Control experiments confirmed that only antibodies affinity 
purified against the corresponding TrpE fusion protein detected the 220kD protein (data 
not shown). 
6.2.2 The Human PRP8 Homologue Co-purifies with U5 snRNP Particles 
It was shown that a proportion of purified U5 snRNP particles from HeLa cell 
extracts contain several specific proteins, two of which are larger than 200kD (Bach et 
submitted). To determine if either of these proteins corresponds to the species 
detected by anti-PRP8 antibodies (see Section 6.2.1), purified U5 snRNP proteins were 
separated on an SDS-polyacrylamide gel, blotted and probed with anti-PRP8 sera and 
antibodies (performed by R. Lührmann and shown in Figure 6.2). Lane 1 shows the 
range of U5 snRNP proteins revealed by Coomassie Blue staining, with the common 
core snRNP proteins B', B, D, D', E, F, and G and the U5 snRNP-specific proteins 
with apparent molecular weights of 40, 52, 100, 102, 116, and >200 (doublet) kD. 
When probed with anti-8.2 (lane 3) or anti-8.4 (lane 5) total sera, signals corresponding 
to the doublets at >200kD and approximately lOOkD were obtained, but with anti-8.2 
(lane 7) and anti-8.4 (lane 6) antibodies affinity purified against the corresponding TrpE 
fusion proteins, only a signal corresponding to a protein of >200kD was observed. This 
provides strong evidence that the human homologue of the yeast U5 snRNP-specific 
PRP8 protein is associated with a proportion of the U5 snRNP particles. 
6.3 	IMMUNOPRECIPITATION FROM HELA IN VITRO SPLICING REACTIONS 
The presence of the PRP8 protein in the yeast spliceosome was demonstrated 
by the ability of anti-PRP8 antibodies to precipitate complexes containing splicing 
intermediates from an in vitro splicing reaction (M. Lossky, Ph.D. thesis; Imperial 
College, London). In order to test for the presence of the homologous protein in the 
human spliceosome, immunoprecipitation reactions were performed on in vitro splicing 
reactions in the HeLa cell nuclear extract. Figure 6.3A shows the time course of 
splicing using a SP6 RNA polymerase-transcribed RNA substrate containing the first 
two exons and IVS1 of the human p-globin gene (Kramer et al., 1984). The RNA 
FIGURE 6.3: IMMUNOPRECIPITATION OF HELA SPLICEOSOME 
Time course of in vitro splicing reaction in a HeLa cell nuclear extract. Splicing 
of radiolabelled /3-globin transcript was allowed to proceed at 30°C for the times 
indicated before RNA was purified and fractionated in a 10% polyacrylamide/7M urea 
gel. 
Immunoprecipitation from HeLa splicing reaction. Reactions were allowed to 
proceed for 60 minutes before being subjected to immunoprecioitation with pre-immune 
8.4 (lane 1) or immune anti-8.4 (lane 2) antibodies. RNA was purified from immune 
complexes and analysed as in (A). Total RNA was purified from a half volume splicing 
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intermediates and products were identified on the basis of their electrophoretic 
mobilities relative to DNA size markers (not shown) and of the kinetics of their 
appearance and disappearance. It was clear that the splicing intermediates, free exon 
1 and lariat intron-exon 2, were most abundant after 1 hour of incubation (compare 
lane 4 with others), suggesting that functional spliceosomes were most abundant at this 
time point. Accordingly, subsequent immunoprecipitation reactions were performed on 
reactions halted after 1 hour. 
Immunoprecipitation reactions from such splicing reactions revealed that anti-8.1. 
anti-8.2 and anti-8.4 antibodies were all capable of precipitating pre-mRNA and all 
intermediate and product species (anti-8.3 antibodies were not tested). A typical 
example of such an experiment is presented in Figure 6.313 for anti-8.4 antibodies where 
antibodies from immune serum (lane 2) clearly precipitated more of the RNA species 
than did antibodies from pre-immune serum (lane 1). Precipitation of the spliced 
mRNA product was unexpected, since this species dissociates from the complex 
containing the lariat intron product (Konarska and Sharp, 1987) and, in addition, is not 
precipitated from yeast splicing reactions by anti-PRP8 antibodies (M.Lossky, Ph.D. 
thesis; Imperial College, London). 
However, when the precipitation reactions were performed with antibodies 
affinity purified against TrpE fusion proteins, the RNA species were not precipitated 
to any significant extent (data not shown). In addition, the precipitation of the RNA 
species by anti-8.1 and anti-8.4 antibodies from total serum was blocked by competition 
with an excess of any /3-galactosidase fusion protein, while that by anti-8.2 antibodies 
was unaffected, even by the corresponding fusion protein (data not shown). These data 
clearly indicate that the precipitation of the RNA species from splicing reactions was 
not specific to antibodies against the PRP8 portions of the 13-galactosidase fusion 
proteins. The precipitation by anti-8.1 and anti-8.4 appears to be due to antibodies 
against the /3-galactosidase portion of the fusion proteins, while that by anti-8.2 appears 
to be due to some other antibody specificity in the serum. 
6.4 	THE HUMAN HOMOLOGUE OF PRP8 IS Sm-PRECIPITABLE 
The findings that anti-PRP8 antibodies failed to precipitate snRNAs from HeLa 
cell extracts (M.Lossky, Ph.D. thesis; Imperial College, London) or spliceosomes from 
HeLa in vitro splicing reactions (see Section 6.3) may, initially, appear inconsistent with 
the discovery that the PRP8 homologue co-purifies with the human U5 snRNP. 
However, it is possible that the anti-PRP8 antibodies fail to recognise the homologue 
in its native form and so cannot precipitate it, or, therefore, any associated species, from 
nuclear extract. The ability of these antibodies to detect the homologue on an 
immunoblot provided the means to investigate the precipitability of this protein by 
anti-PRP8 antibodies and by anti-Sm and anti-m3G antibodies. 
It was shown that anti-PRP8 antibodies were unable to precipitate the 
homologous human protein of approximately 220kD from HeLa cell nuclear extract, as 
assayed by probing blots of the precipitated material with anti-8.4 serum (data not 
shown). To test for the ability of anti-Sm and anti-m3G antibodies (both of which 
precipitate all the spliceosomal snRNPs) to precipitate this species, experiments were 
performed using nuclear extract which had been pre-incubated for 45 minutes under 
"mock splicing" conditions in the presence or absence of ATP. The results, shown in 
Figure 6.4k indicate that anti-8.4 antibodies detect a species of greater than 200kD 
precipitated strongly by anti-Sm antibodies in the presence of ATP (lane 6)  but poorly 
in its absence (lane 5).  Two species, the larger of which co-migrates with the strongly 
Sm-precipitable species, are weakly precipitated by anti-m3G antibodies (lane 2), with 
a slight increase observed upon incubation in the presence of ATP (lane 3). Anti-m3G 
precipitation of this doublet proved to be quite variable, although always very weak, lane 
7 showing an example of their precipitation from an extract which had not been pre-
incubated. A weak signal corresponding to a protein co-migrating with the smaller of 
the two anti-m3G precipitable species was observed in the anti-Sm precipitate (lane 5), 
but was not enhanced by ATP incubation (lane 6), nor was it seen in subsequent 
precipitations (see Figures 6.413 and 6.4C). 
To confirm that the strongly Sm-precipitable species represents the PRP8 
homologue detected in total nuclear extract in Section 6.2.1, Sm-precipitated material 
was blotted and probed with anti-8.1 to anti-8.4 sera. The experiment (Figure 6.413) gave 
the same pattern of detection as was obtained for the homologue of PRP8 identified 
in Section 6.2.1, i.e. anti-8.1 (lane 2), anti-8.2 (lane 3) and anti-8.4 (lane 4) sera 
detected the large protein while anti-8.3 (lane 1) serum did not. This strongly suggests 
that the Sm-precipitable protein is, indeed, the human homologue of PRP8. 
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FIGURE 6.4: THE HUMAN HOMOLOGUE OF PRP8 IS Sm-PRECIPITABLE 
Precipitation from mock splicing reactions in HeLa cell nuclear extracts. Extract was 
incubated at 30°C for 45 minutes in splicing buffer in the absence of ATP (lanes 2 and 5) or 
in the presence of 1.6mM ATP and 8mM creatine phosphate (lanes 3 and 6) and subjected 
to immunoprecipitation with anti-m3G (lanes 2 and 3) or anti-Sm (lanes 5 and 6) antibodies. 
Precipitated material was fractionated in an 8.5% SDS-polyacrylamide gel, blotted to 
nitrocellulose and probed with anti-8.4 serum. Mock immunoprecipitations were performed with 
anti-m3G (lane 1) and anti-Sm (lane 4) antibodies. Sizes of protein molecular weight markers 
(M) are indicated (kD). Lane 7 shows a separate anti-m3G immunoprecipitation performed 
from a nuclear extract which was not pre-incubated. 
HeLa cell nuclear extract was incubated in the presence of ATP, subjected to anti-Sm 
immunoprecipitation, fractionated and blotted as in (A). The lanes were probed with serum 
as follows; anti-8.3 (lane 1), anti-8.1 (lane 2), anti-8.2 (lane 3), anti-8.4 (lane 4). 
HeLa cell nuclear extract was incubated in the presence of ATP, as in (A). Distilled 
H20 (1/10th volume, lane 1) or heparin (1/10th volume of 50mg/mi, lane 2) was added and 
incubation continued at 30°C for 5 minutes. The reaction mixes were subjected to anti-Sm 
immunoprecipitation, fractionated and blotted as in (A) and probed with anti-8.4 serum. 
HeLa cell nuclear extract was incubated in the absence of ATP (lane 1) or in its 
presence (lanes 2 and 3) as in (A). Distilled H20 (lanes 1 and 2) or heparin (lane 3) was 
added, as in (C), and the reactions subjected to anti-Sm immunoprecipitation. RNA was 
purified from immune complexes, fractionated in a 6% polyacrylamide/7M urea gel, blotted to 
Hybond N membrane and probed with 5'-end labelled oligonucleotides specific for human U4, 
US and U6 snRNAs. 
HeLa cell nuclear extract was incubated in the absence (lane 3) or presence of ATP 
(lanes 1 and 2) and dH20 (lanes 2 and 3) or heparin (lane 1) was added, as in (C). The 
reaction mixes were then subjected to electrophoresis through a 4% non-denaturing 
polyacrylamide gel and were blotted to Hybond N membrane. The blot was sequentially probed 
with 5'-end labelled oligonucleotides specific for human U4 snRNA (lanes 1, 2 and 3), U5 
snRNA (lanes 4, 5 and 6) and U6 snRNA (lanes 7, 8 and 9). 
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This result does not distinguish between the possibilities that the homologue of 
PRP8 is an Sm-antigen and is being directly recognised by the antibodies or that it is 
being precipitated through an interaction with Sm antigens, e.g. as a snRNP component. 
It was shown that the Sm-serum used in these precipitation reactions ("Kung") did not 
detect the homologue of PRP8 in an immunoblotting experiment (data not shown). 
This does not preclude the possibility, however, that the anti-Sm antibodies can 
recognise the homologue in its native form in the extract, but not in a denatured form 
on a blot. 
Incubation of a yeast splicing extract in the presence of heparin had a profound 
effect on the snRNP population, seeming to disrupt snRNP-snRNP interactions and to 
partially dissociate individual snRNP particles (see Section 4.4). Following the ATP 
incubation, the effect of a brief incubation in the presence of heparin on the 
Sm-precipitation of the homologue of PRP8 was tested and the result is shown in 
Figure 6.4C. The presence of heparin resulted in an increase in the precipitation of the 
homologue of the PRP8 protein by Sm-antibodies (lane 2) compared to the amount 
precipitated when heparin was absent (lane 1). Figure 6.4D shows a blot of the RNA 
precipitated by the Sm-antibodies after incubation in the presence of ATP (lane 2) and 
in the presence of ATP and heparin (lane 3). The blot was probed with radiolabelled 
oligonucleotides specific for human U4, U5 and U6 snRNAs. The amounts of U5 and 
U6 snRNAs precipitated under these conditions parallels the amounts of the homologue 
of PRP8 precipitated, i.e. heparin increased the precipitation several-fold. 
The effect on snRNP complexes of incubation of nuclear extract in the 
presence of heparin and ATP was analysed by electrophoresis through a non-denaturing 
gel, blotting and probing, sequentially, for U4, U5, and U6 snRNAs (Figure 6.4E). The 
effect of incubation in the presence of ATP (lanes 2, 5 and 8), as compared to 
incubation in its absence (lanes 3, 6 and 9), is essentially the same as previously 
described, i.e. material moves out of the well, U4/U5106 complex accumulates, as do 
free U4 and U6 particles (Konarska and Sharp, 1987; Konarska and Sharp, 1988). 
Incubation with heparin, following the ATP incubation, (lanes 1, 4 and 7) results in 
dissociation of the U4/U5[116 complex and the appearance of several faster migrating 
particles, presumably due to partial dissociation of the snRNP complexes. These faster 
migrating particles are rendered more Sm-precipitable and, if the homologue of PRP8 
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remains associated with the U5 snRNP, this would explain its increased precipitability 
under these conditions. 
If incubation in the presence of ATP, or in the presence of ATP and heparin, 
increases the precipitability of snRNP particles, it is possible that anti-PRP8 antibodies 
might precipitate the PRP8 homologue from a similarly treated extract. However, this 
species was not detectably precipitated by anti-8.1 or anti-8.4 antibodies under these 
conditions (data not shown). 
If the homologue is being precipitated by Sm-antibodies through an interaction 
with the U5 snRNP or, indeed, through an association with the U4/U5/U6 multi-snRNP 
complex formed in HeLa cell nuclear extracts in the presence of ATP (Konarska and 
Sharp, 1988; Black, personal communication), it might be possible to diminish this 
interaction, and hence the precipitation, by disruption of the U4, U5, or U6 snRNAs. 
Disruption was achieved by incubation of nuclear extract with oligonucleotides 
complementary to regions of the snRNAs known to be available for base-pairing (Black, 
personal communication) and with RNase H, which digests DNA-RNA hybrids. Figure 
6.5A shows a blot of total RNA in the nuclear extract following RNase H digestion in 
the presence of a control oligonucleotide (lane 1) or in the presence of oligonucleotides 
specific for U4 (lane 2), U5 (lane 3), or U6 (lane 4) snRNAs, and probed with 
radiolabelled probes for these snRNAs. Under such conditions, U4 and U6 snRNAs 
are essentially completely degraded, while U5 snRNA is approximately 50% degraded, 
consistent with the results of Black (personal communication). Figure 6.513 shows the 
result of probing Sm-precipitates from such RNase H-treated extracts for the homologue 
of PRP8, and it is seen that degradation of U4, US, or U6 snRNAs has little effect on 
the amount of this protein precipitated. 
6.5 	RNA-BINDING PROPERTIES OF THE HUMAN HOMOLOGUE OF PRP8 
A human protein which specifically binds the 3' splice site region of pre-mRNA 
was found to be associated with U5 snRNP particles and was reported as being of 
apparent molecular weight 70kD (Gerke and Steitz, 1986) or lOOkD (Tazi et at., 1986). 
The apparent conflict in the reported size of this protein was, presumably, the result of 
proteolytic degradation during fractionation of the cell extracts. The possibility existed 
that both these species may represent proteolytic products of the PRP8 homologue, so 
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FIGURE 6.5: Sm-PRECIPITATION OF THE PRP8 HOMOLOGUE IS UNAFFECTED 
BY CLEAVAGE OF U4, U5 OR U6 snRNAs. 
HeLa cell nuclear extract was incubated in the presence of ATP, as in Figure 4.1A, but 
with the addition of 2 units of RNase H and lg of oligonucleotide as follows; control (lane 
1), U4 snRNA-specific (lane 2), U5 snRNA-specific (lane 3), U6 snRNA-specific (lane 4). 
Total RNA was purified, fractionated in a 6% polyacrylamide/7M urea gel, blotted to Hybond 
N membrane and probed with 5'-end labelled oligonucicotides specific for human U4, US and 
U6 snRNAs. 
Nuclear extract was treated as in (A), but then subjected to immunoprecipitation with 
anti-Sm antibodies. Precipitated material was fractionated in an 8.5% SDS-polyacrylamide gel, 
blotted to nitrocellulose and probed with anti-8.4 serum. Lanes as in (A). 
FIGURE 6.6: THE HOMOLOGUE OF PRP8 BINDS RNA 
HeLa cell nuclear extract was fractionated in an 8.5% SDS- polyacrylamide gel, blotted 
to nitrocellulose and probed with radiolabelled /3-globin transcript. Sizes of protein molecular 
weight markers (M) are indicated (kD). 
HeLa cell nuclear extract was incubated in the presence of ATP and heparin was added, 
as in Figure 6.4C. The reaction was subjected to immunoprecipitation with anti-Sm antibodies 
and precipitated material was fractionated in an 8.5% SDS- polyacrylamide gel and blotted to 
nitrocellulose. Duplicate lanes were probed with anti-8.4 serum (lane 1) and radiolabelled 
f3-globin transcript (lane 2). Markers as in (A). 
FIGURE 6.7: DETECTION OF AN IMMUNOLOGICALLY RELATED PROTEIN IN 
DROSOPHILA WHOLE CELL EXTRACT 
Drosophila whole cell extract was fractionated in an 8.5% SDS-polyacrylamide gel, 
blotted to nitrocellulose and probed with sera as follows; anti-8.3 (lane 1), anti-8.1 (lane 2), 
anti-8.2 (lane 3), anti-8.4 (lane 4). Sizes of protein molecular weight markers (M) are indicated 
(kD). 
HeLa cell nuclear extract (lane 1) and Drosophila whole cell extract (lane 2) was 
fractionated and blotted as in (A) and probed with IgG from anti-8.1 serum affinity purified 
against FP8.1. Markers as in (A). 
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the RNA-binding properties of the homologue were investigated by probing protein 
blots with radiolabelled transcripts. 
Initially, total protein in HeLa cell nuclear extract was fractionated on a 
SDS-polyacrylamide gel, blotted to nitrocellulose and probed with radiolabelled human 
13-globin transcript containing exon 1, IVS1 and exon 2 (Figure 6.6A). This revealed 
that there is, indeed, a large protein which binds pre-mRNA. In similar experiments, 
where parallel strips were probed with pre-mRNA and anti-8.4 antibodies, this protein 
was shown to co-migrate with the homologue of PRP8 (data not shown). 
The criterion of co-migration on an SDS-polyacrylamide gel was insufficient to 
identify the RNA-binding protein as the homologue of PRP8, so the Sm-precipitability 
of the RNA-binding protein was assayed (Figure 6.613). HeLa cell nuclear extract was 
pre-incubated under "mock splicing" conditions in the presence of ATP, heparin was 
added and incubation continued for 5 minutes before being subjected to 
immunoprecipitation with anti-Sm antibodies. The precipitated material was fractionated 
by SDS-PAGE and assayed for RNA-binding or probed for the presence of the 
homologue of PRP8 as before. Several proteins with RNA-binding capacity were 
precipitated by the Sm-antibodies (lane 2), the largest of which co-migrated with the 
PRP8 homologue detected with anti-8.4 serum (lane 1). This strongly suggests that the 
protein of approximately 220kD, which binds pre-mRNA in this assay, is the human 
homologue of PRP8. 
If this protein is related to the intron-binding protein, then its binding of RNA 
on blots should be specific to intron-containing transcripts (Gerke and Steitz, 1986; 
Tazi et al., 1986). However, the human homologue of PRP8 was shown to bind, with 
equal efficiency, a truncated p-globin transcript which lacked any intron sequence (data 
not shown). 	The RNA-binding properties of this protein are not intron 
sequence-specific, as assayed on protein blots, and it appears, therefore, to be unrelated 
to the intron-binding protein of the US snRNP particle. 
6.6 	IDENTIFICATION BY IMMUNOBLOTFING OF A PUTATIVE DROSOPHILA 
MELANOGASTER HOMOLOGUE OF PRP8 
Total protein extract of Drosophila melanogaster cultured cells was tested for 
the presence of species recognised by antisera to FP8.1-FP8.4 by immunoblotting. The 
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results, shown in Figure 6.7A, revealed a similar pattern to that obtained with HeLa cell 
nuclear extract (see Section 6.2.1), in that many proteins were detected by each 
antiserum and a species with an apparent molecular weight of greater than 200kD was 
detected by anti-8.1 (lane 2), anti-8.2 (lane 3) and anti-8.4 (lane 4) sera, but not by 
anti-8.3 (lane 1) serum. An immunoblot of D.melanogaster cell extract probed with 
affinity purified anti-8.1 antibodies (Figure 6.713, lane 2) showed that the large protein 
was the most strongly detected and migrated slightly slower than the human homologue 
(lane 1). A species with apparent molecular weight of approximately 200kD, also 
detected by affinity purified anti-8.1 antibodies, may represent a degradation product of 
the larger species within this extract. At the moment, no further experimental evidence 
exists in support of this protein representing a true D.melanogaster homologue of the 
yeast PRP8 protein. 
6.7 	DISCUSSION 
In this chapter, it has been demonstrated that HeLa cells contain a protein 
which is recognised on immunoblots by anti-PRP8 antibodies. It has an apparent 
molecular weight some 60W smaller than the yeast PRP8 protein and it is not detected 
by anti-8.3 antibodies, perhaps suggesting that it lacks a domain homologous to that 
represented in FP8.3. The homologous protein is not, however, precipitable by 
antibodies against any of FP8.1 to FP8.4, and this could be due to one of several 
reasons. It may, for instance, possess only small regions of structural similarity which 
are inaccessible to antibody binding in its native form, either due to folding of the 
protein or to its interaction with other molecules. It is, of course, possible that the 
HeLa protein has strong similarity to the PRP8 protein, but that it is completely 
inaccessible to antibody binding within a large complex. 
It was shown that the putative homologue of PRP8 is one of a number of 
proteins which co-purify with human U5 snRNP particles (Bach et al., 1989). This 
strongly supports the idea that this protein is functionally homologous to the yeast PRP8 
protein, since they are both associated with the U5 snRNP particle. There would 
appear to be a difference in the stability of the interaction with the snRNP particle 
between the yeast and human proteins. Only 15-20% of purified human U5 snRNPs 
contain the homologue of PRP8, or any U5-specific proteins, in the presence of low 
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Mg2 concentrations, while high concentrations of this divalent cation completely 
abolish interactions of the specific proteins with the core snRNP particle (Bach et al., 
1989). In yeast, on the other hand, the PRP8-U5 snRNP interaction is stable over a 
wide range of concentrations of monovalent and divalent cations (M. Lossky, in Lossky 
et al., 1987). 
That the PRP8 homologue is precipitable by Sm-antibodies indicates either that 
the protein carries an Sm-epitope(s) and is being directly recognised by the antibodies, 
or that it is associated with other Sm-reactive proteins. The protein is not detected on 
immunoblots by Sm-antisera implying that it does not carry any Sm-epitopes, although 
it is possible that such an epitope is not recognised in the denatured form. The finding 
that Sm-precipitation is dependent on incubation of the extract in the presence of ATP 
suggests that the protein, if being directly recognised by the antibodies, is becoming 
available for precipitation or that it is becoming associated de novo with Sm-reactive 
proteins, presumably in a snRNP particle. Precipitation of U4, U5 and U6 snRNAs 
with Sm-antibodies is increased by pre-incubation in the presence of ATP (Figure 6.4D), 
but not to the extent which would explain the increased precipitation of the PRP8 
homologue, therefore the ATP effect cannot be explained simply by an increased 
precipitation of snRNP particles containing the homologous protein. It is possible that 
some, or all, of the U5 snRNP-specific proteins cycle on and off the core particle, thus 
explaining the small proportion of purified particles which contain them (Bach et al., 
1989) and that upon pre-incubation in the presence of ATP, more of the proteins cycle 
on to the U5 snRNP particle. Alternatively, it could be that the U5 snRNPs which 
become available de novo during ATP incubation are structurally distinct from those 
already available in that they contain the homologue of PRP8. 
The reasons for the poor, and variable, anti-m3G precipitation of the homologue, 
and the additional precipitation of a slightly smaller species, are not clear. 
Immunoaffinity purification over an anti-m3G column constitutes the first stage of the 
U5 snRNP purification (Bach et al., 1989), after which a proportion of US snRNPs still 
contain the PRP8 homologue (see Section 6.2.2). It may be that, under the conditions 
used for the immunoprecipitations in this study, binding of the cap by anti-m3G 
antibodies induces a conformational change which causes the PRP8 homologue to 
dissociate from most of the snRNP particles. Perhaps, due to such a conformational 
change, the PRP8 homologue which remains associated is rendered susceptible to limited 
proteolysis, thus explaining the precipitation of the smaller species. 
Oligonucleotide-directed cleavage of U4 and U6 snRNAs has been shown to 
abolish the formation of an ATP-dependent U4/U5/U6 snRNP complex (Black, personal 
communication). The failure of such cleavage to diminish the Sm-precipitability of the 
homologue of PRP8 shows that this protein does not become associated with snRNPs 
solely during formation of the U4/U5/U6 complex. Cleavage of 50% of U5 snRNA has 
no effect on the Sm-precipitability of the homologue. This could be due to (i) 
precipitation of the homologue not being mediated by the U5 snRNP, (ii) snRNP 
structure not being disrupted by cleavage at this region of the snRNA, or (iii) the 
snRNA in snRNPs associated with the homologue being inaccessible to the 
oligonucleotide and RNase H (i.e. the 50% uncleaved U5 snRNA). 
A protein with apparent molecular weight in excess of 200kD has been identified 
in the human spliceosome and has been shown to become cross-linked to pre-mRNA 
substrate upon UV-irradiation (M.Garcia-Blanco, M.I.T.; personal communication). That 
the yeast PRP8 protein can also be cross-linked to the substrate pre-mRNA 
(E.Whittaker, personal communication) strongly suggests that this protein represents the 
homologue of PRP8 and that it, too, has a RNA-binding role in the spliceosome. 
Interestingly, attempts to immunoprecipitate this protein with anti-PRP8 antibodies gave 
similar results to those obtained when attempting to precipitate spliceosome complexes 
(see Section 6.3), i.e. the cross-linked protein was precipitated by immune antibodies, 
but this effect was not specific to antibodies against the PRP8 portion of the fusion 
proteins (M. Garcia-Blanco, M.I.T.; personal communication) 
The RNA-binding studies in this chapter suggest that the PRP8 homologue does 
not bind a specific sequence in the pre-mRNA. This indicates that the protein is 
distinct from the intron-binding protein (Gerke and Steitz, 1986; Tazi et al., 1986) and 
supports the finding that none of the smaller U5 snRNP-specific proteins are 
degradation products of the larger species (Bach et al., 1989). These results add 
significance to the findings, presented in Chapter 5, that the region of the yeast PRP8 
protein present in TRP8.5 has a non-specific RNA-binding capacity and suggest a role 
for the yeast and human proteins in binding to non-conserved regions of the substrate 
in the spliceosome. Gerke and Steitz (1986) detected a protein of apparent molecular 
weight greater than 200kD which binds RNA, as assayed on blots, and which co-purifies 
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with snRNPs. These properties, combined with the fact that it did not display an 
intron-specific pattern of RNA-binding, suggest that this protein is the human 
homologue of PRP8. 
The immunoblotting experiments using Drosophila melanogaster whole cell 
extracts show that there is a protein in this species which displays a similar pattern of 
immunological cross-reactivity with the yeast PRP8 protein as does the human 
homologue. However, definitive identification of this protein as a true functional 
homologue will require evidence that it is a component of the U5 snRNP particle. 
CHAPTER 7 
FINAL DISCUSSION 
7.1 	PRP8 AND PRE-mRNA SPLICING 
The results described in this thesis can be used, in conjunction with published 
data, to postulate a model for spliceosome formation (Figure 7.1). The PRP8 protein 
is a stable component of U5 snRNP particles, a variable proportion of which exist, in 
splicing extracts, in endogenous snRNP complexes. Upon incubation in the presence 
of ATP, this complex dissociates to give free U5 and U4/U6 snRNP particles which can 
then assemble into "active" U4/U5/U6 snRNP complexes, structurally distinct from the 
endogenous complexes. This ATP-dependent complex then joins the early splicing 
complex III to convert it to complex I, constituting a major step in spliceosome 
formation. The PRP8 protein is an integral component of the functional spliceosome, 
where it directly contacts the pre-mRNA, during the splicing reaction. Following step 
2 of the reaction, the spliceosome dissociates, spliced mRNA is released and the intron 
lariat remains associated with snRNPs, including PRP8-containing US snRNP. 
Therefore, the PRP8 protein is a component of at least four different types of complex 
through the course of spliceosome assembly and disassembly; (i) the U5 snRNP, (ii) the 
ATP- dependent U4/U5/U6 snRNP complex, (iii) the active spliceosome, and (iv) the 
post-splicing, intron-containing complex. 
As yet, there are few clues as to the function of PRP8 in pre-mRNA splicing. 
The role of the U5 snRNP in mammalian splicing is unknown, since suggestions that 
it is involved very early in 3' splice site selection seem to be contradicted by its absence 
from early splicing complexes. It may be that the U5 snRNP acts to deliver the 3' 
splice site-specific intron-binding protein to the pre-mRNA but does not, itself, stably 
join the splicing complex until later in the pathway of formation. In yeast, the 3' splice 
site is not important for complex formation, so there may not be a homologue of the 
intron-binding protein. Thus, the role of the yeast U5 snRNP remains completely 
unknown. 
FIGURE 7.1: MODEL OF PRE-mRNA SPLICING REACTION 
Model postulated on the basis of a combination of published data and results presented 
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The immunological approach which has permitted the identification of the 
various PRP8-containing complexes will, in combination with genetic approaches, be 
instrumental in their further analysis and in the investigation of the specific function of 
PRP8. I will present a brief outline of the lines of investigation which may prove most 
successful, some of which have already been embarked upon in this laboratory. 
Purification of the stable U5 snRNP particle by immunoaffinity chromatography 
would be very useful. In this way, the other protein components of the particle could 
be identified and the Sm-antigen(s) determined and, possibly, sufficient protein sequence 
information could be obtained to allow synthesis of oligonucleotide probes and, hence, 
cloning of the genes encoding them. The raising of antibodies to fusion proteins, 
exactly as described in this thesis for PRP8, would greatly expand the bank of 
immunological probes available to study the role of the U5 snRNP in the splicing 
process. Purified U5 snRNPs, if disrupted, may provide a source of free snRNP 
proteins to achieve successful reconstitution of the particle using radiolabelled snRNA. 
The possibility that sequence specificity of RNA-binding is conferred upon PRP8 by the 
structure of the snRNP could be investigated with purified particles. 
As mentioned in Section 5.4, the anti-PRP8 antibodies have led to the 
demonstration that the PRP8 protein can be directly cross-linked to pre-mRNA in the 
spliceosome, suggesting direct contact (E. Whittaker, personal communication). 
Identification of the RNase Ti fragment which becomes cross-linked to the protein will 
define the PRP8 binding site and give clues as to its function in the spliceosome. 
Comparison of the binding sites in different pre-mRNAs will indicate whether PRP8 
possesses a sequence preference for RNA-binding. 
Affinity purified antibodies against the various regions of PRP8 may have 
different effects on complex formation if present during the splicing or mock-splicing 
reaction. In this way, it may be possible to define the roles played by different regions 
of this huge protein in interactions with other components of the splicing machinery. 
In a similar vein, an analysis of complex formation in heat-inactivated extracts from pp 
mutant strains may provide clues as to the domains of PRP8 involved in certain 
interactions. To date, six different temperature sensitive alleles of PRP8 have been 
isolated and for only one of these, prp8-1, has the mutation been approximately mapped 
within the gene (S. Jackson, Ph.D. thesis). 
110 
With respect to the genetic approach, the isolation of cold-sensitive mutations 
which suppress the heat-sensitive defect of prp8 mutations constitutes the most direct 
route to analysis of the interactions of PRP8. Suppression of the defect caused by 
mutation in one gene by mutation in another strongly implies a direct interaction 
between the products of the respective genes during the execution of their function. 
By this means, the protein-encoding SPR81 gene, certain cold-sensitive alleles of which 
will suppress the defect of the prp8-1 mutation, has been cloned and work is under way 
to raise antisera to fusion proteins expressed from it (DJamieson, personal 
communication). These antisera should allow analysis of the putative interaction 
between the proteins in the splicing process. 
It should be possible to subsequently isolate heat-sensitive suppressors of the 
cold-sensitive mutations of SPR81 and then further cold-sensitive suppressors of those 
ad infinitum. This approach will combine with that of screening banks of temperature 
sensitive mutants for new pjp mutations to identify, genetically, many of the components 
of the yeast splicing machinery. Therefore, the powerful combination of biochemical 
and genetic approaches which are available in Saccharomyces cerevisiae probably 
provides the most direct route to elucidation of the detailed pathway of nuclear 
pre-mRNA splicing. 
7.2 	METAZOAN HOMOLOGUES OF PRP8 
Unequivocal proof of functional homology between the 220kD HeLa protein, 
whose identification is described in Chapter 6, and yeast PRP8 must, obviously, await 
further characterisation of the role of the yeast species in pre-mRNA splicing. 
However, evidence for such homology is provided by certain findings; (i) both are 
components of the U5 snRNP, (ii) the HeLa protein displays sequence-independent 
RNA-binding properties, as does the region of PRP8 present in TRP8.5, (iii) a large 
HeLa protein is cross-linked, like PRP8, to pre-mRNA in the spliceosome. The inability 
of anti-PRP8 antibodies to precipitate this protein from HeLa cell nuclear extracts 
makes an analysis of its role in splicing in these extracts very difficult. 
The cDNA encoding this protein could be cloned using either of two 
approaches. Firstly, the affinity purified anti-PRP8 antibodies, which detect only a single 
species on Western blots of HeLa cell nuclear extract, could be used to screen a human 
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cDNA library in a )gt11 expression vector. Alternatively, the protein present in 
purified U5 snRNP fractions could be subjected to protein microsequencing and an 
oligonucleotide probe, synthesised on the basis of the data obtained, used to screen a 
cDNA library. The derived protein sequence of the human species may show strong 
similarity to PRP8, thus providing further evidence of homology. In addition, antibodies 
could be raised to the human protein which should allow a dissection of its role in the 
in vitro splicing reaction. 
If the derived sequence of the human protein exhibited short regions of more 
pronounced similarity to the yeast species, then these conserved motifs would be strong 
candidates for functionally important elements in PRP8. These would then be likely 
targets for site-directed mutagenesis of PRP8. If an in vitro mutagenesis approach was 
be taken to analyse this huge protein, such indications of important regions would be 
essential. 
Analysis of the protein identified in D.melanogaster cell extracts by 
immunoblotting is at a very preliminary stage and any suggestion of functional homology 
must await demonstration that it is a snRNP component. This system could prove 
invaluable if this protein is, indeed, a snRNP protein and is, unlike the HeLa species, 
precipitable by anti-PRP8 antibodies. Functional analysis of the protein could then be 
undertaken in a Drosophila in vitro splicing system, such as that recently described (Rio, 
1988). Cloning and sequencing of the cDNA encoding the Drosophila protein would, 
as for the human case, provide insight into the functionally significant regions of PRP8. 
In conclusion, the conservation of epitopes in three distinct regions of the 
molecule, and also conservation of its large size, suggest a central role for the PRP8 
protein, and its homologues, in the pre-mRNA splicing process. To date, there have 
been no reports of the identification of metazoan homologues of any other yeast 
splicing proteins. The combination of approaches outlined in this Chapter should prove 
instrumental in the elucidation of the function of this species. 
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APPENDIX 
EVIDENCE THAT THE SNR6 GENE IS TRANSCRIBED BY RNA POLYMERASE C 
A.1 INTRODUCTION 
The majority of snRNAs possess a characteristic trimethyl guanosine cap 
structure and are transcribed by RNA polymerase B (RNA polymerase II). 
Transcription of the U6 gene, however, can be achieved in cell-free extracts lacking 
polymerase B activity, is relatively insensitive to a-amanitin and can be competed by 
excess copies of the class C 5S rRNA gene (Kunkel et al., 1986; Reddy et al., 1987). 
This evidence suggests that the U6 gene is transcribed by RNA polymerase C (III). 
In contrast to the use of internal promoters found in other class C genes 
(Geiduschek and Tocchini-Valentini, 1988), upstream regions alone prove sufficient for 
efficient transcription of a U6 gene in vitro (Das et al., 1988). The upstream promoter 
region shares sequence elements with pol B promoters (Parry et al., 1989). It has two 
conserved regions, the distal and proximal sequence elements, in common with, and 
functionally interchangeable with, the promoters of pol B-transcribed U snRNA genes. 
It also possesses a "TATA box, a feature of many mRNA p01 B promoters, but which 
in this case has been shown to be the element necessary to confer putative pol C 
transcription upon the U6 gene (Mattaj et al., 1988). Taken together these data suggest 
that there is not such a clear cut distinction between class B and class C genes as was 
once thought and raise the possibility that there exists a hybrid pol B/C which acts to 
transcribe the U6 gene. 
This Appendix describes the direct genetic approach taken to analyse the 
possible involvement of pol C in the transcription of the yeast SNR6 gene (as a 
collaboration with the laboratory of A.Sentenac, C.E.N. de Saclay). For this, use was 
made of mutant strains of yeast that carry temperature sensitive defects in the largest 
subunit (RPC160) of RNA polymerase C, resulting in a dramatic reduction in tRNA 
synthesis at the non-permissive temperature (Gudenus et al., 1988). 
A.2 	U6 snRNA IS DEPLETED IN A rpcl60 MUTANT 
Cells of wild-type strain YNN281 and of mutant strains YNN281-31 (rpcl60-31 
temperature sensitive mutation) and YNN281- 41 (rpc160-41) were grown at 25°C and 
the cultures split, half being incubated at 25°C for a further 20 hours and the other half 
at 37°C for the same period, and total RNA was prepared (this procedure was 
performed by A.Moenne, C.E.N. de Saclay). The levels of U4 and U6 snRNAs were 
analysed on a Northern blot using oligonucleotide probes (Figure AAA). Approximately 
equal loading of RNA from the different RNA preparations was achieved by comparison 
of the 28S and 18S rRNA bands on an ethidium bromide-stained agarose gel (data not 
shown) and the U4- and U6-specific signals were compared by densitometric analysis 
of the autoradiograph. The U4 snRNA levels were similar at the two growth 
temperatures in the wild-type and mutant strains. When the densitometric readings 
were corrected for the slight variation in the levels of U4 snRNA, it was seen that the 
U6 snRNA level was depleted during growth at the higher temperature by 21% in 
wild-type cells (lanes 1 and 2), by 28% in rpcl6O-31 cells (lanes 3 and 4) and by 80% 
in rpcl6O-41 cells (lanes 5 and 6 and more clearly seen with a shorter exposure, lanes 
7 and 8). A blot probed with a U2 snRNA-specific oligonucleotide probe showed no 
significant effect of growth temperature on this species in any of the strains (data not 
shown). Analysis of RNA from rpcl6O-41 cells shifted to 37°C for 5 hours revealed a 
much less severe depletion of U6 snRNA (data not shown). 
In order to compare the levels of a wider range of snRNAs in rpc160-41 cells, 
immunoprecipitations were performed using anti-m3G antibodies and the precipitated 
RNA species were 3'-end labelled and analysed by denaturing polyacrylamide gel 
electrophoresis (Figure A.1B). There is little quantitative difference in any of the 
snRNAs, for the wild-type or rpcl6O-41 mutant strains, between cells grown at 25°C 
or shifted to 37°C (compare lanes 1 and 2 with lanes 3 and 4, respectively). This is 
consistent with the major m3G-capped snRNA species being transcribed by RNA 
polymerase B (Dahlberg and Lund, 1988) and demonstrates that the rpc160-41 mutation 
has no general effect on snRNA levels at the non-permissive temperature. 
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FIGURE Al: U6 snRNA IS SPECIFICALLY DEPLETED IN A POLYMERASE C 
MUTANT STRAIN 
Total RNA from wild-type cells (WT), grown at 25°C (lane 1) or 37°C (lane 2), 
from cells carrying the rpcl6O-31 mutation (31), grown at 25°C (lane 3) or 37°C (lane 
4), and from cells carrying the rpcl6O-41 mutation (41), grown at 25°C (lane 5) or 37°C 
(lane 6), was separated on a 6% polyacrylamide/7M urea gel, electroblotted to Hybond 
N membrane and probed with 5'-end labelled oligonucleotides specific for U4 and U6 
snRNAs. A shorter time exposure autoradiograph of lanes 5 and 6 is displayed in lanes 
7 and 8. 
Anti-m3G immunoprecipitations were performed on total RNA samples from 
wild-type and rpcl6O-41 cells, prepared as in (A). RNA recovered from immune 
complexes was 3'-end labelled and analysed by electrophoresis through a 6% 
polyacrylamide/7M urea gel. Markers were an end labelled MspI digest of pBR322 
plasmid DNA. 
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A.3 DISCUSSION 
The results described in Section A.2 indicate that, in cells carrying the rpc160-41 
mutation, the steady state level of U6 snRNA is specifically reduced, providing direct 
genetic evidence to support previous proposals that RNA polymerase C is involved in 
synthesis of this species. The steady state level of U6 snRNA in cells carrying the 
rpc160-31 mutation is not significantly different from that in wild-type cells after 20 
hours heat-shock. This suggests that the defect caused by this particular mutation is in 
the interaction of RNA polymerase C with components necessary for the transcription 
of tRNA genes but not SNR6. 
There remain two other possible explanations for these results. Firstly, and less 
likely, the U6 snRNA may be selectively degraded in the rpc160-41 mutant strain. 
Alternatively, the SNR6 gene may be transcribed by another, as yet undefined, class of 
RNA polymerase which shares the RPC160 subunit with RNA polymerasc C, e.g. a 
hybrid poi B/C as postulated in Section Al. However, the SNR6 gene has now been 
transcribed in vitro by purified RNA polymerase C in the presence of partially purified 
TFIIIB (Camier and Sentenac, personal communication), providing the first direct 
biochemical evidence for the involvement in U6 snRNA synthesis of the same RNA 
polymerase which acts to transcribe the class C genes with internal promoters. This 
argues against the existence of a hybrid RNA polymerase, but suggests that transcription 
factors are not specific to one class of genes, i.e class B and class C factors can interact 
in the formation of transcription initiation complexes. 
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